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ABSTRACT
TIMOTHY KENT TIPPIN: Novel Approaches to Assess the Efficacy and Toxicity of
Intestinal Absorption Enhancers
(under the direction of Dhiren R. Thakker, Ph.D.)
Hydrophilic molecules do not easily cross the intestinal epithelium. One approach to
improve intestinal absorption of hydrophilic compounds is to reversibly modulate tight junctions
by co-administration of a paracellular permeability enhancer (PPE). Currently, there is no
enhancer that has shown sufficient potency or sufficiently low toxicity to be used for this
purpose in humans.
The potency of PPEs is routinely assessed in vitro using cell monolayers. However, in
vitro potency determinations typically underestimate the concentrations of PPEs that are required
to improve the intestinal absorption of hydrophilic compounds in animals. Studies in this work
demonstrated that components present in intestinal fluid, when introduced to cell monolayers,
substantially reduced the potency of amphiphilic PPEs by sequestration in mixed micelles of
intestinal fluid. Addition of serum on the basolateral side, to simulate the presence of blood
components on the serosal side of the intestinal epithelium, had only a modest impact on PPE
potency. Agitation of cell monolayers, representing intestinal motility, increased the apparent
potency of amphiphilic PPEs, by reducing the height of the unstirred water layer. Therefore,
incorporation of 1) components of intestinal fluid and 2) features of intestinal motility into the
cell culture model are recommended for improved predictivity of PPE potency.
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A major concern affecting the use of PPEs in humans is that they may increase the risk of
systemic exposure of toxins, though this has not been studied directly. In this work, the model
amphiphilic PPE, hexadecylphosphocholine, was found to increase the in vitro flux of
lipopolysaccharide across Caco-2 cells, but only at relatively toxic concentrations, as measured
by a novel quantitative histological technique. After transient intestinal administration of the
minimum effective dose of hexadecylphosphocholine to rats, marked intestinal damage was
observed, but no evidence for systemic absorption of lipopolysaccharide was found. These
studies provide evidence that even at high doses of PPEs that might cause some intestinal
damage, significant amounts of lipopolysaccharide are not absorbed. The results obtained in this
study challenge the current dogma that intestinal absorption enhancers are likely to cause
systemic exposure to microbial toxins and resultant toxicity by compromising the intestinal
epithelial barrier.
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CHAPTER 1
INTRODUCTION
2A. Introduction
The intestinal epithelium is composed of a single layer of absorptive enterocytes that
serve to facilitate the absorption of beneficial nutrients, ions and water into the body while at the
same time keeping the potentially harmful external chemicals and toxins out of the body. These
important processes are accomplished by distinct apical (luminal) and basolateral (serosal) cell
membrane domains that contain unique lipid and protein arrangements, and by the intercellular
junctional complexes, which serve to join cells to each other at the luminal side of their
membrane and demarcate the apical and basolateral cell membrane domains.
Drugs and nutrients are absorbed across the intestinal epithelium into the blood primarily
by three pathways (Figure 1.1): by passive diffusion across the cell membranes (transcellular
pathway); by passive diffusion between adjacent cells (paracellular pathway); or by active
transport by membrane-bound transporters (carrier-mediated pathway). Lipophilic molecules
easily cross the cell membrane via the transcellular route. On the other hand, hydrophilic
molecules that are not recognized by a membrane-bound transporter cannot easily traverse the
epithelial barrier via the transcellular pathway, and are therefore relegated to cross the intestinal
epithelium via the paracellular pathway. Furthermore, the transport of hydrophilic molecules via
the paracellular pathway is severely restricted by the presence of the intercellular junctional
complex.
Depending on their physico-chemical properties, drug molecules may be either well-
absorbed or poorly absorbed across the intestinal epithelium. Since the oral route is the preferred
method of drug delivery, much effort in early drug discovery is focused on improving the oral
bioavailability of potential drug candidates. Many times, favorable structural chemical
3properties cannot be incorporated without reducing the potency for the drug target, and therefore,
alternative measures are employed to improve the intestinal absorption of the therapeutic agent.
Among the approaches to improve oral absorption of poorly absorbed compounds is to
modify the intestinal barrier by co-administration of a paracellular permeability enhancer (PPE).
In this method, intercellular junctions are transiently loosened by the PPE, which opens the
paracellular space to allow greater absorption of the poorly absorbed molecule. The search for a
safe and effective PPE has been underway for the past 15 years. This search has been greatly
aided by the discovery and use of in vitro models of the intestinal epithelium, such as Caco-2,
which has allowed the rapid assessment of structure-efficacy relationships for multiple PPE
analogs, as well as elucidation of PPE mechanism of action.
However, despite advances in scientific knowledge of PPE structure-activity and
mechanism of action, as well as great strides by the basic sciences in understanding the
molecular structure and regulation of the tight junction, a safe and effective PPE has yet to be
approved for human use.
The purpose of this review is to summarize the current understanding of the composition
and regulation of the intercellular junctional complex, the limiting barrier to the paracellular
pathway, and to examine the efficacy and mechanism of action of important PPEs studied to
date. With this basis, the reasons why a safe and effective PPE has not yet been found will be
explored.
B. Composition and regulation of the epithelial intercellular junctional complex
The intercellular junctional complex, which is located near the apical or luminal side of
the epithelial cell, regulates the movement of ions and hydrophilic solutes through the
paracellular space via the interactions of specialized membrane domains that interface with like
4regions in adjoining cells. Three distinct specialized regions form the intercellular junctional
complex: the tight junction (TJ), adherens junction (AJ) and desmosomes. The following
sections will review the composition and regulation of the TJ and AJ, which are thought to be the
primary domains which provide the apical intercellular barrier and adhesive properties between
epithelial cells.
1. Tight junction proteins
The TJ is the most apical component and is generally considered to be the limiting barrier
to paracellular permeability (gate function), and the boundary in the cell membrane itself that
divides the apical from basolateral domains (fence function)1. There are numerous proteins
present at the TJ that can be classified according to their function as either integral membrane
proteins that span the extracellular space and interact with similar molecules on adjoining cells,
or as peripheral membrane scaffolding proteins that serve to link the transmembrane proteins to
the actin cytoskeleton and arrange them adjacent to important regulatory molecules.
In the current view of the TJ (Figure 1.2), there are primarily two tetraspan proteins,
occludin (approximately 65 kDa), the claudin family of proteins (approximately 20 – 27 kDa)2,3,
as well as a single transmembrane spanning family of immunoglobulin (Ig)-like proteins, the
junctional adhesion molecules (JAMs, approximately 40 kDa). Additional transmembrane
components continue to be found. For example, another tetraspan protein, tricellulin, has been
identified in the TJ, and interestingly, is only present at multicellular junctions4. This recent
discovery suggests that the composition of the TJ is different depending on whether two cells are
adjoined (bicellular TJ) or whether three or more cells are adjoined (tricellular TJ)4.
The putative extracellular domains of occludin, claudins and JAMs are thought to interact
homophilically and heterophilically with extracellular loops in the adjoining cells thereby
5creating a selective pathway for ions, solutes5, and even whole cells (e.g., leukocytes); the
passage of whole cells and also viruses is thought to be mediated by the JAMs6.
While occludin was the first TJ protein identified, it is the claudin family that is currently
thought to be the primary gatekeeper for ions and solutes7. The claudin family members can be
expressed at varying levels depending on the type of epithelial tissue. Based on the different
expression of claudins in certain epithelia and the known differences in resistance across these
epithelia, it is thought that claudin expression can give a tissue its characteristic permselectivity
to ions and also contribute to the resulting transepithelial electrical resistance (TEER). For
example, in the mouse kidney nephron, claudin-2 is highly expressed in the relatively leaky
proximal tubule8, whereas claudin-8 is highly expressed in tighter distal tubule tissue9. Further
evidence for the role of claudins in mediating paracellular ion flux has been found in vitro by
manipulation of claudin expression in epithelial cell monolayers. For example, the TEER across
the high resistance MDCK I cell line was reduced 20-fold by expression of claudin-2, a claudin
not normally expressed in high resistance MDCK I cells10. The role of claudin family members
at the TJ is rapidly emerging and has been comprehensively reviewed in two recent review
articles7,11.
Occludin has also been shown to play a role in the functional barrier of epithelial tissues,
although there is mounting evidence that the role of occludin is more regulatory and
organizational in nature. For example, the electrophysiological and mannitol flux measurements
across intestine and bladder tissues ex vivo in Ussing chamber experiments from occludin (-/-)
knockout mice did not show any significant differences compared to wild-type epithelial
tissues12. These data suggest that either occludin is not a critical component of the normal
barrier function of these tissues, or that other barrier proteins such as claudins can compensate
6for the barrier role played by occludin. The occludin (-/-) knockout mice were found to have
phenotypic changes, for example, infertility in males and increased inflammation in gastric
tissue13, however, these phenomena could not be tied directly to a change in barrier function. On
the other hand, exogenous application of peptides homologous to the first extracellular loop of
occludin, when applied in vitro to epithelial cell monolayers, have enhanced the paracellular
permeability to mannitol14, thus providing evidence that occludin is an important barrier protein
in the TJ.
Occludin possesses larger N-terminal and C-terminal cytoplasmic domains containing
sequences that are either predicted to, or have been shown to interact with a wide variety of
scaffolding and signaling proteins. For example, the N-terminal region of occludin contains
sequences that are predicted to bind to src homology 3 domains (SH3)15; in contrast, claudins
have shorter N-terminal regions. Furthermore, there are a large number of cytoplasmic serine,
threonine and tyrosine residues in occludin proximate to sequences that could be targets for
acidophilic, basophilic or proline-rich kinases16; phosphorylation of the cytoplasmic regions of
occludin as well as the other TJ proteins, has been shown to be important in TJ assembly,
disassembly and barrier function17.
The JAMs represent the third family of transmembrane proteins that are known to be
present in the TJ. JAMs are single transmembrane proteins that have a relatively short
cytoplasmic C-terminal domain and an N-terminal extracellular domain composed of 2 Ig-like
loops. The extracellular domains interact via homophilic and heterophilic (e.g., with integrin)
mechanisms. The exact role of JAMs at TJ and the information on how they are regulated is still
emerging, but clearly they, and other Ig-like proteins such as coxsackievirus and adenovirus
receptor (CAR), play a large role in interactions with immune cells and aid in their passage
7through the intercellular space18. The nomenclature for the JAMs is also emerging. A recently
proposed unifying system uses letter suffixes for the first 3 JAMs, JAM-A, B, C19. Though some
JAMs, for example, JAM-4, which is thought to regulate permeability in jejunal, ileal and
proximal kidney tissue20, are still unclassified under the new system. This and other key
components and roles of the JAMs in the TJ have been recently reviewed by Mandell and
Parkos6.
Occludin, claudins and JAMs are linked to intracellular scaffolding proteins, such as
zonula occludens (ZO)-1, ZO-2, and ZO-3 through their cytoplasmic C-terminal regions. The
linkage of claudins and JAMs to ZO proteins is thought to be via short peptides, comprising
hydrophobic amino acid residues, that interact with the PSD95/disc large/ZO-1 homology (PDZ)
domains of the ZO proteins21,22. Diversity in the C-terminal region of claudin family members,
suggests that this region could play a role in directing distribution and amount of claudin family
members in a particular tissue16. Occludin is thought to associate with ZO-1, 2 and 3 via its
coiled-coil C-terminal region, a region that has also been shown to interact with several kinases,
including protein kinase C-zeta, c-Yes, and phosphatidylinositol 3-kinase23,24. Thus, the
scaffolding proteins have multiple binding regions that interact not only with the C-terminal
region of occludin, claudin and JAMs, but also interact with signaling molecules, and with the
actin cytoskeleton25. Furthermore, the ZO-proteins can also interact with each other forming
heterodimers, or with themselves forming homodimers, as has been shown recently for ZO-126.
The proportions of ZO-protein heterodimers and homodimers may have implications for the
scaffolding function of these proteins26.
In addition to the ZO-proteins, there are other scaffolding proteins that are localized to
the tight junction including the membrane-associated guanylyl kinase inverted (MAGI) family of
8proteins, which bind JAMs, the multi-PDZ domain protein-1 (MUPP-1), the partitioning
defective proteins, PAR-3 and PAR-6, and the MAGUK protein associated with Lin-7 (PALS-
1). These proteins, and additional binding partners and their effects have been recently reviewed
by Schneeberger and Lynch27.
2. Adherens junction proteins
The adherens junction proteins also play a role in the intercellular junctional barrier, and
are thought to be the initial adhesive event that leads to formation of the apical junctional
complex28. The AJ is located sub-apically to the TJ and is composed of single transmembrane
protein E-cadherin, which requires Ca2+ for adhesion, as well as the Ca2+-insensitive nectin
family of proteins.
The N-terminal portion of E-cadherin extends into the extracellular space and has been
shown to dimerize with other E-cadherin proteins in the same cell (cis-dimers), and importantly,
forms trans-dimers to E-cadherin proteins in adjoining cells via interactions between one or
more of the five repeating extracellular domains (EC-1 to EC-5)29. The cytoplasmic C-terminal
region of E-cadherin is linked to scaffolding protein -catenin, which in turn is linked to other
scaffolding proteins, such as -catenin, forming a complex that serves to link the E-cadherin
proteins to the apical perijunctional actin-myosin ring30,31.
The Ca2+-insensitive transmembrane proteins, the nectins, are also present in the adherens
junction and contribute to apical cell-cell adhesion. Nectins are Ig-like single transmembrane
proteins that form cis- and trans-dimers by interactions mediated through their Ig-like loops32.
Nectins are linked to the scaffolding partner afadin, which in turn is linked to the actin
cytoskeleton33. Thus, the AJ complex is organized similarly to the TJ complex, with
9extracellular-interacting players that are linked to scaffolding proteins, which in turn are linked
to the actin cytoskeleton.
The removal of extracellular Ca2+ in vitro has been shown to disrupt E-cadherin
interactions and lead to multiple intracellular events including the endocytosis of AJ and TJ
proteins (E-cadherin, p120 and -catenins, occludin, JAM-1, claudins 1 and 4, and ZO-1)34.
This cascade of events due to disruption of the AJ extracellular domains provides evidence that
the AJ contributes to the stability and regulation of both TJ and AJ intercellular junctional
complexes. A more detailed review of AJ regulation and its impact on the TJ has been recently
published by Miyoshi and Takai35.
3. Regulation of the intercellular junctional complex
Regulation of the TJ and AJ domains is accomplished by multiple signaling pathways,
which either promote and maintain the intercellular junctional complex, or act to loosen or
disassemble it. The intercellular junctional complex is a dynamic barrier that modifies its
properties in response to physiological stimuli such as the need for nutrient absorption, or to
pathological stimuli, such as the invasion of microorganisms or wound repair. The focus of this
section will be to briefly describe the stimuli and the resulting intracellular pathways that have
been shown to loosen or disassemble existing intercellular junctional complex.
Changes to the phosphorylation state of the transmembrane and/or scaffolding proteins
can result in changes to the paracellular barrier. Both occludin and the claudin family members
have multiple serine, threonine and tyrosine residues in their cytoplasmic regions that can be
substrates of various kinases16. For example, levels of occludin tyrosine phosphorylation
correlated with different stages of TJ assembly and disassembly, possibly mediated via the non-
receptor tyrosine kinase c-Yes36. In other studies, increased tyrosine phosphorylation mediated
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by c-src in carboxy terminal fragments of occludin decreased its interactions with ZO-proteins37,
and were thought to be the cause of the downregulation of the TJ barrier in Caco-2 cells caused
by oxidative stress38.
In addition to tyrosine kinase-mediated phosphorylations, serine/threonine kinases have
also been implicated in the modulation of the paracellular pathway by phosphorylation of TJ
proteins. For example, PKC has been shown to be involved in an increase in phosphorylation
of occludin and a decrease in the TEER across IEC-18 cell monolayers after treatment with
phorbol-12-myristate-13-acetate (PMA)39. In other studies in LLC-PK1 cells, however, PKC
activation by PMA resulted in decreased phosphorylations of occludin threonine residues with a
corresponding decrease in TEER, suggesting that PKC activation is an upstream event that may
be inhibiting downstream kinases or activating downstream phosphatases in this cell model17.
More recently, the novel PKC was shown to be important in maintaining barrier function of
intestinal epithelial monolayers by phosphorylation of serine and threonine residues on claudin
family members, claudin-1 and claudin-440. The role of the PKC families in maintenance and
repair of the intestinal epithelium has been recently reviewed41.
Upstream regulators of protein kinases have also been implicated in regulation of TJ
proteins by changing phosphorylation state. For example, inhibition of phospholipase C- in
MDCK cells by 3-nitrocoumarin has been shown to open the paracellular pathway, and this
effect has been linked to hyperphosphorylation of occludin, ZO-1, and ZO-242.
Changes in the actin cytoskeleton mediated through GTPases Rho, Rac, and Cdc42, have
also been shown to disrupt the paracellular barrier43,44. For example, expression of constitutively
active or dominant negative RhoA, Rac1 or Cdc42 resulted in paracellular permeability
enhancement that was due to changes in the perijunctional actin-myosin ring as well as
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redistribution of other TJ proteins44. This is consistent with previous studies that have
demonstrated inactivation RhoA, Rac1 and Cdc42 by Clostridium difficile toxins have caused
actin disorganization and dissociation of TJ proteins from the TJ45. The redistribution of F-actin
and loosening of the TJ barrier is also observed in vitro by exogenous application of
cytochalasins46,47.
It has also been demonstrated that contraction of the actin-myosin ring occurs in response
to glucose uptake mediated by the sodium-dependent glucose transporter (SGLT1)48. This
contraction, which is due to a PKC-mediated phosphorylation of myosin light chain1, causes the
paracellular pathway to become leaky. It has been proposed and demonstrated with some in vivo
studies that this paracellular leakiness, termed “solvent drag”, results in enhanced absorption of
glucose and other small hydrophilic compounds49,50. However, this hypothesis, is controversial51,
and others have failed to find any significant increased absorption of co-administered
hydrophilic compounds in the presence of high glucose loads52,53.
In addition to nutrients, other endogenous agents affect intracellular signaling pathways
that open TJs, including hormones, neurotransmitters, for example, vasopressin, angiotensin II,
epinephrine54, and cytokines such as tumor necrosis factor alpha (TNF)55. Thus, the
permeability through the TJs can be enhanced through a variety of signaling pathways resulting
in reversible changes to the phosphorylation state of intercellular junctional proteins and/or
modification of the apical F-actin ring as represented schematically in Figure 1.3.
C. Assessing the integrity and changes to the functional state of the intercellular
junctional pathway
The tightness of the epithelial junction varies depending on the type of epithelial tissue:
the small intestinal and kidney proximal tubule epithelium are “leakier” compared to the urinary
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bladder epithelium. Furthermore, the intestinal epithelium varies in tightness along its length
due to different intestinal functions, the upper small intestine being “leakier” than the colon,
since it is designed for the rapid absorption of nutrients. The tightness of the epithelial barrier is
typically assessed in two ways: by the transepithelial electrical resistance (TEER); and by the
flux of hydrophilic solutes across the epithelium.
Ions do not easily flow across pure phospholipid membranes, and therefore pure
membranes have very low conductance and high TEER (approximately 1015 ohm*cm2)56.
Biological membranes contain ion channels which permit some flux of ions, thereby
substantially lowering the membrane resistance to approximately 103 – 104 ohm*cm2 57.
However, the paracellular space for relatively leaky epithelia has much lower resistance
compared to the membrane. Thus, if the transcellular and paracellular pathways are viewed as a
parallel electrical circuit, with one arm of the circuit across the membrane (apical plus
basolateral) and the other being across the paracellular space between the cells, >75% of ion
conductance is through the paracellular pathway for leaky to moderately tight epithelium such as
that found in the intestinal epithelium57,58. Thus, an increase in total ion conductance (decrease
in TEER) across the epithelium, due to addition of a PPE, for example, is thought to reflect an
increase in the paracellular permeability (of ions) across epithelial cell monolayers, rather than
an increase in the transmembrane flux of ions57. This has been confirmed in Caco-2 cells using
the ionophore amphotericin B, which did increase membrane conductance to ions, but did not
change TEER59.
In the intestine, TEER is the average of different subpopulations of cells, including
undifferentiated crypt cells (leaky), fully differentiated villus absorptive cells (tight) and goblet
cells (leaky) 60,61. Recent evidence suggests that different claudin family members provide the
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characteristic permselectivity to ion flow through the paracellular space and thus could impact
TEER11. In earlier work, differing permselectivity to ions along regions of human small
intestinal tract was noted62. Recently, the longitudinal (i.e., duodenal to colon) and radial (i.e.,
villus to crypt) expression of different claudins along the rodent GI tract has been
documented63-65, revealing a complex expression pattern of multiple claudin family members.
Table 1.1 summarizes the approximate TEER values for different epithelial tissues or cell culture
models, and the claudin family members that are expressed in them, if known.
Hydrophilic solutes are also largely excluded from passing across lipid membranes.
Therefore, unless they are substrates for transmembrane solute carriers, a change in
transepithelial flux of these molecules is also indicative of changes in paracellular permeability.
Based on multiple lines of experimental evidence, mannitol has long been used as a hydrophilic
marker that is thought to cross epithelium primarily via the paracellular space. For example, the
permeability coefficient for mannitol across pure lipid membranes is quite low, 10-11 to
10-10 cm/sec66, and mannitol is largely excluded from red blood cells, suggesting that it does not
readily traverse the lipid membrane via either passive or facilitated processes67. Mannitol has a
low octanol:water partitioning coefficient (logP = -3.1)68 and an estimated molecular radius
sufficiently small to pass through the paracellular space (Mr mannitol = 4 Å; effective
paracellular pore radius for Caco-2 cells = 5 Å)69. Therefore, the observed permeability of
mannitol across Caco-2 cell membranes of 10-7 cm/sec, which is at least 3 orders of magnitude
faster than across pure lipid membranes, is reasonably thought to be exclusively through the
aqueous medium of the paracellular pathway70.
Other small hydrophilic molecules that have been used as paracellular markers include
neutral markers like urea (Mr = 2.7 Å)69, cationic markers such as atenolol (Mr = 4.8 Å)69,
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creatinine (Mr = 3.2 Å)49, ranitidine71, and anionic markers such as formate (Mr = 2.5 Å)69,
lactate (Mr = 3.1 Å)69, 51Cr-EDTA (Mr = 5.4 Å)72, and fluorescein (Mr = 5.5 Å)73. In general,
the cationic hydrophilic markers have been found to have higher paracellular permeability
relative to their neutral and anionic counterparts of approximately the same size, presumably due
to the anionic nature of the paracellular space69. However, evidence for facilitated
transmembrane flux has recently been found for ranitidine, a compound previously thought to
traverse the epithelium solely via the paracellular pathway74. Therefore, care should be
exercised when using charged molecules as paracellular permeability markers.
Larger hydrophilic molecules have also been used to gauge both the baseline paracellular
pore size and to assess changes to the paracellular pore size caused by intestinal disease or PPEs.
For example, large carbohydrate polymers such as inulin (Mr = 7.5 Å)72 and fluorescein
isothiocyanate (FITC)-dextrans of increasing molecular weight from 3 kDa to 70 kDa
(Mr = 14 - 60 Å) have been used to assess the dimensions of the paracellular space in cell
monolayers73,75. The visualization of these fluorescently-labeled molecules provides evidence
that their primary route of transepithelial permeability is via the paracellular space76. Likewise,
the linear hydrophilic polymers polyethylene glycols (PEGs) have been utilized to characterize
the paracellular pathway77. The PEGs have been shown to exhibit biphasic permeability across
Caco-2 and T-84 cell monolayers such that the smaller PEGs (MW 280 - 400 and Mr < 4.5 Å)
exhibited a marked decline in permeability with relatively small increments in size, while the
larger PEGs (MW 400 – 1380, Mr = 4.5 to 7.4) exhibited lower permeability that decreased only
slightly over this larger size range78,79. When fit to a sieving model having pores of two distinct
populations, this permeability behavior revealed an abundant, restrictive pore (Mr 4.3 to 4.5 Å),
which is proposed to be the dominant pathway for small hydrophilic solutes, and a less abundant,
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non-restrictive pore that allows passage of larger molecules79. This model has been used to
assess changes in the paracellular space caused by PPEs79, though others have cautioned about
the use of PEGs to characterize the paracellular pathway due to the flexibility of these
polymers78. PEG polymers and non-metabolized sugars have also been administered orally to
animals and humans to assess intestinal integrity. Typically, absorption is inferred from the
urinary excretion of these markers, since after iv administration, >80% of the dose is rapidly
recovered in the urine80,81.
Clearly, the measurements of TEER and hydrophilic solute flux have been successfully
applied to understand the nature of the unperturbed paracellular pathway, as well as how it
changes in the presence of PPEs. It has been noted however, that differences in baseline TEER,
or decreases in TEER due to PPEs, do not always result in changes in permeability of
hydrophilic solutes78. In addition, recent evidence provided by genetic manipulations of cell
monolayers suggests that expression levels of certain claudins can change TEER, but not
necessarily hydrophilic solute flux82. Thus, for thorough evaluations of paracellular permeability
enhancement, both the change in TEER, a reflection of increased paracellular permeability to the
relatively smaller, charged ions, as well as the change in flux of larger hydrophilic solutes should
be employed to estimate the paracellular permeability enhancement properties of PPEs.
D. Efficacy and mechanism of action of known PPEs
Over the past 15-20 years, there has been growing interest in modulating the intestinal
epithelial barrier in order to improve the absorption of poorly absorbed compounds. The PPEs
studied to date may be loosely classified by chemical structure into either amphiphilic or non-
amphiphilic classes. The initial attempts to enhance paracellular permeability were made with
relatively small (< 500 Da), endogenous compounds such as bile acids, fatty acids, and fatty acid
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esters (Table 1.2). With the increase in knowledge about the TJs has come a renewed interest by
researchers to more specifically modulate TJs. For example, non-amphiphilic peptides that bind
to the extracellular loops of TJ proteins or mucoadhesive polymers that bind to the cell surface
resulting in disassembly of TJ proteins have shown promising selectivity to open the paracellular
space (Table 1.3).
In the sections below, the research that has been conducted with many of the known
amphiphilic and non-amphiphilic PPEs will be summarized, with particular emphasis on the
concentrations that caused paracellular permeability enhancement in vitro and in vivo, and the
effect on TJ proteins and/or the signaling pathways that have been implicated in the PPE
mechanisms of action.
1. Amphiphilic PPEs
Many of the currently known PPEs are amphiphilic molecules, possessing a polar head
group, which is typically charged, and a non-polar tail. Because of their structural similarity to
membrane phospholipids, it is likely that these PPEs partition to a great extent into membranes
and in so doing may disturb the normal membrane order. Controlled changes in membrane order
due to externally applied compounds have been reported to affect the enzyme activity of integral
or membrane-associated proteins83,84. For example, biophysical perturbation of the membrane
by amphiphilic compounds that destabilize the lamellar phase toward formation of the HII-phase
has been proposed to be the mechanism for protein kinase C (PKC) activation83. Furthermore,
the claudins and occludin are embedded in membrane microdomains, or detergent-insoluble lipid
rafts, which are characterized as having high levels cholesterol, sphingolipids, and lipid-
conjugated signaling molecules85. Thus, the potential exists that amphiphilic PPEs could disturb
the lipid raft structure, thereby leading to disruption of structural or signaling components that
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are embedded in the TJ membrane microdomains. Depletion of cholesterol by
methyl--cyclodextrin has been shown to change the TJ composition and result in a decrease in
the barrier function in Caco-2 cells86. At high enough concentrations, amphiphilic PPEs may
accumulate to such an extent so as to cause more extensive membrane damage or lysis87. Thus,
the physico-chemical properties of amphiphilic PPEs and their propensity to accumulate in
membranes may be one reason why there is only approximately a 2- 3-fold difference between
the concentration that causes controlled and reversible opening of the tight junction, and the
concentration that causes irreversible cytotoxicity88.
a. Acylcarnitines
Acylcarnitines are a family of zwitterionic amphiphiles that differ from each other in the
length of the long chain fatty acid that is linked to the carnitine head group via an ester linkage.
The most widely studied member of this family, palmitoyl carnitine chloride (PCC, Table 1.2), is
an endogenous molecule that is involved in shuttling palmitic acid across mitochondrial
membranes for generation of energy through fatty acid oxidation89. When added exogenously to
cell monolayers at a concentration of approximately 200 µM, a decrease in TEER and an
increase in the flux of hydrophilic marker molecules is observed69,90. PCC has been shown to be
effective in two cellular models of the intestinal epithelium, Caco-2 cell monolayers76,91 and
IEC18 monolayers92, as well as in excised intestinal tissue from rats93. Approximately 5 to
10-fold higher concentrations (1 – 2 mM) of PCC or the 12-carbon analog lauroyl carnitine
chloride (LCC) were required to significantly increase the permeability of hydrophilic marker
compound lucifer yellow across excised rat colonic mucosa compared to concentrations that
caused similar enhancement across cell monolayer systems.
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Acylcarnitines have been given orally or administered directly into intestinal regions of
animals, and have been shown to improve the intestinal bioavailability of poorly absorbed
molecules. For example, the intestinal bioavailability of a cyclic peptide analog of somatostatin
and the hydrophilic antibiotic cefoxitin were significantly enhanced (>10-fold) in rats after
intestinal or rectal co-administration of PCC at concentrations of 12.5 – 46 mM (5 - 20 mg
PCC/kg body weight)94. The intestinal bioavailability of cefoxitin was also significantly
improved in dogs after jejunal or rectal administration of the 46 mM concentration of PCC (2 mg
PCC/kg body weight)94, though the magnitude of the improvement was less pronounced (2 to 5-
fold) than that seen in rats. The 12 carbon analog lauroylcarnitine chloride (LCC) was also
shown to cause a significant improvement in intestinal bioavailability of these94 and other poorly
absorbed compounds, including salmon calcitonin, in vivo in dogs95. Investigation of PCC
formulated in tablet form, also afforded up to a 10-fold improvement in cefoxitin bioavailability
in rats and dogs after doses of 60 mg PCC/kg body weight96. Thus, PCC can be effective in vivo
when administered as a solution or solid to animals, however, effective (solution) concentrations
are several fold higher than effective concentrations observed in vitro in cell monolayers or
excised tissue.
The mechanism of action of acylcarnitines is at least partly due to perturbing membrane
order. For example, LeCluyse, et al. found a correlation between changes in membrane order of
rat intestinal membranes caused by a series of acylcarnitines of 2 to 18 carbon chain length and
their ability to improve the in vivo absorption of poorly absorbed compounds; for an acyl chain 	
10 carbons, they found minimal disturbance in membrane order and negligible improvement in
colonic absorption of cefoxitin in rats, but for acyl chains 
 12 they found a change in membrane
order of at least 15-20% and an improvement of cefoxitin absorption of at least 10-fold97. Others
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have also found that membrane permeability is altered in cell monolayers by effective PCC
concentrations based on the increased intracellular accumulation of membrane impermeant
solutes92.
The signaling pathways that lead to effects on tight junctions, either because of changes
in membrane order or by direct interaction with PCC are not entirely clear. PCC has been
reported to inhibit Ca2+-dependent PKC activity in cell-free systems98. In contrast, PCC has also
been reported to augment the activation of PKC caused by some phorbol esters such as 4-O-
methylphorbol 12-myristate 13-acetate99. PKC is one of several enzymes that have been
implicated in altering the phosphorylation state of the TJ-associated proteins, resulting in
increased paracellular permeability100. Thus, modulation of PKC activity by PCC in epithelial
cells that results in a change in phosphorylation state of TJ proteins, may be part of the
mechanism of TJ modulation, although this has not been shown directly in studies where
changes to TJ protein distribution or phosphorylation state have been correlated to modulation of
PKC activity. Based on the role of endogenous palmitoyl carnitine in shuttling palmitic acid
across mitochondrial membranes for generation of ATP, it is possible that high intracellular
concentrations of PCC may affect the energy balance and generation of ATP in cells. Indeed, it
has been postulated that PCC may open TJs by lowering ATP levels in cells90. However, other
researchers have shown that the kinetics of TEER decrease after rapid ATP depletion in the
presence of glycolytic and oxidative inhibitors occurs gradually over a period of 90 min101.
Therefore, the acute affects of PCC to cause a rapid decrease in TEER (< 15 min) are likely to be
unrelated to ATP depletion. Little has been published on changes in TJ protein localization, but
it has been shown that PCC does not affect actin organization90.
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b. Alkylphosphocholines
The alkylphosphocholines are structurally related to the acylcarnitines as both possess a
zwitterionic polar head group and a non-polar hydrocarbon tail, with the alkylphosphocholines
having a phosphate-containing, phosphocholine head group rather than the carnitine headgroup
of acylcarnitines (Table 1.2). Based on this structural similarity, dodecylphosphocholine (DPC)
was identified as a PPE88, and later the potency of a homologous series of alkylphosphocholines
was related to the length of their alkyl chain102. One of the most potent members of the
alkylphosphocholines is hexadecylphosphocholine (HPC), which causes a TEER decrease and a
10-fold increase in 14C-mannitol permeability across MDCK cells at a concentration of
approximately 30 µM103. HPC was found to be slightly less potent (effective at 50 – 100 µM) in
Caco-2 cell monolayers104.
The effect of HPC in vivo to increase the absorption of hydrophilic molecules across the
intestine has not been studied. However, HPC has been administered orally to animals and
humans for the treatment of cancer, and more recently, for the treatment of the parasite-derived
disease leishmaniasis. The oral bioavailability of HPC in rats is greater than 80% after doses of
70 – 200 mg HPC/kg body weight, however the rate of absorption is slow, with the time for
maximum HPC plasma concentration (Tmax) occurring 24 to 48 h after dose
administration105,106. Furthermore, there is a high percentage of HPC-related radioactivity (8%)
that remains in the intestinal tissue up to 24 h after oral administration to mice107. The slow in
vivo absorption of HPC may potentially aid the duration of its paracellular permeability
enhancing effect in vivo since the enhancer may remain at effective concentrations throughout
the entire small intestine. The rapid absorption of other amphiphilic PPEs has been proposed to
be a negative trait, and the reason for the relatively small and transient in vivo absorption
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enhancement of polar molecules relative to the enhancement of absorptive transport observed in
vitro in cell monolayers108.
In contrast to PCC, HPC appears to have only a slight effect on the membrane fluidity of
Caco-2 cells in the concentration range that enhances paracellular permeability (20 - 200 µM)102.
The paracellular permeability enhancing potency in MDCK cells caused by HPC and other
alkylphosphocholine analogs is correlated to their potency to inhibit the ATP-stimulated
phopholipase C activity (i.e., the PLC- activity)103. This finding supports previous research
that HPC inhibits PLC activation in human leukemia cell lines109. HPC is reported to be
metabolized by PLC in vivo in mice and in vitro with purified enzyme, cleaving HPC as if it
were a glycerophospholipid to hexadecanol and phoshocholine107.
The changes to TJ-associated proteins that occur after treatment with HPC at
concentrations that enhance paracellular permeability, include actin disorganization in MDCK
cells103 and Caco-2 cells104, and a change in the cellular localization of claudin-1 in Caco-2
cells104. ZO-1, occludin and E-cadherin were not affected by HPC104. The 12-carbon analog of
HPC, dodecylphosphocholine, has affected the cellular localization of ZO-1 at the effective
paracellular enhancing concentration of 750 µM88.
The mechanisms of action by which HPC causes cytostasis or cytotoxicity to tumor cells
or kills the parasite Leishmania have been extensively investigated. While the effect on
paracellular permeability was not examined directly in these studies, these therapeutic
mechanisms of action of HPC may be related to those which act to open TJs, especially those
PPE studies that utilize cancer cell-derived monolayers such as Caco-2 cells. Despite the large
number of studies, the mechanisms by which HPC exhibits anti-cancer activity are not entirely
clear. In addition to PLC inhibition, other enzymes that have been implicated in anti-tumor
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activity include phospholipase A2110, and mitogen activated protein kinase (MAPK)111. In
addition, HPC inhibits PKC (IC50 = 15 µM) in tumor cells112 and phosphatidyl choline
biosynthesis via CTP:phosphocholine cytidylyl transferase (IC50 = 50 µM) in MDCK cells113.
The membrane fluidity of mouse fibroblast cells and human lymphoid B cells were significantly
changed, and the permeability of membrane impermeant compound propidium iodide was
significantly enhanced in the presence of HPC at of 10 – 50 µM114. This finding is in contrast to
the lack of HPC effect on the membrane fluidity in Caco-2 cells102.
Some of the same enzyme systems have also been implicated as the mechanism by which
HPC kills Leishmania protozoa. The effective in vitro concentrations for Leishmania
promastigotes (extracellular phase) ranges from 0.1 – 13 µM, and the effective concentration is
slightly higher for the amastigotes (intracellular macrophage phase), 1- 37 µM, depending on the
species being treated115. It is thought that the anti-parasitic action of HPC is mediated through
phosphatidyl choline synthesis inhibition, resulting in decreases in sphingomyelin, which in turn
increases the membrane levels of ceramide, leading to apoptosis. The effective oral dose of HPC
(miltefosine) for leishmaniasis is 2.5 mg HPC/kg body weight and it is currently in Phase IV
clinical trials115.
c. Glyceride analogs
Glyceride analogs are a group of amphiphilic compounds that have carbon chain
substituents on at least two of the 3 carbinol groups of glycerol. While all glycerides are
amphiphilic, not all contain a charged anionic phosphate headgroup. For example, mixtures of
mono-, di- and triglycerides of medium chain length fatty acids (C8 to C12), termed medium
chain glycerides, have been shown to increase the in vitro flux of mannitol 6-fold across rabbit
ileal tissue in an Ussing chamber model after exposure to 5 % medium chain glycerides for 20
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min, though this enhancement was not thought to be due to selective paracellular permeability
enhancement116. At higher concentrations that formed water-in-oil microemulsions, medium
chain glycerides increased the oral bioavailability of the polar molecule calcein in rats by
approximately 20-fold when administered directly into the duodenum at a dose of 3.3 mL/kg117.
Glycerides that contain a phosphate headgroup have also been shown to enhance the
permeability of polar molecules. For example, palmitoyllysophosphatidyl choline enhanced the
permeability of the 9-mer peptide, 1-deamino-8-D-arginine vasopressin, by approximately 8-fold
across Caco-2 cell monolayers after treatment with 0.05% (w/v), a concentration with relatively
low cytotoxicity as measured by trypan blue exclusion118. The structure-activity relationships for
a series of alkylamidophosphocholines to enhance paracellular permeability across Caco-2 cells
were examined by modifying the alkyl chain length of the two alkyl tails119. Phosphatidyl
choline analogs with tails of medium chain length, for example chain length between 9-11 linked
by an amide linkage at carbon-3 of the glycerol backbone, in combination with a chain length
6 - 10 carbons linked by a ether linkage at carbon-2, were found to cause significant
enhancement of 3H-mannitol permeability and decrease TEER at concentrations of 250 – 400
µM without causing substantial cytotoxicity119. Longer chain lengths at C-3 (11 – 17 carbon
length) and C-2 (8 – 12 carbon length) were not effective up to concentrations as high 5 mM,
whereas long chains at C3 (17 – 19 carbon length) combined with short chains at C-2 (1 – 2
carbon length) tended to have less separation between efficacious and cytotoxic effects119.
Given the structural similarity to membrane phospholipids, it is likely that the mechanism
of action of these molecules is related to interactions with cell membranes. However, the
paracellular permeability enhancement of the more potent alkylamidophosphocholines was
surprisingly not related to changes in membrane fluidity of Caco-2 cells as measured by
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fluorescence anisotropy102. Further work in MDCK monolayers demonstrated that the
paracellular permeability enhancing properties of the most potent alkylamidophosphocholines
was associated with their ability to inhibit ATP-stimulated PLC-dependent pathways102.
d. Fatty acids and bile salts
Medium chain fatty acids such as sodium caprate (NaCap) and bile salts such as sodium
taurocholate (NaTC) have been explored for use as PPEs. These molecules, which are
components of food or endogenous to the body, respectively, are structurally similar to each
other in that they possess an anionic head group, however, they differ in the nature of the
lipophilic structural component--NaCap possesses a relatively short alkyl chain, whereas NaTC
has a rigid steroid ring system (Table 1.2).
The striking difference with these PPEs versus other amphiphilic PPEs is that the
concentrations required to increase the permeability of hydrophilic solutes across cell
monolayers is significantly higher. For example, the effective concentration for NaCap is
reported to be approximately 10-13 mM120,121, and for NaTC is slightly higher at approximately
20 mM122. Thus, NaCap and NaTC appear to be at least 50-fold less potent than the 16-carbon
zwitterionic PPE, PCC in cell monolayers (Table 1.2).
The use of NaCap in vivo has been studied in multiple species, including humans. There
has been mixed success in improving the absorption of poorly absorbed compounds by co-
administration with NaCap. As seen with other amphiphilic PPEs, the studies that successfully
improved the absorption of a poorly absorbed compound employed NaCap dose concentrations
that were significantly higher than those that increased the permeability of hydrophilic solutes in
vitro (10-13 mM). For example, NaCap solutions of 300 – 400 mM (100 mg NaCap/kg body
weight) were co-administered orally to rats to obtain a 3-fold increase in oral bioavailability for
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ardeparin, a poorly absorbed low molecular weight heparin123. In another study, ileal
administration of NaCap to rats at a concentration of 500 mM produced a 5-fold improvement in
bioavailability of a model D-decapeptide, from 2% to 11%124. In pigs, jejunal co-administration
with NaCap solutions of 250 – 500 mM (25 – 50 mg/kg), delivered via an in-dwelling cannula,
improved the plasma bioavailability of the poorly absorbed phosphorothioate antisense
oligonucleotide ISIS104838 from 0 to approximately 2%108. In other in vivo studies, very little
improvement in oral absorption of poorly absorbed compounds has been observed. For example,
oral co-administration with solutions of NaCap up to 50 mM did not improve the oral
bioavailability of acamprosate in rats125, nor did colonic perfusion of NaCap at a concentration of
18 mM result in any significant improvement in absorption parameters of
phenoxymethylpenicillin in humans126.
The mechanism of action for NaCap has been extensively investigated. Interestingly,
NaCap is reported to open tight junctions by activating PLC121,127,128. Long term (> 12 min)
efficacy of NaCap was partially inhibited by U73122, a PLC inhibitor, and by chelating the
increase in intracellular Ca2+, a downstream result of PLC activation. However, the acute effect
(<12 min) caused by NaCap was not diminished by chelating intracellular calcium or by
inhibiting other downstream PLC events121,127, suggesting that the acute mechanism by which
NaCap opens tight junctions is not mediated by PLC activation. Tight-junction associated
proteins F-actin87, ZO-1 and occludin127 were observed to be redistributed after long-term
treatment of Caco-2 cell monolayers by NaCap. After short term treatment with 30 mM NaCap,
claudin-1, claudin-4, JAM, and -catenin as well as F-actin were found to be displaced from
their normal position at the junctional complex in airway epithelial cells101.
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2. Non-amphiphilic polymer PPEs
Another large class of PPEs that can be loosely categorized based on their structural
commonality are those PPEs that are composed of repeating sugar or amino acid monomers.
These molecules can have a relatively large molecular weight compared to the amphiphilic PPEs
and in some cases are not absorbed into the cells to any appreciable extent, but rather initiate
their action externally via interaction with the cell-surface. For example the mucoadhesive
chitosan polymers can have a molecular weight up to 1000 kDa and exert their action through
charge-charge interactions between their cationic moieties and anionic cell surface moieties.
Other polymer PPEs, such as certain toxin-derived peptide fragments like Clostridium
perfringens enterotoxin, have the machinery to gain access into the cell and exert their effect by
binding specifically to the intercellular junctional proteins. The current knowledge of these
diverse molecules will be summarized below under the subheadings entitled mucoadhesive
polymers, peptide fragments of toxins and synthetic peptides with homology to extracellular
loops of junctional proteins.
a. Mucoadhesive polymers
1. Chitosans
Chitosan polymers are natural products derived from chitin, a component of the
exoskeleton of some crustaceans, by partial deacetylation of repeating N-acetamide substituted
1,4-linked -D-glucopyranose units (Table 1.3). The primary amino group that is exposed upon
deacetylation is a key component that confers mucoadhesive properties, as well as improved
aqueous solubility and paracellular permeability enhancing properties to chitosans129.
Depending on the degree of deacetylation obtained, these cationic polymers with molecular
weight between 4.7 and 190 kDa can achieve effective enhancement of hydrophilic molecules
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across Caco-2 cells130,131. For example, 0.3 µM (50 µg/mL) chitosan with a molecular weight of
170 kDa and a 35% degree of acetylation increased mannitol flux 8-fold at pH 5.5130. Due to the
apparent pKa of chitosans that range from 5.6 to 6.5, the pH of the cell culture medium can
change the in vitro effectiveness these PPEs131,132. This has led to derivitization of the natural
chitosans to produce quaternized nitrogen analogs such as N, N, N-trimethyl chitosan (TMC),
which remains cationic and effective even in a neutral pH environment. For example, at a pH of
6.2, both a natural chitosan polymer and its quaternized analog TMC caused a pronounced
reduction in TEER across Caco-2 cells; however, the increase in paracellular permeability was
minimal at pH 7.4 for the natural chitosan analog133. Additionally, confocal laser scanning
microscopy has been used to visualize the distribution of fluorescein isothiocyanate (FITC)
labeled dextrans (4 – 20 kDa, FD4, FD20) in the presence or absence of chitosans in order to
confirm paracellular permeability enhancement. Kotze, et al.133 detected fluorescence only in the
paracellular space after treatment with chitosans and FD4 – FD-20 and therefore concluded that
chitosan primarily increased the paracellular rather than the transcellular permeability of these
hydrophilic compounds across Caco-2 cells.
While chitosans appear to be useful PPEs in vitro, studies in animals have shown variable
efficacy. For example, the systemic availability of the hydrophilic compound atenolol was not
improved in the presence of chitosan at approximately 5-fold higher concentrations than
effective in vitro concentrations, 0.25% (w/v; 250 µg/mL), when perfused at a constant
concentration through rat ileum for 2 h, although the effective permeability coefficient (Peff,
determined based on disappearance of atenolol from the perfusate) was significantly
increased134. These researchers hypothesized that the presence of the anionic mucus layer in the
intestine was preventing chitosan interaction with the epithelial surface, thereby lowering
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efficacy. This hypothesis was confirmed by studies in the mucus-producing cell line HT-29-H,
wherein the permeability enhancing effects of chitosan were reduced compared to mucus-free
monolayers134. In other rat studies, co-administration of the partially quaternized chitosan TMC
at a concentration of 1% (w/v), with the somatostatin analog octreotide directly into the jejunum,
resulted in a 5-fold improvement in bioavailability, from 3% to 16%135. While this improvement
is encouraging, it was modest compared to the 80-fold improvement observed at the same TMC
concentration in vitro in Caco-2 cells135. Even higher concentrations of TMC were injected into
the jejunum of pigs (5-10%, w/v) to affect a slightly greater improvement in octreotide
bioavailability, from 2% in the absence of TMC to 13-25% in the presence of TMC. Similar
improvements in exposure to the peptide drug buserelin were found after intraduodenal co-
administration of 1% TMC to rats, from 0.8% to 6-13%136. So chitosans, like other PPEs, will
require high local concentrations at the epithelial cell surface, which may be achieved in the
future with particulate dosage forms129.
The mechanism of action of the chitosans involves the interaction of the cationic polymer
with the apical cell surface of intestinal epithelial cells. There is some evidence that chitosans
modulate intracellular signaling events, and exert their effect, at least in part, via their influence
on the TJ-structure through these signaling events. For example, they cause PKC activation137,
perhaps leading to the alteration in the distribution pattern of the TJ-associated protein ZO-1 and
occludin, and subsequent disruption of the cytoskeletal F-actin network131,138.
2. Thiolated polymers
Another class of mucoadhesive polymers that have recently been shown to enhance the
permeability of hydrophilic compounds across intestinal epithelium is the thiolated polymers or
thiomers. For these compounds, thiol groups are the active chemical moiety that affects
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mucoadhesive properties and paracellular permeability enhancement. Thiomers are synthesized
by covalent incorporation of cysteine or related molecules into the base polymer. For anionic
polymers such as polyacrylic acid, carboxymethylcellulose or polycarbophil, this is
accomplished through an amide linkage between the carboxyl moiety of the anionic polymer and
the amino group of cysteine, after activation of the carboxyl groups with carbodiimide139.
Alternatively, cationic polymers such as chitosan can be used as the base polymer wherein the
covalent bond is created between the free amino group of chitosan and either the carboxyl of the
thiol-containing compound forming an amide140 or the amino group of the thiol-containing
compound forming an amidine141. Thiomers are thought to be especially helpful for
enhancement of peptide bioavailability, since they not only possess paracellular permeability
enhancing properties, but also have covalent mucoadhesive properties that help to localize the
co-administered peptide to the epithelial surface, and because of their Zn2+ chelating properties,
inhibit proteases that could degrade peptides in the intestinal lumen142.
In vitro evidence for the paracellular permeability enhancing properties of thiomers is
based on Ussing chamber studies using guinea pig intestine as the epithelial model, and sodium
fluorescein or rhodamine as the hydrophilic marker molecules143. In a representative study,
where cysteine was incorporated into polycarbophil at 2.2% of the available sites, a relatively
modest decrease in TEER (to 86% of starting TEER achieved by 60 min after dosing) and an
increase in fluorescein Papp (1.6-fold) were observed using a 0.5% (w/v) thiomer in buffer144. In
addition, a 30% increase in insulin and bacitracin permeability was also observed under these
conditions. While modest, these effects were remarkable in that they were achieved across
epithelial tissue in which the mucus layer, a likely barrier to direct interaction of the thiomer with
the epithelial cell surface, was confirmed to be present.
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Improvement in oral bioavailability of peptides and low molecular weight heparin
(2 - 8 kDa) has been demonstrated after oral co-administration of thiomers to rats and mice. For
example, administration of 5 mg of polycarbophil-cysteine compressed into tablet form along
with glutathione (GSH), which has been shown to enhance the thiomer effect, increased the oral
bioavailability of low molecular weight heparin in rats approximately 3-fold (from 6% to 20%)
relative to that obtained from tablets containing unmodified polycarbophil145. In other studies,
significant pharmacological activity was observed after oral administration of insulin plus
polyacrylic acid-cysteine polymer to diabetic mice146, or after oral administration of salmon
calcitonin plus thiolated chitosan to rats147, whereas control formulations did not result in any
substantial pharmacological effect.
The mechanism of action of thiomers is primarily speculative, based in part on the
enhanced flux of fluorescein across guinea pig intestinal tissue when GSH is co-administered
with the polycarbophil-cysteine thiomer, and the ability of polycarbophil-cysteine thiomer to
increase the amount of reduced glutathione in aqueous solutions148. The authors hypothesize that
the polycarbophil-cysteine thiomer raises the cellular level of GSH resulting in protein tyrosine
phosphatase inhibition. Covalent modification of protein tyrosine phosphatase by GSH and
resulting hyperphosphorylation of occludin, and subsequent opening of the TJs had previously
been postulated by others149. However, further work will need to be done in order to substantiate
the PTP-mediated mechanism of thiomers.
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b. Peptide fragments of toxins
These peptide PPEs are grouped together based on their peptide nature and their origin
from pathological organisms. Interestingly, while the microorganisms that produce them are
potent enterotoxins, the TJ-active components of these toxins have been found to be non-toxic.
Furthermore, they have an apparent selective and reversible action on the TJ proteins, either by
binding the extracellular loops of TJ proteins, as in the case of carboxy-terminal Clostridium
perfringens enterotoxin (c-CPE), or by binding to a cell surface receptor that triggers subsequent
intracellular signaling pathways that directly affect TJ protein localization, as seen with zonula
occludens toxin (Zot).
1. Carboxy-terminal Clostridium perfringens enterotoxin (c-CPE)
Clostridium perfringens enterotoxin (CPE) is a 35 kDa enterotoxin that is associated with
food poisoning in man150. It is thought that the N-terminal region of CPE is primarily
responsible for the cytotoxic effects to intestinal enterocytes by creating pores in the apical
membrane, whereas the 30 amino acid carboxy-terminal fragment of CPE (c-CPE) can interact
with the extracellular domains of tight junction proteins claudins and occludin151 thereby
contributing to the diarrhea seen in afflicted individuals152.
Sonoda et al. demonstrated the ability of c-CPE to induce paracellular permeability
changes in vitro in MDCK cells151. After basolateral treatment with c-CPE (2.5 µg/mL) for 4 h,
they found a 2-fold increase in the permeability of FITC-dextran (FD-4) and an 80% drop in the
original TEER (from 9000 to 2000 ohm*cm2) across MDCK type I cells. A similar percent
decrease in the original TEER (from 180 to 30 ohm*cm2) was reported in Caco-2 cells after
basolateral treatment with a c-CPE concentration of 10 µg/mL153.
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The ability of c-CPE to enhance the in vivo absorption of FD-4 has also been shown in
animals. After bolus administration to a ligated 5 cm segment of rat jejunum, 50 µg/mL of c-
CPE (total dose approximately 40 µg/kg) resulted in a 13-fold increase in the area under the
plasma concentration versus time curve (AUC) of FD-4 over the 4 h treatment period154.
Doubling the dose concentration of c-CPE resulted in a corresponding increase in AUC;
interestingly, doses to ligated colon segments were not effective at all even up to 200 µg/mL.
No measurable toxicity was seen at these doses of c-CPE. While the onset of enhanced FD-4
absorption following jejunal co-administration with c-CPE was slow (approx 90 min required for
significant increase in FD-4 absorption), it was remarkably effective given that no enhancement
was observed in vitro when c-CPE was administered to the apical (luminal) side of Caco-2 and
MDCK cells153.
The mechanism of action of c-CPE has been postulated to involve selective binding to
claudin-3 and claudin-4 (but not claudin-1 or claudin-2), and consequent disruption of the
homophilic interaction of the tight junction strands from adjacent cells151. Furthermore, it has
been shown that the final 16 amino acids are the minimum peptide sequence required for binding
to claudin-4 since deletion of this segment results in lack of binding and subsequent lack of
paracellular permeability enhancing ability of the peptide153. Interestingly, prior to the
identification of the claudin family members, these binding partners for CPE had been
previously identified by other groups and named Clostridium perfringens enterotoxin receptor
(CPE-R; which later became known as claudin-4)155 and rat ventral protstate 1 receptor (RVP1;
which later became known as claudin-3)156. In addition to the use of c-CPE as a PPE, it has
recently been shown in vitro to be a targeted drug delivery tool for certain cancers, such as breast
cancer, that have overexpression of claudin-3 and claudin-4157,158.
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2. Zonula occuldens toxin (Zot)
Vibrio cholorae can produce several enterotoxins that contribute to the severe diarrhea
observed in afflicted individuals. Among these enterotoxins is Zonula occuldens toxin (Zot;
45 kDa), so named for its reversible effects on the zonula occludens or TJ proteins159. Extensive
studies have been conducted to understand the efficacy and mechanism of action for Zot and its
truncated peptide, deletion mutant G-Zot (G-Zot; 12 kDa)160.
Initial in vitro studies were conducted ex vivo with rabbit intestinal tissue in Ussing
chambers. Both insulin (5.7 kDa) and IgG (140 – 160 kDa) flux were significantly enhanced and
TEER was decreased by 20% across jejunal and ileal tissue by incubation with 0.11 nM
(5 ng/mL) Zot in the luminal chamber for 80 min161. Interestingly, no effects were observed in
these studies after similar treatment to rabbit colon tissue161, supposedly due to differences in
tissue distribution of the cell-surface receptor responsible for the initiation of TJ effects162.
In cell culture models that possess Zot receptor (Caco-2, IEC6, but not MDCK and T-84)
the efficacy of Zot to enhance traditional markers of paracellular permeability was also shown.
For example, following a 30-min pretreatment with Zot, 14C-mannitol permeability was
enhanced by 2-, 10- and 15-fold across Caco-2 cell monolayers at concentrations of 1, 2 and
4 µg/mL (approximately 22, 44 and 88 nM), respectively163. Furthermore, larger molecular
weight hydrophilic markers, such as 14C-inulin (5 kDa) and PEG4000 (4 kDa), but not FITC-
dextran 10 (10 kDa), were significantly enhanced by 4 µg/mL Zot, 2.5 h after treatment (30 min
preincubation followed by 2 h flux measurement)163. In this same study, treatment with Zot at 1,
2, or 4 µg/mL for 30 min resulted in a 30% decrease in TEER, regardless of concentration. The
TEER was maintained at the decreased level throughout the 2 h Zot treatment and was fully
reversed 1 h after removal of Zot163.
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Similar in vitro studies with the truncated Zot, G-Zot, have also been conducted164. For
example, following a 30-min pretreatment with G-Zot, 14C-mannitol permeability was
enhanced by 3-fold across Caco-2 cell monolayers at the minimum effective concentration of
100 µg/mL(approximately 8400 nM)165 over a 2 h period. In another study, 14C-inulin
permeability was enhanced approximately 2-fold at a slightly higher concentration of
180 µg/mL166.
Effectiveness of Zot and G-Zot have also been demonstrated in vivo in animal models.
For example, when Zot was perfused through jejunal or ileal segments of anesthetized rabbits at
a concentration of 0.11 nM (5 ng/mL), a 2 – 3-fold increase in PEG4000 or insulin absorption
was observed over the 60 min treatment period161. Furthermore, intraduodenal bolus
administration of G-Zot with 14C-mannitol at a dose of 417 µg/kg (estimated concentration
100 – 200 µg/mL) to rats resulted in a 2.5-fold improvement in mannitol plasma AUC compared
to control, but required inclusion of a protease cocktail in order to gain this effect165. At slightly
higher doses of G-Zot (720 µg/kg), again in the presence of the protease inhibitor cocktail, the
plasma AUC for 14C-inulin was improved 6-fold after intraduodenal administration to rats166.
The mechanism of action of Zot involves binding to the cell-surface Zot receptor162,
followed by increased polymerization of F-actin that is purportedly mediated by PKC167. In
addition to the small intestine, the Zot receptor has been found in brain168 and nasal tissue169, but
not in the colon, lending the possibility of some specificity to the TJ-modulating action of Zot159.
Recent studies have discovered a eukaryotic analog to Zot, zonulin, which is thought to
physiologically regulate the small intestinal epithelial barrier170. Abnormally high levels of
zonulin have been found in animal models of autoimmune diseases, leading to the hypothesis
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that prolonged leakiness of the epithelial barrier may contribute to autoimmune diseases in
genetically susceptible human patients171.
c. Synthetic peptides with homology to extracellular loops of junctional proteins
With the increased knowledge about the composition and regulation of the junctional
protein complex has come the opportunity to target these proteins in a more selective way in
order to increase the absorption of poorly absorbed compounds across the intestinal epithelium.
Indeed, multiple studies have been conducted using peptides with homology to the extracellular
loops of the TJ proteins as tools to understand the nature of TJ protein interactions and the
functional consequences of interference with their normal binding partners. For example,
synthetic peptides homologous to the second, but not the first, extracellular loop of chick
occludin were found to decrease TEER and increase the flux of 3H-mannitol and larger
paracellular markers across developing A6 cell monolayers172. Subsequent experiments with
smaller peptides from different segments also demonstrated the importance of occludin to the
formation of TJs. For example, synthetic peptides homologous to the first and second halves of
the first extracellular loop of human occludin inhibited cell-cell adhesion in an experimental
fibroblast model in which occludin was expressed173; and 8- and 9-mer peptides homologous to
segments of the first external loop of chick occludin slowed the reformation of TJ barrier in A6
cells174. Recently, a 19-mer peptide corresponding to the middle third of the second loop of
human occludin was used to demonstrate selective association of this region of occludin with
claudin-1 and JAM-A in T-84 cells175.
While these studies clearly show that exogenously added synthetic occludin peptides can
modulate the TJ barrier function in vitro, the application of these peptides to improve the
absorption of poorly absorbed drugs is still in its infancy. This is primarily due to factors
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involved in the effective use of peptides such as degradation by peptidases and slow onset of
action due to limited access to the site of action within previously formed TJs.
In an elegant study by Tavelin et al.14, it was demonstrated that many of these factors
could be overcome. Using Caco-2 cell monolayers grown on Transwells® as the model system,
a synthetic peptide homologous to the N-terminal region of the first extracellular loop of
occludin (OP90-103) was found to increase the permeability of mannitol by 5-fold after treatment
at 100 µM concentrations for 4 h, if applied to both the apical and basolateral compartments.
The lack of efficacy of OP90-103 after apical-only application was shown to be due to a
combination of peptidase degradation of OP90-103 and aggregation of OP90-103 into multimers,
which as an aggregate had diminished access to the site of action from the apical versus
basolateral side. In order to address these issues, a lipophilic amino acid conjugate was
synthesized (C14-OP90-103). This molecule, which turned out to be a prodrug for the active OP90-
103 peptide, stabilized OP90-103 against peptidase degradation and rapidly caused dramatic
increases in 14C-mannitol permeability (approximately 15-fold in <30 min) after apical
application of 200 µM C14-OP90-103. Recently, this prodrug has been tested by others and shown
to significantly increase the permeability of larger hydrophilic markers (up to 2000 kDa) across
primary cultures of airway epithelia 60 min after apical application176.
Synthetic peptides to extracellular loops of adherens junction proteins have also been
tested for their ability to improve paracellular permeability across cell monolayers. For example,
synthetic 6-mer peptides with homology to extracellular domain 1 (EC1) of E-cadherin,
gradually decreased the TEER to 60% of the pretreated values over a 2 h period, and increased
the flux of 14C-mannitol by as much as 18-fold across MDCK cell monolayers after apical
treatment with 500 µM concentrations177. Modest changes in TEER and 14C-mannitol flux
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(70 - 80% of pretreated TEER and 4 – 5-fold, respectively) were also observed after treatment
with larger 10-mer peptides, but only if applied to the basolateral compartment178. This finding
led the authors to postulate that the larger 10-mer peptides were not accessible to the adherens
junction from the apical side due to their size.
3. Non-amphiphilic small molecule PPEs
a. Calcium chelators
Ethylene diamine tetraacetic acid (EDTA, Table 1.3) and its analog, ethyleneglycol
tetraacetic acid (EGTA), are non-amphiphilic, multi-anionic chelators of extracellular calcium.
These molecules have been used by cell biologists as tools in the Ca2+-switch assay, an assay that
is used to understand the cellular processes associated with disassembly and reformation of the
junctional protein complex179,180. The Ca2+-switch assay has recently been adapted by
pharmaceutical scientists as a way to understand whether drug candidate absorption is primarily
transcellular or paracellular181. In this application, Ca2+ is temporarily removed (15 -45 min;
2.5 mM EGTA) from the cell culture medium, and then permeability of drug candidates is
assessed. If substantial increases in drug permeability are observed under Ca2+-free conditions,
then it is inferred that the transcellular pathway is a relatively minor pathway compared to the
paracellular pathway181. In addition, EGTA has been used as a tool to quantify changes to the
paracellular space69,79, and to benchmark the magnitude of non-membrane damaging paracellular
permeability enhancement relative to amphiphilic paracellular permeability enhancement119.
When Ca2+ is depleted by effective concentrations of EDTA or EGTA in cell culture
media, cell-cell junctions are reportedly opened by initially removing extracelluar Ca2+ that is
required for homophilic adhesion between the extracellular domains of E-cadherin in adjacent
cells179,182. Subsequent intracellular events also occur including endocytosis of adherens
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junction and TJ proteins (E-cadherin, p120 and-catenin, occludin, JAM-1, claudin-1, claudin-4,
and ZO-1) via a clathrin-mediated mechanism34 that is mediated by the reorganization of apical
F-actin183. Intracellular signaling pathways involving protein kinases184 have been implicated in
the reorganization of TJ and AJ proteins. Thus, while the initial event of chelation of
extracellular Ca2+ may abolish E-cadherin-mediated cell-cell adhesion, subsequent signal
transduction cascades and endocytosis of additional TJ proteins may also contribute to the
opening of the paracellular space.
If titrated carefully with regard to treatment time, Ca2+ chelators at concentrations of
(1 - 5 mM) can increase paracellular permeability without causing gross cytotoxicity. For
example, the permeation of FITC-dextran 4000 was increased approximately 6-fold and TEER
was decreased to 70% of the pre-treatment TEER across Caco-2 cell monolayers after treatment
with 1 mM EDTA185. This effect was fully reversible and did not significantly cause measurable
cytotoxicity to cells185. Interestingly, the enhancement of paracellular permeability is only
significant in the presence of low Ca2+ concentrations in the basolateral compartment. Thus,
Ca2+-free media can be used on the apical side with minimal effect on monolayer integrity and
can be useful when co-administering drugs or PPEs (for example, NaCap) that have lower
solubility in the presence of Ca2+. 87
Clearly, chelators can not be administered to lower Ca2+ levels enough to increase the
paracellular permeability sufficiently in vivo without disrupting a variety of physiological
junctions186. Although not useful clinically, Ca2+ chelators are still useful tools for research into
regulation of paracellular permeability.
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b. Non-amphiphilic phospholipase C inhibitors
Recently, two non-amphiphilic phospholipase C inhibitors, which were originally
investigated as potential cancer chemotherapeutic agents187,188 or anti-inflammatory drugs189,
have been shown to enhance paracellular permeability across MDCK cell monolayers.
Interestingly, both molecules possess moieties in their structure that may act as Michael
acceptors for enzyme nucleophiles188.
The aminosteroid, 1-(6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-
pyrrole-2,5-dione (abbreviated U-73122, Table 1.3), was shown to increase the flux of mannitol
by 10-fold and decrease the TEER by 50% across MDCK cell monolayers at a concentration of
5 µM103. The permeability enhancement profile of U-73122 correlated to its potency to inhibit
the ATP-stimulated phopholipase C activity (i.e., the PLC- activity) in MDCK cells
overexpressing the G-protein coupled receptor P2Y2 receptor103. Furthermore, the actin
cytoskeleton was noticeably changed at concentrations that enhanced paracellular permeability.
Interestingly, the chemical analog U-73343, which lacks the , -unsaturated carbonyl moiety,
did not enhance paracellular permeability nor inhibit PLC- activity at concentrations that were
several-fold higher than that of U-73122103. Thus, U-73122 seems to enhance paracellular
permeability by inhibiting PLC- dependent processes with subsequent changes to the actin
cytoskeleton. Interestingly, the amphiphilic alkylphosphocholine HPC also inhibited PLC-
with subsequent actin disorganization103.
The coumarin derivative, 3-nitrocoumarin (3-NC; Table 1.3), was originally investigated
as a specific inhibitor the PLC- isoform present in human melanoma cell line RPMI7272 for use
as a cancer chemotherapeutic agent188. Recently, 3-NC also was shown to significantly enhance
the paracellular permeability across MDCK cell monolayers. The concentration of 3-NC
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required to increase the flux of mannitol by 10-fold and decrease the TEER by 50% across
MDCK cell monolayers was approximately 30 µM42. At this concentration, 3-NC was also
shown to inhibit the epidermal growth factor (EGF)-stimulated phopholipase C activity (i.e., the
PLC- activity) in MDCK cells, suggesting that inhibition of PLC- was part of the mechanism
of paracellular permeability enhancement42. The actin cytoskeleton appeared more punctate
after treatment with effective concentrations 3-NC42. In addition, 3-NC caused
hyperphosphorylation of TJ proteins, occludin, ZO-1 and ZO-2. Both the hyperphosphorylation
of ZO-2 and the decrease in TEER caused by 3-NC were inhibited by staurosporine, a
serine/threonine kinase inhibitor, suggesting that ZO-2 hyperphosphorylation was associated
with the mechanism of action of 3-NC42. Thus similar to HPC and U-73122, 3-NC also inhibits
PLC. However, it differs from HPC and U-73122 in the specific isoform of PLC that it inhibits,
as well as the downstream events that are affected by its action on TJ permeability42.
E. Reasons for lack of current use in humans
Despite the advances made in understanding of the composition and regulation of the
intercellular junctional complex, and the demonstration that PPEs can enhance the permeability
of hydrophilic solutes in vitro and in vivo in animal models, there has not yet been a PPE that has
been approved for use in humans. Multiple reasons may contribute to the failure to register a
PPE for use in a drug product.
Certainly, amphiphilic PPEs by their chemical nature are likely to lack selectivity for
opening tight junctions. This structural class of PPEs can reversibly open the TJs to improve the
flux of small hydrophilic molecules, however, at slightly higher concentrations membrane
damage can occur. For example, palmitoyl carnitine (alkylphosphocholines) was found to cause
paracellular permeability enhancement across cell monolayers at concentrations of
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approximately 200 µM with minimal damage90, yet at slightly higher concentrations cytotoxicity
was observed88,92. At even higher concentrations that are typically required in vivo in order to
elicit absorption enhancement, concerns about the non-selectivity of amphiphilic PPEs are
magnified. In fact, epithelial damage has been observed in vivo after treatment with PPE
concentrations that enhance the absorption of poorly absorbed compounds190,191.
Peptides that can interact directly with the extracellular domains of transmembrane TJ
proteins occludin and claudins have the potential to be more selective PPEs compared to
amphiphilic PPEs. However, the ability to interact with already formed TJs may slow the onset
of action to open the paracellular space, and many times compounds have been active only when
applied from the basolateral side of monolayers178. Furthermore, the in vivo potency of these
compounds is likely to be reduced due to degradation by intestinal peptidases, as observed with
peptide fragment Zot, thus requiring co-administration of peptidase inhibitors in order to
maintain any effect on TJs166.
The lack of in vivo potency is a common problem with both amphiphilic and non-
amphiphilic PPEs studied to date. Furthermore, the concentrations that are found to enhance the
permeability of hydrophilic solutes in cell culture models are much lower (i.e., PPEs are more
potent) compared to efficacious concentrations that improve the intestinal absorption of poorly
absorbed compounds in vivo. The reasons for poor predictability of in vivo PPE potency based
on in vitro data are not always clear. Like any simplified in vitro model, cell monolayers such as
Caco-2 cells do not possess all of the properties of the intestinal epithelium in vivo. For
example, Caco-2 monolayers resemble colonic epithelia in their relative tightness, whereas other
in vitro models, such as IEC-18 cells or 2/4/A1 cells, better approximate the tightness of the
jejunum73,192. Furthermore, cell monolayers are relatively homogeneous, composed of fully
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differentiated absorptive cells, whereas the intestinal epithelium contains cell types that differ in
their maturity (increasing from crypt to villus) and function. The secretions and endocytic nature
of these other cell types might also influence the permeability of molecules in vivo. For example,
goblet cells, which secrete a protective layer of mucus on top of the epithelium, are not present in
most cell monolayer models used to assess PPE effects. The presence of mucus is a barrier to
the passive diffusion of lipophilic compounds like testosterone193, and appears to be the reason
for the reduced in vivo potency of certain amphiphilic PPEs122, as well as cationic polymers such
as chitosans134. Other confounding factors that affect our ability to assess the in vivo efficacy of
the PPEs include the continual movement, dilution and absorption of administered agents
through the natural processes that occur in the intestine such as peristalsis and intestinal
secretions. This results in PPE concentrations that may be rapidly diluted or depleted. In
addition, the PPE and therapeutic agent are exposed in the gastrointestinal tract to environments
with different pH, high concentrations of bile salts, mucosal enzymes and bacterial microflora.
This highly dynamic setting in vivo is clearly more complex than the controlled, relatively static
setting of the in vitro cell monolayer system. Thus, a potent PPE in cell monolayers may have
less potency in vivo for a multitude of reasons. Understanding these in vitro-in vivo differences is
critical to extrapolating the results obtained with PPEs in cell monolayers to in vivo systems.
Eventually more potent and selective enhancers will be found, however, there is still
concern that even controlled opening TJs will be too detrimental to be used as a drug delivery
tool for hydrophilic drugs. Clearly the TJ barrier function is physiologically important in that it
maintains electrolyte gradients, membrane polarity and keeps macromolecules out of the body.
Indeed, certain intestinal inflammatory diseases are characterized by heightened paracellular
permeability194. While the etiology of intestinal inflammatory disease is still speculative, one
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hypothesis is that patients have abnormally leaky colonic epithelium that allows luminal
bacterial fragments to penetrate into the subepithelial spaces resulting in an inflammatory
response from macrophages or monocytes that reside in the lamina propria195. This hypothesis is
supported by the finding that first-degree relatives of inflammatory disease patients have
heightened paracellular permeability195. However, recent evidence indicates that leakiness in
first degree relatives (i.e., parents, children or siblings) may be due to sub-clinical
inflammation196, and other studies of first degree relatives have not found heightened intestinal
leakiness. Alternate hypotheses for etiology of inflammatory intestinal disease are also equally
plausible, including the dysregulated production of cytokines or matrix metalloproteinases, an
abnormal mucus layer thickness or composition, decreased paneth cell secretions, abnormal
expression of apical transporters such as P-gp and PepT1, or abnormal expression of toll-like
receptors (TLRs)197,198.
Other conditions have been documented to cause TJ leakiness and lead to inflammation.
For example, NSAID enteropathy is hypothesized to be caused by increased paracellular
permeability to luminal toxins resulting in infiltration of neutrophils and subsequent
inflammation199. Pathogens have also been shown to cause epithelial leakiness by attacking TJs
and opening paracellular pathways. For example, it has recently been shown that TJs in lung
epithelia are dissolved by proteases contained in dust mite fecal pellets200. These researchers
hypothesize that the resulting increase in paracellular permeability of this 22 kDa protein
initiates a sensitization that results in an allergic response to dust mites. Based on these
examples suggesting that TJ leakiness, albeit chronic TJ leakiness, leads to inflammatory
conditions, the concern arises that PPE-induced opening of the TJs may also lead to
inflammation.
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A variety of intestinal pathogens are thought to act, at least in part, by disrupting TJs
leading to adverse events such as diarrhea. For example, a protease that has been shown to
specifically degrade occludin with subsequent rearrangement of ZO-1 is a hemaglutenin/protease
protein that is secreted by Vibrio cholerae201. A second toxin secreted by V. cholerae, Zonula
occludens toxin (Zot), interacts with a cell surface receptor that activates intracellular events that
result in TJ disassembly159. The resulting opening of the TJs that is thought to be augmented by
the host analog of Zot, zonulin, is thought to be a protective response to microorganism invasion,
generating a flushing mechanism when TJ permeability is increased202. Interestingly, high levels
of zonulin are also associated with the acute phase of celiac disease203, a condition characterized
by over-reactivity to components in gluten. Other intestinal pathogens cause disruption of the
TJs by different mechanisms. For example, Clostridium difficile inactivates RhoA by
glucosylation, which results in reorganization of F-actin, dissociation of F-actin from ZO-1, and
dissociation of occludin, ZO-1, and ZO-2 from the TJ204. Enteropathogenic E. Coli, also
reorganizes cytoskeletal F-actin, but via phosphorylation of myosin light chain and ezrin, as well
as dephosphorylation of occludin and disassociation of occludin and ZO-1 from the TJ205. JAMs
have been shown to bind to reoviruses and thus are implicated in mediating reovirus infection206.
Similarly, another Ig-like transmembrane protein, CAR, has been implicated in the mechanism
for these pathogens to enter cells, based on the tight binding to them (Kdiss = 1 nM), though it is
not clear how the viruses would access CAR when it is part of the intact TJ207. As noted earlier,
C. perfringens enterotoxin (CPE) targets claudin membrane proteins claudin-3 and claudin-4 as
part of the mechanism contributing to the diarrhea seen in afflicted individuals152.
Intestinal injury can also result in TJ leakiness which may result in absorption of luminal
components such as bacteria or bacterial toxins such as lipopolysaccharide (LPS). For example,
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it has been observed that ischemia can result in increased levels of LPS in systemic
circulation208,209. High levels of intestinally-derived LPS, which are absorbed to a greater extent
across traumatized intestinal tissue, are thought to be the major contributing factor for
endotoxemia or septic shock210.
Thus, disease conditions, pathogens and intestinal trauma have all been documented to
cause abnormally leaky intestinal epithelium which can give rise to adverse events such as
intestinal inflammation, diarrhea or life-threatening conditions such as septic shock. For these
reasons, the purposeful modification of intestinal TJs by PPEs are thought by some to represent a
pathological rather than a pharmacological technology that could lead to these unwanted adverse
conditions.
Furthermore, there is an additional concern that chronic disruption of the TJ fence
function by PPEs could predispose the epithelial cells to become cancerous by allowing the
movement of basolateral protein receptors into regions where they could be exposed to growth
factors that could then induce cell proliferation211. Supporting this hypothesis is the finding that
chronic treatment with agents that increased colonic permeability also gave rise to pre-cancerous
colonic lesions in rats212. In human populations where intestinal epithelium is chronically
injured, as in alcohol abuse, or in chronic inflammatory diseases such as ulcerative colitis, a
higher incidence of cancer is found in the affected tissues of these individuals16.
F. Conclusions and future directions
A tremendous amount of knowledge has been acquired in recent years regarding the
proteins that make up and regulate the intercellular junctional complex. The claudin family of
transmembrane proteins is now understood to be the key transmembrane protein that provides
selectivity to ions that move through the paracellular pathway. As has been shown in the kidney
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nephron, it now seems clear that different expression levels of claudin family members can result
in differential permselectivity to ions. Less is known about how the expression levels of
different claudins might control the passage of solutes, and this will be a key piece of
understanding that will impact the successful implementation of PPE-induced TJ modulation.
The nature of the paracellular pores (or channels) that are formed by the extracellular
domains of TJ proteins continues to emerge. The recent application of a sieving model to
describe the flux behavior of PEG oligomers of differing size has revealed the possibility of two
distinct populations of pores, a relatively abundant restrictive pore that dominates the solute
selectivity of smaller molecules, and a less abundant, non-restrictive pore that allows passage of
larger molecules79,213. This model is particularly intriguing in light of the recent discovery that
the composition and barrier at tricellular TJ is leakier compared to that of bicellular TJ4. The use
of more structurally rigid hydrophilic markers will be helpful to confirm the two pore model of
the paracellular pathway and determine how these pores change in the presence of PPEs.
Gauging the size limitations that exist in opened TJ pores will be particularly important to
determine whether PPE technology can successfully be applied to improve the intestinal
absorption of larger hydrophilic peptide or protein therapeutic agents.
The structural class of PPEs that can loosely be categorized as amphiphilic, which
contains many endogenous molecules and food components, was the first group of PPEs to be
investigated and still is an active area of research. Despite the demonstration of increased
permeability of hydrophilic solutes in vitro and in vivo in animal models, the registration of these
agents for use in humans has not yet been accomplished. Many of these have failed perhaps due
to high concentrations required in vivo and the narrow window of selectivity between TJ opening
and cytotoxicity. Furthermore, the in vivo potency is not well-predicted based on in vitro data,
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suggesting that there has been over-reliance on current in vitro intestinal models to predict in
vivo efficacy of PPEs. Modification of the existing in vitro models to better mimic the in vivo
setting could improve the in vivo predictivity of the in vitro models, and could also lead to PPE
structural modifications that may result in improvement in their in vivo potency.
Non-amphiphilic PPEs demonstrate much less membrane perturbation and typically
lower cytotoxicity, and can also offer additional advantages. For example, the cysteine-
containing mucoadhesive polymers or thiomers demonstrate not only paracellular permeability
enhancing activity, but also have mucoadhesive and protease inhibiting properties which may all
contribute to higher absorption of hydrophilic peptide and protein molecules. Non-amphiphilic
PPEs that act via cell surface receptors, such as Zot, or peptide fragments that interact with
extracellular loops of TJ proteins show greater promise to be TJ-selective. Recent work has
demonstrated that lipophilic prodrugs moieties of TJ peptides have resulted in PPEs that are
more stable to peptidases, and can rapidly open TJs after apical application to cell monolayers14.
While this represents a vast improvement over non-modified TJ peptides, further studies will be
needed to demonstrate the in vivo efficacy of these PPEs. Also showing promise with regard to
greater TJ selectivity are the non-amphiphilic PPEs that inhibit PLC-dependent pathways
(e.g., U-73122). An intriguing implication of this finding is that since PLC activity is regulated
by cell surface receptors such as P2y2, it is conceivable that an endogenous ligand acts to
maintain TJ tone via a cell surface receptor—an interaction that could be selectively modulated
with extracellular antagonists resulting in a selective opening of the TJs.
While the etiology of inflammatory bowel disease is likely to be multifactorial, at least
one possible contributing factor is pre-existing chronic leakiness of the intestinal epithelium,
which results in passage of luminal antigens, or in turn leads to inflammation of intestinal
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tissues. This, as well as the heightened leakiness of traumatized intestinal epithelium that is
known to result in passage of bacterial fragments such as LPS, with life-threatening
consequences due to septic shock, raise concerns that breaching the intestinal barrier by a PPE
may result in absorption of unwanted toxins into the body. However, it is important to note that
these concerns are not founded on published studies wherein PPEs have been shown to cause
systemic toxicity. Furthermore, it is important to balance these concerns based on the purported
role of TJ leakiness in various intestinal pathologies against the knowledge that TJ leakiness
occurs due to normal physiological processes. For example, intestinal TJs are opened to
facilitate the rapid absorption of glucose and amino acids, to allow paracellular passage of
neutrophils or to allow rapid repair of wounded epithelium. Future studies will need to address
whether the perceived danger of increasing absorption of luminal toxins after transient
modification of paracellular permeability through the action of a PPE actually results in adverse
events.
G. Rationale and overview of proposed research
Hydrophilic molecules do not easily cross the intestinal epithelium. One approach to
improve intestinal absorption of hydrophilic compounds is to reversibly modulate tight junctions
by co-administration of a PPE. Currently, there is no enhancer that has shown sufficient potency
or sufficiently low toxicity to be used for this purpose in humans.
The potency of PPEs to open TJs is routinely assessed in cell monolayers such as Caco-2.
However, in order to achieve efficacy in vivo in animal models, much higher concentrations are
typically required versus those that improve the permeability of hydrophilic solutes in vitro; thus,
the in vitro models often overestimate the potency of PPEs being tested. The reasons for this
different potency are not entirely clear; further, the idea that in vitro models overestimate the
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potency is not generally known. Thus, in vitro potency values for PPEs may mislead
investigators into designing studies that would fail to identify potentially useful agents.
Therefore, a primary aim of the proposed research was to evaluate the hypothesis that in vitro
epithelial cell models overestimate (or underestimate) PPE potency because these systems lack
certain in vivo components (Chapter 2). Studies were designed to determine the effect of
intestinal fluid on the mucosal (apical) side, blood components on the serosal (basolateral) side
of monolayers, or gastrointestinal (GI) motility (treatment time and thickness of the unstirred
water layer) on the potency of a small set of known PPEs with diverse chemical structures
(Chapter 2). The observed changes in PPE potency (decrease in TEER and increase in mannitol
flux) due to these biorelevant modifications were examined in the context of how these changes
affect the ability of the enhancers to interact with their cellular targets. For example, the PPE
flux across monolayers as well as the PPE accumulation within the cell, which is typically not
measured in PPE efficacy studies, can potentially provide additional information regarding the
reasons for lack of in vivo potency of PPEs (Chapter 2). Thus, the in vitro evaluation of PPE
potency in these studies, in the presence of in vivo components that are typically absent from
PPE evaluations, and the measurement of corresponding changes to PPE dispositon across the
cell monolayer system represent novel approaches to make better estimates of PPE potency.
Many intestinal pathologies are characterized by a leaky intestinal epithelium that allow
increased penetration of luminal toxins. This has led to the concern that PPE-induced changes to
the intestinal epithelium may also result in increased absorption of unwanted toxins, although
this has not been demonstrated directly. Therefore the second aim of the proposed research was
to investigate whether a PPE-induced increase in paracellular permeability will result in an
increased exposure to bacterial-related products that have been implicated in pathological
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conditions such as inflammatory intestinal disease or intestinal injury (Chapters 3 and 4). Since
many of the existing amphiphilic PPEs are known to have a relatively narrow window between
concentrations that selectively act to open TJs and those that cause membrane damage and cell
death, studies were designed to characterize the cytotoxicity to cell monolayers in the presence
of PPEs and to relate these to the permeability of hydrophilic markers of differing size and to the
permeability of bacterial toxin LPS (Chapter 3). Much of the characterization of the cytotoxicity
of amphiphilic PPEs to date has focused on the assessment of toxicity to cell membranes or cell
energy production. However, the overall gross damage to the cell monolayers caused by PPEs
(e.g., cell sloughing) has not been often quantified. This gross assessment would be particularly
important in understanding the increased flux of relatively large bacterial fragments such as LPS
across cell monolayers. Therefore, a histological technique that could visualize and quantify the
aberrant monolayer area was used to characterize the monolayer damage and relate this
measurement to the increased flux of LPS caused by a single amphiphilic PPE (Chapter 3). This
approach has provided support to the hypothesis that relatively non-cytotoxic concentrations of
PPEs will not result in major increases in toxin flux across cell monolayers.
In order to assess to what extent the in vitro mechanistic studies were relevant to the
conclusions regarding systemic toxicity of PPEs, additional studies were designed using an in
situ rat intestinal model that allowed transient exposure to known concentrations of a single PPE
in an intact animal (Chapter 4). This is particularly important because cell monolayers do not
possess the full complement of cell types that could be involved in an inflammatory response
due to increased absorption of luminal toxins. Studies were designed to establish the minimum
PPE concentration required to improve the absorption of hydrophilic markers, to characterize the
epithelial damage (if any) caused by this concentration of PPE and then to investigate the effects
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of this PPE concentration on the penetration of exogenously administered LPS (Chapter 4).
These studies may provide initial in vivo information on whether transient PPE-induced
improvement in the absorption of probe hydrophilic compounds may also result in non-specific
damage to the epithelium or in an increased intestinal penetration of unwanted luminal toxins.
The overall goal of this research is to identify the deficiencies in the current evaluations
of PPE potency and the safety concerns around PPE modulation of TJs that together may have
negatively influenced the use of PPE technology in humans, and to develop more biorelevant in
vitro models for evaluation of efficacy and toxicity of PPEs. The biorelevant refinements to cell
culture models that are described in this research have the potential for improving the
predictivity of in vitro potency measurements, which are likely to become the foundation for
cellular models implemented for initial PPE evaluations and structure-PPE potency relationships.
Furthermore, these and future biorelevant refinements should be helpful in the design and
evaluation of novel PPEs that have increased potency despite the complex milieu that is present
in vivo in the intestine. This research also describes an investigation into whether a PPE-induced
intestinal leakiness in vitro or in vivo also results in the enhanced absorption of unwanted
luminal toxins that have been implicated in intestinal pathologies. The novel methodology
employed to characterize the efficacy to toxicity continuum of PPE-induced leakiness will be an
important contribution to the evaluation of toxin absorption caused by future PPEs that will have
more TJ-selectivity than the currently known molecules.
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Table 1.1 Relationship between TEER and claudin expression in various epithelial tissues
and cell lines
Classification Epithelial Tissue TEERa
(ohm*cm2)
Claudin
Expressionb
Reference
Very leaky Proximal renal tubule
(rat, rabbit, dog)
6-7 Cln-2, 10, 11
(Mouse, rabbit)
214
Leaky Small intestine, jejunum
(rat)
30-70 Cln-2, 3, 4, 7, 15
(mouse)
64, 65
Small intestine, ileum
(rat, rabbit)
90-100 jejunal Cln, plus
Cln-12 (mouse)
64, 65
Choroid plexus
(frog)
80 Cln-1, 2, 11
(mouse)
215
IEC-18
(rat ileal cell line)
55
2/4/A1
(rat fetal intestinal cell
line)
25 Cln-1, 3 216
Intermediate to
tight
Gallbladder
(Necturus)c
300
Colon
(rabbit, turtle)
290-500 Cln-2, 3, 4, 7, 8, 13
(mouse)
64, 65
Caco-2 
(human, colon cell line)
230-1000 Cln-1, 3, 4 (No
Cln-2)
86, 217
LLC-PK1
(pig, kidney cell line)
170 Cln-2, 3, 4, 7 218
Distal renal
tubule/collecting
duct (rat, rabbit)
150/870 Cln-3, 4, 8 214
MDCK II
(dog, kidney cell line)
150-350 Cln-1, 2, 3, 4, 7 214
Very tight MDCK I
(dog, kidney cell line)
1000-3000 Cln-1, 3, 4, 7
(No Cln-2)
214
Gastric mucosa
(Necturus) c
1700-2200 Cln-3, 5
(rat)
63
Urinary bladder
(rabbit)
5000-10000 Cln-4, 8, Cl-12
(rat, mouse, rabbit)
214, 219
Skin
(frog)
2000-8700 Cln-1, 4
(mouse)
220
aTEER values from reference 221, except distal renal tubule value added from reference 222.
bClaudin expression in tissues may be for different species than reported TEER values, as noted in
parentheses. References for claudin expression are noted in a separate column.
cNecturus is a large American salamander.
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Table 1.2 In vitro potency and putative mechanism of action of representative amphiphilic
PPEs
PPE Structure In VitroPotency
Putative
Mechanism Reference
PCC
N
O
O
O
O
Cl
-
+
0.2mM;
 mannitol
flux
10-fold
Membrane
perturbation; no
effect on actin
organization;
Ca2+
independent
mechanism
90, 97
HPC N O P O
O
O+
-
0.03 mM;
 mannitol
flux
10-fold
PLC
inhibition
leading to actin
disorganization
103
NaTC
Na
+
O
OH
OH
OHNH
S
O
OO
20mM;
 mannitol
flux 5-fold
membrane
perturbation,
alteration of
intracellular
events:  Ca2+,
actin
disbandment
122
NaCap O
O
Na
+ -
10 mM;
 mannitol
flux 8-fold
Activation of
PLC, increased
intracellular
Ca2+
121, 127
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Table 1.3 In vitro potency and putative mechanism of action of representative non-
amphiphilic PPEs
PPE Structure In VitroPotency
Putative
Mechanism Reference
Chitosans
O
O
O
NH3
+
NHOH
OH
*
*
n
O
0.3uM
(170kDa, 35%
degree of
acetylation);
 mannitol
flux 8-fold
mucus adhesion;
apical
membrane
permeability;
actin
depolymerization
; change in ZO-1
localization;
PKC activation
130, 131,
204
EDTA
O
O
O
O
N
Na
+
O
O
O
O
N Na
+Na
+
Na
+
1mM;
 FD-4 flux
6-fold
Extracellular
chelation of Ca2+,
leading to
disruption of
extracellular E-
cadherin
185
U-73122
O
NH
N
O
O 0.005 mM
 mannitol by
10-fold
PLC inhibition
leading to actin
disorganization
103
3-NC
O O
N
+
O
O
0.03 mM
 mannitol
flux 5-fold
PLC inhibition
leading to
hyperphosphoryl-
ation of ZO-2 
42
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Carrier
ParacellularTranscellular
Tight Junction (TJ)
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Metabolism
Efflux
Figure 1.1 Permeability across the intestinal epithelium.
Molecules cross the intestinal epithelium into the blood primarily by three pathways: by
passive diffusion across the cell membranes (transcellular pathway); by passive diffusion
between adjacent cells (paracellular pathway): or by active transport by membrane-bound
transporters (carrier-mediated pathway). Biochemical barriers to transcellular drug
absorption include efflux transporters and metabolizing enzymes.
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Claudins
JAMs
Occludin
Cell 2Cell 1
ZO-1
Actin
Figure 1.2 Schematic representation of the proteins in the TJ and their interactions.
The TJ is currently thought to be composed of transmembrane proteins (claudins, occludin
and JAMs) that interact through their extracellular domains with like proteins in adjoining
cells thereby creating a barrier to paracellular flux of ions and solutes. The cytosolic
domains of the transmembrane proteins are linked to the actin cytoskeleton via scaffolding
proteins (ZO-1, ZO-2, ZO-3, MAGI, PAR-3, PAR-6 or MUPP-1). Adapted from references
27, 221, 223.
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Figure 1.3 Schematic representation of signaling pathways involved in dynamic regulation
of the intercellular junctional complex.
Following an external cellular stimuli, a variety of intracellular signaling pathways may be
activated which may result in reversible changes to the phosphorylation state of intercellular
junctional proteins and/or modification of the apical F-actin ring. See text for further details.
CHAPTER 2
BIORELEVANT REFINEMENT OF THE CACO-2 CELL CULTURE MODEL TO
ASSESS EFFICACY OF PARACELLULAR PERMEABILITY ENHANCERS
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Abstract
Previous studies have demonstrated the ability of paracellular permeability enhancers
(PPEs) to selectively open tight junctions in Caco-2 cells. The purpose the present work was to
investigate how biorelevant refinements to the Caco-2 cell model impact the in vitro paracellular
permeability enhancing effect (decrease in transepithelial resistance (TEER) and increase in
mannitol Papp) of PPEs. Standard transport buffer was replaced by fasted-state simulated
intestinal fluid (FaSSIF) in the apical compartment or serum in the basolateral compartment, or
stirring was performed to decrease the thickness of the unstirred water layer. FaSSIF
significantly reduced the paracellular permeability enhancing potency of palmitoylcarnitine
chloride (PCC) and hexadecylphosphocholine (HPC), and reduced the amount of these PPEs in
cell extracts, measured using LC-MS, relative to standard conditions. In contrast, FaSSIF did
not reduce the potency of sodium caprate (NaCap), ethylenediamine tetraacetic acid (EDTA) or
3-nitrocoumarin (3-NC). Basolateral serum increased the flux of PPEs by several fold, but did
not dramatically lessen their potency. Stirring increased the flux of all PPEs, and also reduced
the potency of PCC and HPC. The modified conditions were applied to the novel PPE (2R,3Z)-
2-(decanoylamino)-8-phenyl-3-octen-1-yl methyl phosphate lithium salt (GW4936), with
somewhat different effects compared to known PPEs. These data demonstrate the importance of
including intestinal fluid and agitation in order to better predict the in vivo potency of PPEs. We
conclude that the contents of intestinal fluid may reduce the access of some amphiphilic PPEs to
the intestinal epithelium and thus contribute to the lack of in vivo potency of these PPEs.
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Introduction
The oral route is the preferred route of administering drugs. However, orally
administered drugs may exhibit poor bioavailability because they are not able to traverse the
intestinal epithelium. The intestinal epithelium is composed of individual cells that are joined to
each other at the luminal side of their membrane by junctional complexes. The role of the
luminal cellular membranes and the intercellular junctional complex is to allow beneficial
nutrients, ions and water to be absorbed into the body while at the same time keeping the
potentially harmful external chemicals and toxins out of the body. Thus, the intestinal
epithelium may pose a significant barrier to drug molecules if their physico-chemical properties
are not favorable. For example, drug molecules that have a hydrophilic nature, containing too
many hydrogen bond donor or acceptor moieties, presence of a charged moiety, or a large polar
surface area, may not partition well across the lipophilic cell membranes. Therefore, they are
relegated to cross the intestinal epithelium via the aqueous paracellular pathway, which is
inefficient due to the relatively low surface area and strict regulation by the tight junctions (TJs).
In order to improve intestinal absorption, hydrophilic molecules may be modified to
increase lipophilicity, for example, by minimizing the hydrogen binding sites. However, these
modifications may lead to loss of pharmacological activity. Thus a more attractive chemical
modification is the transient addition of lipophilicity or addition of a structural component that
will make the molecule a substrate for a membrane uptake carrier, which is cleaved upon
absorption. These prodrug strategies have been used successfully. For example, oral
administration of the lipophilic prodrug enalapril improved the oral absorption of the hydrophilic
therapeutic agent enalaprilat1, and the oral absorption of acyclovir was improved by synthesizing
the prodrug valacyclovir, which is a substrate for intestinal peptide uptake transporters2,3.
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An alternative approach to improve oral absorption of poorly absorbed compounds is to
modify the intestinal barrier itself by use of a paracellular permeability enhancer (PPE). In this
method, cell-to-cell tight junctions are transiently and selectively loosened by co-administration
of a PPE, which opens the paracellular space to allow greater absorption of the poorly absorbed
molecule. This technique has advantages over the prodrug approach since it could be applied
generically to many hydrophilic compounds, including small molecules, as well as larger
peptide-containing molecules. Furthermore, since molecules remain in the paracellular spaces,
they would bypass the intracellular metabolizing enzymes and the mucosal membrane efflux
transporters that can pose a formidable biochemical barrier to transcellularly absorbed
molecules4.
Molecules of widely different chemical structures and mechanisms of action have been
employed to improve the oral absorption of poorly absorbed compounds by opening the
paracellular pathway. The PPEs studied to date may be loosely classified based on their
chemical structure into either amphiphilic or non-amphiphilic classes. The amphiphilic PPEs are
likely to act in part by perturbing the cellular membrane. This perturbation may lead to
downstream modulation of membrane associated proteins such as protein kinase C5,6, which may
in turn affect the phosphorylation state of the tight junction proteins resulting in opening of the
TJ complex7. The non-amphiphilic class of molecules includes some small molecules, such as
the chelating agent EDTA or the phospholipase C (PLC) inhibitor 3-NC, but also structurally
diverse polymers, such as chitosan8, or peptides and proteases that bind to the cell surface or the
extracellular loops of TJ proteins, resulting in disassembly or degradation of TJ proteins9,10.
The ability of PPEs to improve the intestinal absorption of hydrophilic compounds has
been studied in vivo using animal models, and in vitro using cell culture systems. The advantage
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to using animal models is that the in vivo complexity is intact, and therefore a molecule that is
effective in animals is more likely to be effective in humans. However, these studies are fairly
labor intensive, and furthermore, if the PPE is not effective in vivo, then the reasons for lack of
efficacy are hard to trace. The cell culture model, on the other hand, is less complex, easily
manipulated and less labor intensive, and therefore can be used to study structure-activity
relationships of large numbers of chemically-related PPEs or to study mechanisms of action.
The effective concentration of a PPE in cell culture models is typically much lower
compared to that found to increase absorption of hydrophilic molecules in vivo in animal models.
For example, PCC was effective in vitro at a concentration of 200 µM11, however, 10 to 100-fold
higher concentrations were required to achieve significant in vivo absorption improvement12. We
hypothesized that the in vitro epithelial cell model may be overestimating PPE potency since this
system lacks certain in vivo components, for example intestinal fluid on the mucosal (apical) side
or blood on the serosal (basolateral) side of monolayers. Indeed, the presence of simulated
intestinal fluid or serum components in place of balanced salt solutions has been shown to
impact the permeability of certain drug molecules across cell monolayers13,14. Furthermore, the
typical in vitro 60 min PPE treatment time may also result in an overestimation of PPE potency
since the actual time that a PPE would be in contact with a particular segment of the small
intestine due to gastrointestinal (GI) motility is estimated to be less than 15 min15. Alternatively,
GI motility may reduce the thickness of the unstirred water layer (Hw) relative to that of an
unstirred in vitro cell monolayer system, which may result in enhanced in vivo potency of certain
PPEs whose access to the cells is limited by Hw. Another parameter that may contribute to
overestimation of PPEs in vitro is that Caco-2 cells more closely resemble colonic epithelia in
their relative tightness, as evidenced by relatively high TEER and low permeability of
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hydrophilic paracellular markers compared to cell monolayers derived from small intestine
origin16. This may lead to a greater fold-increase in flux of paracellular markers or a larger
decrease in TEER due to PPE treatment17.
Given the lack of certain in vivo components in the in vitro cell culture model, we
wondered if we could improve the in vitro evaluation of PPE potency by implementing modified
conditions that would address these deficiencies. The objective of this study was to
systematically introduce modifications to the cell culture model that would address the perceived
deficiencies, and evaluate the impact of these modifications on the potency of structurally and
mechanistically diverse PPEs. Three modifications were examined: standard buffers were
replaced with simulated intestinal fluid on the apical side of monolayers, serum on the
basolateral side of monolayers, or monolayers were agitated at different rates to change the
unstirred water layer thickness (Hw). In order to further substantiate the observed changes in
PPE efficacy, the disposition of the PPEs across the cell monolayer system was assessed using
LC-MS.
Methods
Materials The synthesis of 3-NC was as described previously18. GW4936 was provided by
GlaxoSmithKline. D-(1-14C)-mannitol (55 mCi/mmol) was purchased from American
Radiolabeled Chemicals, Inc. (St Louis, MO). EDTA was obtained from USB Corp (Cleveland,
OH). Other chemicals and reagents, including PCC, HPC, NaCap, phosphatidylcholine,
taurocholate, Hanks’ balanced salt solution, HEPES buffer, and glucose were purchased from
Sigma Chemical Co. (St Louis, MO). Cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). Transwellswere purchased from Corning Costar (Cambridge, MA). Fasted-
state simulated intestinal fluid (FaSSIF) was prepared as previously reported19. The mixture
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contained 3 mM sodium taurocholate and 0.75 mM phosphatidylcholine in a buffered, isosmotic
sodium salt solution (pH 7.1). Male human serum was obtained from Bioreclamation, Inc.
(Hicksville, NY). The thawed serum was filtered through a 0.22 µM filter and adjusted to pH
7.1 immediately prior to use.
Cell Culture The Caco-2 cell line was obtained from American Type Culture Collection. Caco-2
cells were grown in 75 cm2 tissue culture flasks in the presence of cell culture medium,
(minimum essential medium (MEM) with Earle’s salts, 10% (v/v) fetal bovine serum, and 1:100
dilutions of 100X stock solutions of non-essential amino acids and antibiotic-antimycotic
(penicillin G, streptomycin, amphotericin B)). Cells were passaged approximately every four
days. At approximately 90% confluency, the cells were detached using 0.05% trypsin containing
EDTA. Cells between passage numbers of 26 and 40 were used for transport studies, except
when noted otherwise. The cells were seeded at a density of 120,000 cells/cm2 on polycarbonate
membranes of Transwell™ cell culture inserts (pore size 0.4 µm, diameter 1 cm2). Cell culture
medium was replaced every second day. Cells were considered fully differentiated and ready for
PPE experiments after 21-days. TEER values of mature cell monolayers were between 300 and
600 ohm*cm2, as measured using Endohm Voltohmmeter (World Precision Instruments,
Sarasota FL) after correction for filter resistance.
Evaluation of paracellular permeability enhancement The ability of the selected PPEs to
modulate paracellular permeability was measured after treatment of cell monolayers on the
apical side of the Transwell™ compartment with increasing concentrations of PPEs. Two
parameters were measured: 1) a decrease in TEER measured at the end of the treatment period;
and 2) an increase in the amount of the paracellular marker compound mannitol appearing in the
basolateral side during the PPE treatment period.
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Prior to the addition of PPEs, cell monolayers were equilibrated for approximately 60
min in transport buffer (Hanks’ balanced salt solution supplemented with 25 mM D-glucose and
25 mM HEPES, pH 7.1) at 37ºC. At the end of the equilibration period, TEER was measured
using Endohm Voltohmmeter maintained at 37ºC with slide warmer. This measurement was
defined as initial TEER. Measurements of changes to cell monolayers due to PPE treatment
were initiated upon replacement of the apical transport buffer with dose solutions (0.4 mL)
containing 14C-mannitol and the PPE dissolved in transport buffer, which was modified slightly
to improve stability. For amphiphilic compounds, 1% FaSSIF (v/v) in transport buffer was used
to stabilize dose preparations. Dose solutions of NaCap were prepared in Ca2+-free transport
buffer. Dose solutions of 3-NC were prepared in transport buffer adjusted to pH 5.6. These
modifications were included in control wells and did not adversely affect the integrity of the
monolayers. The basolateral compartment contained 1.5 mL of pre-warmed transport buffer.
14C-mannitol that had accumulated in the basolateral compartment over the entire treatment
period was quantified by mixing 0.5 mL aliquots with 5 mL of UniverSolES scintillation fluid
(ICN, Costa Mesa, CA). Radioactivity in each sample was measured in a Tri-Carb 2500TR
scintillation spectrometer (Perkin-Elmer Life and Analytical Sciences, Boston, MA).
The effect of FaSSIF on the ability of the PPEs to increase paracellular permeability of
mannitol or decrease TEER was determined by preparing dosing solutions of each PPE in
FaSSIF rather than standard transport buffer. Control monolayers for this condition contained
FaSSIF without PPE in the apical compartment. Other procedures were the same as those
described above for standard conditions.
The effect of human serum on the ability of the selected PPEs to increase paracellular
permeability of mannitol or decrease TEER was determined by putting 1.5 mL of serum in the
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basolateral compartment rather than standard transport buffer. Control monolayers for this
condition contained standard transport buffer without PPE in the apical compartment and serum
in the basolateral compartment. Dosing solutions of PPEs as well as other procedures were the
same as those described above for standard conditions.
The effect of stirring and the associated changes to the unstirred water layer (Hw) on the
paracellular enhancing ability of the selected PPEs were determined in separate experiments in
the presence of standard transport buffer. The unstirred water layer thickness (Hw) was reduced
by agitating monolayers on a rotary shaker (Lab-line Model 3520 Orbit Shaker) at low (80 rpm),
moderate (120 rpm) and high (160 rpm) speeds in the presence of increasing concentrations of
PPEs. The marker compound 3H-testosterone (100 µM) was used to calibrate the change in Hw
at each stirring rate as described previously20,21 using the equations shown below. In order to
simulate the transient exposure to a particular intestinal segment, the duration of PPE treatment
was reduced to 15 min. Control monolayers for this condition contained standard transport
buffer without PPE in the apical compartment and were agitated at the same speeds as PPE-
treated monolayers. Dosing solutions of PPEs were prepared in the same manner as described
for standard conditions.
PPE disposition across cell monolayers In order to further substantiate the observed changes in
PPE potency due to biorelevant refinements, the disposition of the PPEs across the cell
monolayer system was assessed under standard and modified conditions. At the end of the
treatment period, aliquots of apical and basolateral compartments were mixed with ethanol and
were centrifuged at 14,000 rpm (20,800xg) for 3 min as necessary in order to remove
precipitated components prior to analysis by LC-MS as described below.
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Measurement of PPE that was associated with cell monolayers was accomplished by
rinsing the cell monolayer once with cold transport buffer, followed by excising the filter-
monolayer from the plastic support and immersing in 1 mL of ethanol. The sample was vortexed
and sonicated briefly to lyse cells. Aliquots of the cell extract were further diluted with ethanol
and analyzed by LC-MS as described below.
LC-MS Analysis of PPEs Separation of PPEs from buffer components was accomplished with
an Agilent high performance liquid chromatograph (LC, Palo Alto, CA) using a Phenomenex
C18 Luna column (2 x 100 mm, 3 µm particle size), and a mobile phase consisting of acetonitrile
and 13 mM ammonium formate (pH 3.5) (or ammonium acetate (pH 6.8) for NaCap analysis) at
a flow rate 0.3 mL/min. The percentage of acetonitrile was changed over a 2-3 min linear
gradient so that the PPEs were retained on the LC column for 4-6 min. This retention allowed
the first 3 min of eluate to be diverted to waste. PPEs were detected using a Sciex API 100 mass
spectrometer (Applied Biosystems, Foster City, CA) equipped with a Turboionspray interface
operated in the positive ionization mode, except for NaCap, which was detected in negative
ionization mode. Nitrogen was used as both the sheath and drying gas at a pressure of 10
arbitrary units and a flow-rate 7 L/min, respectively. The spray voltage was set at 5.0 kV and the
drying gas temperature was set at 425°C. Declustering potential (DP) and focusing potential (FP)
were optimized at 25 and 225 V, respectively. For some analyses, an Agilent mass selective
detector equipped with an electrospray interface was used, with nitrogen as the drying gas at a
flow-rate 12 L/min and temperature of 350°C. The nebulizing pressure was set at 35 psig. The
capillary voltage was set at 4.0 kV. The fragmentor voltage was set at 100 V and the dwell time
was 1000 msec. The elution of each PPE was monitored by single ion monitoring (SIM) for the
M+H+ ions at m/z 400.5 (PCC), 408.5 (HPC), 468.2 (GW4936), 192 (3-NC), and M – H ions for
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NaCap at 171. Mass/charge peak area was quantified using calibration standards with known
PPE concentrations prepared in blank matrix. LC-MS analysis was successfully conducted on
PCC, HPC, NaCap, 3-NC and GW4936. EDTA was not suited to LC-MS measurements, and
therefore not included in the PPE disposition studies. 3-NC samples were acidified after
collection to pH 2 in order to prevent degradation of the compound. Basolateral PPE
concentrations were input into equation (1) to calculate Papp values for each PPE.
Calculations. TEER was measured across control and PPE-treated monolayers at the end of the
treatment period. The change in TEER due to PPE-treatment is normalized to the change in
TEER measured across control monolayers (% control). The % control TEER values for
individual wells were plotted versus PPE concentration, and fit to a four parameter Hill model
with power-of-the-mean variance. The median EC50 TEER, which is defined as the PPE
concentration which decreases TEER to 50% of the control TEER value, was estimated from the
fitted curves.
The amount of 14C-mannitol appearing in the basolateral compartment at 37ºC from t=0
to t=T after each treatment condition was used to calculate the mannitol apparent permeability
coefficient (Papp) according to equation (1),
Papp = dQ/dt * 1/(A)*1/(C0) units = nm/sec (1x10-7 cm/sec) (1)
where dQ/dt is the amount Q of mannitol measured in basolateral compartment after time T, A is
membrane surface area and C0 is the initial concentration of compound.
The marker compound 3H-testosterone was used to calculate Hw at different stirring
speeds. In order to insure sink conditions were maintained over the experimental period, the
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apical compartment was transferred to naïve basolateral solutions at 5 min intervals up to 20
min. The testosterone flux was obtained from a linear fit of the testosterone amount versus time
plot and input into equation (1) to obtain a Papp value for testosterone at each stirring speed. The
testosterone Papp values at stirring rates of 40, 80, 120, 160 and 180 rpm were input into
equations (2) – (5) to determine Hw,
Rapp = 1/Papp = 1/PW + 1/Pc + 1/Pf (2) 
 1/Pf = Hf / (n *  * rp2 * Daq) (3) 
 1/Pw = 1/KV0.8 = Hw / Daq (4) 
 1/Papp = 1/KV0.8 + (1/Pc + 1/Pf) (5) 
 
where the apparent resistance (Rapp) to testosterone flux across the monolayer system is equal to
the reciprocal of apparent permeability (Papp) of testosterone. Papp is comprised of sum of the
permeability across the unstirred water layer (PW), the cell (Pc), and the filter (Pf), respectively.
The 1/Pf may be determined from equation (3), where Hf is the thickness of the filter (10 µm), n
is the number of pores per filter area (1 x 108/cm2), rp is the pore radius (0.2 µm), and Daq is the
aqueous diffusion coefficient for testosterone (7.8 x 10-6 cm2/sec).20 The 1/PW is equal to a 1
divided by constant (K) comprised of the Daq, buffer viscosity and geometrical factors of the
Caco-2 cell model times the rate of stirring, V, in terms of rpm, raised to the 0.8 power21.
Substitution of equation (4) into equation (2) yields equation (5) from which the term Pc may be
derived from a plot of 1/Papp versus V0.8. Substitution of Pc and Pf into equation (2) allows
calculation of Pw. Using the relationship between Daq and PW in equation (4), the desired term
Hw may be obtained at each stirring rate.
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Data Analysis Data are expressed as mean ± standard deviation (SD) from at least three
measurements. Statistical significance for all studies, except EC50 TEER comparisons, were
evaluated using a two sample Student’s t test. The samples were assumed to have unequal
variance. Significant differences were assigned at p<0.05. For comparisons of EC50 TEER in
standard versus modified conditions, Bayesian methodology was employed. A four-parameter
Hill model was fit to the dose-response data. Because there was no prior information (a
necessary component for Bayesian modeling), normally distributed priors with extremely large
variances were used, which is nearly non informative. The model was used to back-calculate the
PPE concentration, that yields a TEER value of 0.5 (i.e., EC50 TEER). The Bayesian modeling
method produces a posterior distribution for the set of parameters, which can be used to draw
inference about the EC50 TEER. The median fold difference between the EC50 TEER values for
standard and modified conditions were determined along with 95% Bayesian credible intervals
(i.e., the fold difference is inside the interval with 95% probability). If the median fold
difference for no effect (i.e., fold difference = 1) was not within the 95% Bayesian credible
intervals for fold differences, the fold difference result was considered significant.
Rationale for the selection of the paracellular permeability enhancer test set
Five PPEs with well-established paracellular permeability enhancing properties were
chosen to test the refinements to the Caco-2 cell model. The PPEs were selected in order to
represent the diverse chemical space of PPEs studied to date, as well as the multiple mechanisms
by which PPEs act to open tight junctions.
Many PPEs are amphiphilic molecules. HPC, PCC and NaCap were selected to represent
this class of PPEs (Figure 2.1). HPC and PCC both possess a zwitterionic polar head group (left
hand side of molecules as depicted in Figure 2.1) and a 16-carbon non-polar tail, however they
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differ in the chemical nature of the head group; HPC has a phosphocholine head group while
PCC has a carnitine head group. NaCap further deviates structurally from the other two
amphiphilic PPEs, possessing a shorter alkyl chain and an anionic carboxylic acid head group.
PCC has been shown to alter the membrane fluidity of cell monolayer systems22. In contrast,
HPC has been found to have little impact on membrane fluidity23, and in other studies was found
to inhibit the signaling enzyme PLC resulting in actin disbandment24. PCC does not affect actin
organization11. Interestingly, NaCap has been reported to open tight junctions by activating
rather than inhibiting PLC25,26. Long term (> 12 min) efficacy of NaCap was partially inhibited
by U73122, a PLC inhibitor, and by chelating the increase in intracellular Ca2+, a downstream
result of PLC activation. However, the acute effect (<12 min) caused by NaCap was not
diminished by chelating intracellular calcium25,26or by inhibiting other downstream PLC events,
suggesting that the acute mechanism by which NaCap opens tight junctions is not mediated by
PLC activation. So while the mechanism(s) of action are not entirely clear, the ultimate effect
that HPC, PCC and NaCap exert on cells to cause opening of the tight junction proteins is quite
different. The reported potencies of these three amphiphilic PPEs extend over two orders of
magnitude (Table 2.1).
EDTA and 3-NC were selected to add further diversity to the PPE test set. EDTA and its
analog ethyleneglycol tetraacetic acid (EGTA) are non-amphiphilic, multi-anionic chelators of
extracellular calcium, and reportedly open cell-cell junctions by initially removing extracelluar
calcium from adherens junctions resulting in loss of adhesion between e-cadherin proteins in
adjacent cells27,28. EDTA and EGTA are widely used to transiently open epithelial junctions to
study the paracellular transport of drugs29 and to study mechanisms of tight junction assembly30.
The recently discovered, non-amphiphilic PPE 3-NC is the only PPE in the test set that is not
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charged at physiological pH. It purportedly opens tight junctions via inhibition of PLC
resulting in altered phosphorylation of the tight junction protein ZO-2. Thus similar to HPC,
3-NC also inhibits PLC. However, it differs from HPC in the specific isoform of PLC that it
inhibits, as well as the downstream tight junction or cellular proteins that it impacts18. The
potency of 3-NC is similar to that of HPC, and approximately 30-fold more potent than the other
non-amphiphilic PPE EDTA18,31.
Results
PPE potency in Caco-2 cells using standard conditions
The effect of the amphiphilic PPEs, HPC, PCC and NaCap, as well as the two non-
amphiphilic PPEs, EDTA and 3-NC, on TEER and mannitol permeability across Caco-2 cell
monolayers is shown in Figure 2.2. After 60 min incubation with HPC, monolayer resistance
was reduced and the apparent permeability coefficient (Papp) of 14C-mannitol was increased in a
dose dependent manner. A much larger increase in mannitol Papp was observed over the
60 - 120 min period after HPC treatment (data not shown). Over the same concentration range,
PCC caused a decrease in TEER at slightly lower concentrations, as well as a greater increase in
mannitol Papp compared to HPC-treated cells. The maximum increase in mannitol Papp caused
by 500 µM PCC was approximately 10-fold above that in control monolayers. NaCap required
much higher concentrations to produce decreases in TEER and increases in mannitol Papp, with
significant changes occurring after a apical concentration of approximately 10 mM. Thus, the
rank order of potency for the amphiphilic PPEs in Caco-2 cell monolayers under standard
conditions was PCC>HPC>NaCap.
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The non-amphiphilic compound EDTA, when applied to both the apical and basolateral
compartments for 60 min caused increases in mannitol Papp beginning at 2 mM, with a
maximum increase of approximately 5-fold. Higher concentrations of EDTA up to 20 mM did
not cause any further increase in mannitol Papp or decrease in TEER (data not shown). When
3 NC was applied in modified transport buffer (pH 5.6), it caused a 3-fold increase in mannitol
Papp at the highest concentration tested (600 µM), with a decrease in TEER to approximately
35% of TEER in control monolayers. Thus, 3-NC is slightly more potent than the other non-
amphiphilic compound EDTA under standard conditions.
PPE potency in Caco-2 cells using biorelevant conditions: Fasted-state simulated
intestinal fluid (FaSSIF) in the apical compartment
In order to simulate the GI environment present in the lumen of the upper small intestine,
an isosmotic phosphate buffer solution that contained 3 mM taurocholate and 0.75 mM
phosphatidylcholine was used in the apical compartment of Caco-2 Transwell™ model system in
place of standard transport buffer. This proportion of taurocholate and phosphatidylcholine has
previously been reported to be a good mimic of fasted-state intestinal fluid19, and has also been
shown to be non-toxic to Caco-2 cell monolayers32. When FaSSIF alone was applied to the
apical side of Caco-2 cell monolayers, a drop in TEER of approximately 20% was observed
(data not shown). This drop in TEER due to FaSSIF has been observed by others and has been
explained to be due to differences in the salt composition of FaSSIF compared to that of the
transport buffer solution on the basolateral side of the monolayer32.
When solutions of PCC were prepared in FaSSIF rather than in the standard dosing
vehicle, much higher PCC concentrations were required to cause the same magnitude in TEER
decrease (Figure 2.3A). The EC50 TEER, which is defined as the enhancer concentration that
decreases the TEER to 50% of the TEER measured in control monolayer, increased from
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approximately 160 µM in the standard dosing vehicle to 2000 µM in the presence of 100%
FaSSIF in the apical compartment. When the effect of PCC on TEER was examined at 250 µM
in different dilutions of FaSSIF, it was clear that FaSSIF, even at 25% (v/v) concentration, did
not allow PCC to exert any effect on Caco-2 cell monolayers (Figure 2.3B). Partial effect of
PCC was observed at 10% (v/v) FaSSIF concentration, and only at 1% (v/v) FaSSIF
concentrations did PCC exert its full effect. The data on the percentage of PCC dose that was
associated with the cells show that FaSSIF, at 10% (v/v) and higher concentrations, sequesters
PCC, thus reducing its cell-associated concentrations by as much as 3-fold at 100% FaSSIF
(Figure 2.3B). .
The effect of FaSSIF on the EC50 TEER of all the PPEs examined in this study is shown in
Table 2.2. FaSSIF had no effect on the two non-amphiphilic PPEs, EDTA and 3-NC. FaSSIF
had a modest effect on the efficacy of HPC while for the structurally similar PCC, FaSSIF
reduced efficacy by > 10-fold. Consequently, HPC, which was approximately half as potent as
PCC in the standard buffer, was > 3-fold more potent than PCC in 100% FaSSIF. Although
NaCap is amphiphilic, FaSSIF had no effect on its potency, presumably because NaCap was
tested at much higher (millimolar) concentrations relative to the affected PPEs, and thus
sequestration by FaSSIF may not be as effective.
At concentrations approximately equivalent to EC50 TEER, the PPEs caused significant
increases in the permeability of mannitol, a paracellular marker (Figure 2.4). The enhancement
of the mannitol permeability caused by HPC and PCC, prepared in standard transport buffer was
completely eliminated when dose solutions were prepared in 100% FaSSIF. NaCap and the non-
amphiphilic compounds EDTA and 3-NC, on the other hand, remained fully effective as
enhancers of mannitol permeability even in the presence of 100% FaSSIF. In fact, the increase
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in mannitol Papp resulting from apical and basolateral treatment with 2 mM EDTA seemed to be
enhanced 3-fold in the presence of FaSSIF. The reason for this FaSSIF-induced enhancement of
mannitol Papp by EDTA is unknown.
Consistent with the observed changes in potency, the amount of HPC and PCC in cell
extracts was significantly reduced in the presence of FaSSIF (Inset Figure 2.4). However, no
change in the amount of 3-NC or NaCap in cell extracts was observed. These data suggest that
FaSSIF decreased the potency of HPC and PCC by their incorporation into the
taurocholate-phosphatidylcholine mixed micelles of FaSSIF thereby reducing their access to, and
their accumulation in the cell.
PPE potency in Caco-2 cells using biorelevant conditions: Serum in the basolateral
compartment
In order to simulate the in vivo environment on the serosal side of the small intestine,
human serum was used in the basolateral compartment of Caco-2 monolayers grown on
Transwells™ in place of aqueous transport buffer. This condition by itself did not change the
TEER or mannitol permeability across the cell monolayers.
Since many of the PPEs tested in this study are lipophilic and could potentially be bound
by serum components, it was important to first examine whether serum in the basolateral
compartment would impact the disposition of the PPEs. As shown in Table 2.3, the
transepithelial Papp values of HPC and PCC in the presence of standard buffer were quite low
compared to NaCap and 3-NC. However, in the presence of serum in the basolateral
compartment Papp values of HPC, PCC and NaCap were increased several fold. The increase in
NaCap Papp should be interpreted with caution since NaCap was observed to precipitate on the
basolateral side of the filter membrane in standard transport buffer, which could have artificially
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lowered the Papp value in standard buffer. NaCap crystal deposits were not observed on the
filter membrane in the presence of serum.
The disposition of PPEs in the Transwell™ system was further examined by measuring
the amount of compound associated with the cell monolayers. Despite the increase in PPE Papp
in the presence of serum in the basolateral compartment, there was no change in the amount of
HPC and PCC that was associated with the cells (Table 2.3). The cell association of NaCap and
3-NC was significantly reduced by the presence of serum in the basolateral compartment.
However, the decrease in cell-association of NaCap could be accounted for by the NaCap that
was associated with the bottom of the filter itself due to precipitation in calcium-containing
transport buffer (data not shown).
Despite the increase in Papp for HPC and PCC, or the decrease in cell association for
3-NC, these PPEs remained fully effective in the presence of serum in the basolateral
compartment as evidenced by their ability to increase the Papp of mannitol (Table 2.3). In
addition, serum did not significantly impact the ability for EDTA or NaCap to increase the Papp
of mannitol. Thus, the paracellular permeability enhancing potency for all five of the PPEs
tested were unaffected by the biorelevant modification of serum in the basolateral compartment.
PPE potency in Caco-2 cells using biorelevant conditions: Modulation of the unstirred
water layer thickness
GI motility can decrease the unstirred water layer thickness (Hw) and contact time of a
compound at a given intestinal absorption site. Both these parameters can affect the transfer of
lipophilic compounds from bulk solution to the lipid bilayer of the cell membrane, which in turn,
could affect the efficacy of the PPEs that are being examined in this study. In order to examine
the effect of GI motility on the potency of PPEs, the cell monolayers grown on Transwells™
were agitated on a rotary shaker at different rates. The marker compound 3H-testosterone was
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used to calibrate the change in Hw at each stirring rate. As stirring rates were increased from 40
to 180 rpm, the Papp of 3H-testosterone increased from 500 nm/sec to 1600 nm/sec. Based on
these changes in flux, the decrease in Hw was calculated to change from 1400 to 320 µm. These
data for testosterone are consistent with those reported previously by Adson et al21. As expected,
the Papp of 14C-mannitol was unchanged by stirring (data not shown).
Having established the change in Hw with the marker compound testosterone, the effect
of stirring rate on the potency of the selected PPEs was determined. Several doses of each PPE
were tested at low, moderate, and high stirring rates and their ability to decrease TEER was
compared to that under unstirred conditions. In order to mimic the limited contact time that a
PPE would have in a particular intestinal segment due to GI motility, the experimental treatment
time for the agitation experiments was limited to 15 min.
As the stirring rate increased, the TEER decrease versus PPE concentration curves
gradually shifted to the left for PCC and HPC, indicating enhanced potency of these PPEs
(shown for HPC in Figure 2.5). At the highest stirring rate tested, the EC50 TEER of PCC and HPC
decreased several fold relative to unstirred conditions (Table 2.4). Due to a greater shift in EC50
TEER for HPC with agitation, the less potent HPC became equipotent to PCC when Hw was
decreased by stirring. Agitation had no effect on the ability of amphiphilic compound NaCap,
nor of the non-amphiphilic compounds EDTA and 3-NC to decrease TEER (Table 2.4).
The Papp values of all PPEs increased under stirred conditions (Table 2.4). Thus, the
transepithelial flux of both the amphiphilic and the non-amphiphilic PPEs are controlled to some
extent by the Hw. However, the improved access to the cell monolayers due to reduction in Hw
did not result in improved efficacy for NaCap and 3-NC, indicating that access to the cells was
not the rate limiting step for these compounds to exert their effect. Indeed NaCap and 3-NC both
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had high baseline permeability under standard conditions in the absence of stirring compared to
HPC and PCC (Table 2.3).
At the abbreviated exposure time of 15 min, a relevant intestinal contact time, HPC, PCC
and NaCap were fully effective. However, 3-NC was not effective during the shorter 15 min
treatment period but required at least 30 min to cause a decrease in TEER across cell monolayers
(data not shown). If the 3-NC dosing solution was removed at the 15 min time point and
replaced with blank transport buffer, a decrease in TEER was still observed at later times, which
was of similar magnitude to that achieved when 3-NC dose solution was left in contact with the
monolayers for the duration of the experiment (data not shown). Thus for 3-NC, in contrast to
HPC, a lag time in onset of PPE-induced TEER decrease is observed even after Hw is reduced
by agitation of monolayers.
Evaluation of the novel PPE GW4936 in Caco-2 cells using standard and biorelevant
conditions
In order to further assess the impact of biorelevant refinements on potency assessment of
PPEs using the Caco-2 cell model, the novel PPE GW4936 was tested using standard and
biorelevant conditions. GW4936, a phospholipase A2 inhibitor, was discovered to have
paracellular permeability enhancing properties during routine permeability screening of drug
candidates.
The structure of GW4936 differs significantly from the previously described PPEs used
to test biorelevant refinements (Figure 2.1). GW4936 is an amphiphilic compound possessing
two alkyl tails, one of which contains a phenyl group at the end of the alkyl tail, and an anionic
phosphate head group. Thus, the structure of GW4936 is analogous to that of a membrane
sphingolipid, though the alkyl chains in GW4936 are much shorter in length, among other small
structural differences.
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The EC50 TEER and the increase in mannitol Papp caused by GW4936, as well as the
disposition of GW4936 across Caco-2 cell monolayers under standard and biorelevant conditions
are summarized in Table 2.5. GW4396 had similar potency under standard conditions to that of
PCC, the most potent PPE tested in this study (under standard conditions). When solutions of
GW4936 were prepared in FaSSIF rather than standard buffer, the dose response curve (i.e., the
decrease in TEER caused by increasing concentrations of GW4936) was shifted to the right
compared to dose solutions prepared in standard transport buffer, as seen for PCC and HPC.
Consistent with the effect on TEER, the 9-fold enhancement of mannitol permeability caused by
a single effective concentration of GW4936 (250 µM) was completely eliminated when dose
solutions were prepared in FaSSIF. Furthermore, the amount of GW4936 in cell extracts was
significantly reduced in the presence of FaSSIF, which was similar to the effect observed with
PCC and HPC.
In the presence of basolateral serum, the increase in mannitol permeability caused by
GW4936 was significantly lessened, though the mannitol permeability still remained
significantly higher compared to vehicle-treated control monolayers. Consistent with the
mannitol data, the cell association of GW4936 was significantly lessened in the presence of
basolateral serum. Thus, in contrast to the other amphiphilic PPEs, the paracellular permeability
enhancing ability and cell-association of GW4936 was reduced in the presence of basolateral
serum.
When the Hw was reduced by stirring, a gradual shift to the left of the TEER versus PPE
concentration curve was observed for GW4936, as observed for PCC and HPC. At the highest
stirring rate tested, the EC50 TEER of GW4936 decreased by approximately 30% relative to
unstirred conditions (Table 2.5). The Papp of GW4936 also increased by several fold by stirring,
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from a moderate value under standard conditions to high permeability at the highest stirring rate
tested.
Discussion
Epithelial cell monolayers grown on semi permeable membranes are well-established
models for the intestinal epithelium, and have been used to evaluate the paracellular permeability
enhancing potency, cytotoxicity and mechanisms of action of PPEs33. In the present study, three
biorelevant modifications have been applied to the Caco-2 cell monolayer system, and the
impact on the potency of six structurally diverse PPEs was examined.
Selection of the appropriate dosing buffer was a key initial step in these experiments
since PCC, NaCap and 3-NC were not stable in unmodified transport buffer (Hanks’ balanced
salt solution supplemented with 25 mM D-glucose and 25 mM HEPES, pH 7.1). Precipitation of
PCC occurred sporadically over the course of the treatment period in unmodified transport
buffer, which resulted in diminished and variable effect on TEER and mannitol flux, the two
measures of paracellular permeability enhancement used in these studies. Precipitation of PCC
could be prevented by including 0.1% (v/v) hydroxypropyl-beta-cyclodextrin or 1% (v/v)
FaSSIF in transport buffer (data not shown). These percentages of additives did not affect the
integrity of the cells or the ability of PCC to open tight junctions (data not shown for
hydroxypropyl-beta-cyclodextrin; for PCC data see Figure 2.3). Thus, 1% (v/v) FaSSIF was
selected as the stabilizing additive and included in all dose solutions of amphiphilic PPEs as the
standard dosing vehicle. Despite inclusion of 1% FaSSIF, NaCap precipitated immediately upon
preparation in this vehicle. Therefore, dose solutions of NaCap were prepared in Ca2+-free
transport buffer containing 1% FaSSIF. As others have found, the lack of Ca2+ on the apical side
did not adversely impact cell monolayer integrity, provided that Ca2+ was present on the
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basolateral side34. For 3-NC, chemical degradation was observed in unmodified transport buffer,
with a half-life of 2 h at 37°C (data not shown). Degradation was arrested by lowering the pH in
the dose solution to 5.6. This lower pH in the apical compartment increased the TEER across the
monolayers by approximately 10%, but did not otherwise adversely affect the cells as has been
observed by others35.
Five of the selected PPEs had previously been examined by others for their in vitro
potency using in vitro conditions11,18,24,26,31. The in vitro potency found in the current study for
PCC, NaCap and EDTA using standard conditions was comparable to that found previously,
with effective concentrations of in the range of 160 - 250 µM, 11 – 13 mM, and 1 - 2 mM,
respectively. However, for HPC and 3-NC approximately 20-fold higher concentrations were
required for to cause a decrease in TEER or an increase in mannitol Papp compared to previous
determinations in cell monolayers. Significant differences in the experimental conditions in the
current study are likely to have contributed to higher 3-NC and HPC effective concentrations,
including the use of Caco-2 cells rather than MDCK cells, lack of a 30 min pretreatment period
prior to commencement of measurements, and use of pH-adjusted transport buffer (pH 5.6) in
the apical compartment of 3-NC studies rather than the typical pH 7.4 used in previous studies.
The use of biorelevant fluids with in vitro monolayers systems in order to enhance the
evaluation of drug permeability measurements has been reported by other researchers36. The
focus of this study was to evaluate how biorelevant refinements to the Caco-2 cell monolayer
impact PPE ability to open the paracellular space to allow increased flux on hydrophilic solutes
or ions. The use of FaSSIF in the apical chamber instead of typical balanced salt solutions
produced a large negative impact on PPE potency, and a concomitant decrease in cell-association
of PCC, HPC and GW4936 (Figures 2.2, 2.3, 2.4 and Tables 2.2, 2.5). All of the negatively
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affected PPEs were in the amphiphilic structural class, a class which contains a large number of
the PPEs studied to date. Each had a charged head group and at least one lipophilic carbon chain
of considerable length making their incorporation into the mixed micelles of FaSSIF highly
probable. The 3 to 4-fold decrease in the amount of these PPEs recovered in cell extracts in the
presence of FaSSIF provides strong evidence that PCC, HPC and GW4936 are incorporated into
mixed micelles of FaSSIF, resulting in a reduced cellular amount of the compounds.
Interestingly, one of the amphiphilic compounds, NaCap, was not affected by FaSSIF.
NaCap has a carbon chain that is shorter than that of PCC and HPC (10 carbons versus
16 carbons). Furthermore, the reported critical micelle concentration (CMC) for NaCap of 13
mM (determined in standard transport buffer34) is 10 to 100-fold higher than that of GW4936 (1
mM, unpublished results), PCC (50 - 75 µM37), and HPC (10 µM38). These properties may
allow NaCap to partition into and out of the mixed micelles of FaSSIF with relative ease
compared to the longer chain PPEs. Alternatively, the relatively high effective concentration of
NaCap may exceed the capacity of the micellar components of FaSSIF (3 mM taurocholate and
0.75 mM phosphatidylcholine), allowing a sufficient amount of free NaCap to interact with the
cells.
The PPE 3-NC was also not affected by the presence of FaSSIF in the apical
compartment. This result, however, is consistent with the lack of amphiphilicity of 3-NC. Ingels
et al. have also observed minimal impact of FaSSIF in the donor compartment of Caco-2 cells on
the transepithelial permeability for some drugs13. However, for compounds with appreciable
lipophilicity, improved recovery from the apical compartment was observed in the presence of
FaSSIF. Thus, the presence of FaSSIF in the donor compartment may lead to changes in the
disposition of lipophilic or amphiphilic compounds across cell monolayers in vitro. Whether this
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also occurs in the dynamic and more complex setting of the GI tract is still largely unknown.
However, it has been previously observed that PCC, the PPE most affected by the presence of
FaSSIF in these studies, is not effective when administered into the duodenum of rats, yet is
effective when administered in the jejunum, ileum and colon39. Since the duodenum is the
intestinal region with the highest concentration of bile, a plausible explanation for the lack of in
vivo efficacy of PCC in the duodenum is the sequestration of PCC in bile micelles. Based on the
potential for this type of adverse interaction of certain amphiphilic PPEs with intestinal fluid,
amphiphilicity may be a structural feature to avoid in the design of future PPEs.
With the exception of GW4936, PPEs were fully effective in the presence of serum in the
basolateral compartment of Caco-2 cell monolayers grown on Transwells™ (Table 2.3). There
was a 50% reduction in the mannitol Papp and approximately the same reduction in the cell-
association after treatment with 250 µM GW4936 in the presence of basolateral serum (Table
2.5). Interestingly, the transepithelial flux of all amphiphilic PPEs was increased several fold by
basolateral serum (Tables 2.3, 2.5). Similar increases in transepithelial flux by serum
components have been reported for lipophilic, highly plasma protein bound drug candidates. For
example, flux was increased for several drugs by as much as 5 to 40-fold across Caco-2 cell
monolayers in the presence basolateral albumin compared to typical transport buffer40. The
increase observed with the amphiphilic PPEs was of similar magnitude. While the increase in
flux did not result in a large change in the cellular amount of these PPEs in Caco-2 cell
monolayers (except for GW4936), we speculate that high PPE flux in vivo due to serosal blood
components could result in rapid depletion of certain PPEs from the intestine. Indeed, the rapid
in vivo absorption of NaCap has been reported after oral administration to pigs41. Thus, the
enhancement of paracellular permeability in vivo for these and other rapidly absorbed PPEs is
103
likely to be of short duration and be localized to the upper small intestine unless timed-released
formulations are employed.
Also a likely contributing factor to lack of adequate in vivo PPE potency after oral
administration is the transient PPE exposure to intestinal cells in a given intestinal segment due
to GI motility. In the present study, we simulated transient intestinal exposure by treating cell
monolayers for 15 min, instead of the typical 60 min treatment period, and included agitation to
lessen the unstirred water layer thickness (Hw). The in vitro potency (EC50 TEER) after shorter
treatment time was not dramatically different for most PPEs (with agitation) as many of the
selected compounds exerted their effect within the first few minutes after treatment (Table 2.2
and Table 2.4). Thus, even brief exposure of PPEs to cells resulted in paracellular permeability
enhancement. These results suggest that conceivably, a reduction in the height of the unstirred
water layer (Hw) could improve the efficiency with which the amphiphilic (lipophilic) PPEs can
interact with the cell membrane, and thus compensate for the reduced contact time available due
to intestinal motility. For 3-NC, however, no changes to TEER were observed during the 15 min
treatment period. This PPE required at least 30 min for the onset of paracellular permeability
enhancement. The delay in the onset of paracellular permeability effect for this PPE is not
related to cell access of 3-NC since it has high permeability (Papp = 500 nm/sec). Furthermore,
3-NC-induced paracellular permeability enhancement does not require sustained exposure to
high concentrations of 3-NC, because after a 15 min exposure to 3-NC followed by removal and
replacement with fresh buffer, the same change in TEER at later times was observed as when 3-
NC dose solution was allowed to remain in contact with the monolayers. Thus, the delay in
paracellular permeability enhancement after 3-NC treatment is likely related to its mechanism of
action that involves inhibition of PLC18 and subsequent secondary events that require time for
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changes to be manifested. This represents a potential disadvantage for the in vivo use of 3-NC,
as it would require PPE administration at least 30 min prior to administration of the poorly
absorbed drug in order to achieve maximum efficacy.
Another aspect of GI motility investigated by these studies was how changes to Hw
impacted the ability of the PPEs to decrease TEER. The minimum Hw achieved by placing the
Transwell™-grown Caco-2 monolayers on a rotary shaker was 320 µm. This value is similar to
what others obtained using the same mechanical agitation method to modulate Hw21, but still
several fold higher than the reported in vivo Hw of 40 µm42. This relatively thick Hw could be
related to the geometry of the in vitro system and the mechanical agitation method employed in
these measurements. As others have reported43, we achieved a more biorelevant Hw (60 µm) in
separate studies using Caco-2 cells grown on Snapwells™, wherein Hw was modulated by gas
lift in an Ussing-type chamber (data not shown). While the Ussing chamber system provided a
more biorelevant Hw, the damage that could be caused to the integrity of the monolayer during
Snapwell™ placement into the Ussing chamber was a major concern. This was based on the
observation that the action of placing the monolayers into the Ussing chamber caused as much as
a 50% decrease in TEER relative to the TEER value measured before removal from the plastic
support (data not shown). Since TEER decrease was one of the primary parameters used to
assess changes to the monolayer barrier after PPE treatment, this large change in TEER prior to
PPE addition was deemed unacceptable. Therefore, the monolayer system (Transwell™-rotary
shaker) that kept the cells relatively undisturbed prior to the initiation of PPE treatment was
employed. Indeed, PPE potency changes could be ascertained using this system, since a 3-fold
increase in Hw for testosterone was observed over the range of agitation employed.
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When Hw was decreased by agitation of monolayers, the potency of GW4936, PCC and
HPC increased by several fold, while that of NaCap, 3-NC and EDTA was not affected (Figure
2.5, Table 2.4, Table 2.5). Examination of the disposition of the PPEs by LC-MS revealed that
transepithelial flux (Papp) of all five quantifiable PPEs increased several fold when Hw
decreased by stirring (Table 2.4, Table 2.5). The increase in flux with a decrease in Hw for these
compounds is consistent with their amphiphilicity (or lipophilicity, in the case of 3-NC). Indeed,
others have reported an impact of Hw on the flux of amphiphilic carboxylic acids44 and
lipophilic drug candidates45. Thus, transepithelial movement of amphiphilic or lipophilic PPEs
across cell monolayers is controlled to some extent by the Hw. By implication, the access of
these PPEs to the apical surface of the cells, and subsequently to the site of action inside the cell,
is also controlled by Hw and could be underestimated in vitro if evaluated in the absence of
sufficient stirring. The lack of a significant change in efficacy for NaCap and 3-NC with stirring
may suggest that Hw is not rate limiting in their access to the cell membrane.
The qualitative impact of the cell monolayer refinements on the measured potency of the
six PPEs is summarized in Table 2.6. The use of FaSSIF as a donor vehicle on the apical side of
the cells had a significant negative effect on the potency of the three amphiphilic compounds
GW4936, PCC and HPC. Thus, an in vitro model that does not attempt to examine the effect of
intestinal fluid on the potency of PPEs is likely to over-estimate the potency of amphiphilic
permeability enhancers leading to a significant disconnect between the in vitro results and the in
vivo results. It is also worth noting that the effect of FaSSIF on the potency of different
amphiphilic PPEs is significantly different. Thus, it is not possible to extrapolate the in vivo
efficacy of a PPE from its predicted in vitro potency measured in the absence of FaSSIF.
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These PPEs were also affected by a decrease in Hw due to monolayer agitation, but in the
opposite direction—potency was increased by agitation of monolayers. In order to test whether
these opposing effects on potency would be additive resulting in a net effect of zero, the PPEs
were tested with FaSSIF in the apical compartment using agitation of the monolayers. The
results indicated that FaSSIF still acted to decrease the potency of GW4936, PCC and HPC to
the same extent, even though stirring was present (data not shown). Thus the overriding factor
with these PPEs is prevention of cell access by FaSSIF, even when Hw is reduced by stirring. It
is important to evaluate the potency of amphiphilic/lipophilic PPEs in an in vitro model that
incorporates the effect of Hw because a static model would not only underestimate the potency
of many PPEs, but it would also not be able to assess if a PPE would be effective over a short
contact period (with intestinal epithelium) encountered in vivo due to intestinal motility.
In summary, these data demonstrate the importance of including intestinal fluid and
agitation as part of a thorough in vitro assessment of the potency of PPEs to increase the
paracellular permeability of poorly absorbed compounds. We recommend inclusion of FaSSIF
and agitation in cell culture models in order to better predict concentrations of amphiphilic PPEs
that will effectively enhance the oral delivery of important hydrophilic drug therapies to humans.
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Table 2.1. Effective concentration and putative mechanism of action for selected PPEs
PPE EffectiveConcentration Putative Mechanism of Action References
Amphiphilic PPEs
HPC 0.03 mM increased
mannitol flux 10-fold
PLC inhibition leading to actin
disorganization 24
PCC
0.2 mM increased
Lucifer Yellow flux 9-
fold
Membrane perturbation; no effect on
actin organization, Ca2+independent
mechanism
11, 22
NaCap 10 mM increased
mannitol flux 8-fold
Activation of PLC, increased
intracellular Ca2+ 25, 26
Non-amphiphilic PPEs
EDTA 1 mM increased FITC-Dextran4 flux 6-fold
Extracellular chelation of Ca2+,
leading to disruption of extracellular
E-cadherin
31
3-NC 0.03 mM increased
mannitol flux 5-fold
PLC inhibition leading to
hyperphosphorylation of ZO-2 18
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Table 2.2. EC50 TEER evaluated in Caco-2 cell monolayers after PPE treatment using
standard buffer or FaSSIF in the apical compartment
PPE EC50 TEER (µM)a Fold Increased
Standard buffer b FaSSIF c
HPC 350 800 2.3*
PCC 160 2000 12.5*
NaCap 11000 8700 0.8
EDTA 2200 1800 0.8
3-NC 510 350 0.7
a TEER was measured across Caco-2 cell monolayers 60 min after apical treatment with
solutions of PPEs prepared in either standard transport buffer or FaSSIF as described in
Methods.
bStandard buffer for HPC, PCC and NaCap was 1% (v/v) FaSSIF in transport buffer.
Ca2+-free transport buffer was used for NaCap solutions. Standard buffer for EDTA and
3-NC was not modified, except that pH was adjusted to 5.6 in 3-NC solutions. EDTA was
added to both the apical and basolateral compartments.
cFasted-state simulated intestinal fluid was used in the apical compartment with PPEs instead
of standard transport buffer.
d The median fold-difference between the EC50 TEER curves for standard and modified
conditions. The asterisk indicates that the fold difference was significant based on Bayesian
analysis, as described in Methods.
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Table 2.3. PPE disposition and effect on mannitol Papp evaluated in Caco-2 cell
monolayers after PPE treatment in the presence or absence of human serum in the
basolateral compartment
Treatme
nt
PPE Papp (nm/sec)a PPE % Cell
Associationb
Mannitol Papp
(nm/sec)a
Standard
bufferc
Serum Standard
buffer
Serum Standard
buffer
Serum
Control -- -- -- -- 2.5 (0.3) 1.9 (0.6)
HPC 1.8 (0.4) 22 (9) 31.2 (2.0) 33.0 (1.1) 9.0 (1.1) 11 (2)
PCC 1.4 (0.4) 30 (1)* 10.2 (0.3) 10.7 (0.4) 14 (4) 12 (3)
NaCap 230 (21) 622 (34)* 2.0 (0.2) 0.5 (0.1)* 13 (6) 15 (7)
EDTA -- -- -- -- 20 (4) 6 (8)
3-NC 500 (6) 670 (95) 7.4 (1.2) 2.8 (0.5) 10 (2) 7 (1)
a Permeability coefficients (Papp)for each PPE or Mannitol were calculated from the amount
of test compound appearing in the basolateral compartment during the 0 – 60 min period
(0 - 90 min for HPC) after co-treatment with a single concentration of PPE (250 µM HPC
and PCC, 13 mM NaCap, 2 mM EDTA and 600 µM 3-NC). The basolateral compartment
contained either transport buffer or human serum.
bThe amount of each PPE in the cell extract was determined by LC-MS as described in
Methods, and normalized to the amount of PPE initially added. Values are mean % dose
(SD) for three monolayers.
cStandard buffer was used in the basolateral compartment for all PPEs. EDTA was added to
both the apical and basolateral compartments. Asterisks indicate a significant difference
(p<0.05) between parameters determined in the presence of serum compared to those
obtained with standard buffer in the basolateral compartment.
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Table 2.4. EC50 TEER and PPE Papp evaluated in Caco-2 cell monolayers after PPE
treatment with or without agitation
Treatment 15 min EC50 TEER a
(µM)
Fold
Decrease b
PPE Papp (nm/sec) c Fold
Increase
Standard
condition
Agitation With
Agitation
Standard
condition
Agitation With
Agitation
HPC 370 110 3.4* 1.6 (0.6) 17 (6)* 11
PCC 220 83 2.7* 6.1(2.5) 29 (28) 4.8
NaCap 12000 14000 0.9 230 (20) 705 (20)* 3.1
EDTA 1100 1200 0.9 -- -- --
3-NC No
efficacy
No
efficacy -- 500 (80) 1100 (20)* 2.2
a TEER was measured across Caco-2 cell monolayers 15 min after treatment with solutions
of PPEs prepared as described previously without agitation (standard condition) or with
agitation on a rotary shaker at 160 rpm.
b The median fold-difference between the EC50 TEER curves for standard and modified
conditions. The asterisk indicates that the fold difference was significant based on Bayesian
analysis, as described in Methods.
c PPE permeability coefficients (Papp) were calculated from the amount of PPE appearing in
the basolateral compartment during the 0 – 15 min period after treatment with a single
concentration of PPE in standard transport buffer (250 µM HPC and PCC, 13 mM NaCap,
2 mM EDTA and 600 µM 3-NC) with or without agitation on a rotary shaker at 160 rpm.
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Table 2.5. EC50 TEER, effect on mannitol Papp and disposition of novel PPE GW4936
evaluated in Caco-2 cell monolayers using standarda and biorelevant conditionsb
Conditions EC50 TEER Mannitol Pappc GW4936 Cell
Association
GW4936
Papp
µM nm/sec Foldincrease % Dose nm/sec
Standard 240 17 (6)† 9 18 (3.3) 20 (6)
FaSSIF 760** 1.8 (0.4)* 0 4.3 (0.1)* --
Serum -- 9 (4)*† 4 9.7 (1.6)* 50 (12)*
Stirring 160** -- -- -- 150 (19)*
a Standard conditions for GW4936: GW4936 was prepared in 1% (v/v) FaSSIF in transport
buffer and added to the apical compartment, basolateral compartment contained transport
buffer; no agitation; 60 min treatment period.
bThree separate biorelevant conditions for GW4936 were used: GW4936 was prepared in
100% FaSSIF; basolateral compartment contained human serum; or agitation at 160 rpm (15
min treatment period).
c Permeability coefficients (Papp)for 14C-mannitol were calculated from the amount of 14C-
mannitol appearing in the basolateral compartment during the 0 – 60 min period after co-
treatment with 250 µM GW4936. The basolateral compartment contained either transport
buffer or human serum.
dThe amount of GW4936in the cell extract was determined by LC-MS as described in
Methods, and normalized to the amount of PPE initially added. Values are mean % dose
(SD) for three monolayers.
Mean values from at least 3 monolayers are reported. Numbers within parentheses indicate
standard deviation. Single asterisks (*) indicate a significant difference (p<0.05) between
parameters determined under standard conditions and those determined using each
biorelevant modification. Single cross(†) indicates a significant difference (p<0.05) in
mannitol Papp caused by GW4936 treatment versus control monolayers. Double asterisks
(**) indicates that the median EC50 TEER fold-difference was significant based on Bayesian
analysis, as described in Methods.
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Table 2.6. Impact of biorelevant refinements on PPE potency
FaSSIF (AP) Serum (BL) Agitation
Amphiphilic PPEs
HPC    
PCC    
NaCap   
GW4936   
Non-amphiphilic PPEs
EDTA   
3-NC   
Key: 	 2-fold;  ~ 2 to 10-fold;  
 10-fold
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Figure 2.1. Structures of selected PPEs
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Figure 2.2. Effect of PPEs on TEER (solid circles) and mannitol permeability (open circles) across Caco-2 cells.
TEER was measured across Caco-2 cell monolayers 60 min after apical treatment with solutions of PPEs; mannitol permeability
coefficient (Papp) values were calculated from the amount of 14C-mannitol appearing in the basolateral compartment during the
0 - 60 min period after co-treatment with PPEs. Solutions for HPC, PCC and NaCap were prepared in 1% (v/v) FaSSIF, and solutions
for EDTA and 3-NC were prepared in unmodified transport buffer. The dose solution for NaCap was free of Ca2+ ions to avoid
precipitation. The dose solution for 3-NC was adjusted to pH 5.6. EDTA was added to apical and basolateral chambers. Mean values
from at least 3 monolayers are plotted. Error bars indicate standard deviation.
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Figure 2.3. Impact of fasted-state simulated intestinal fluid (FaSSIF) on the ability of
PCC to cause a decrease in TEER across Caco-2 cell monolayers.
(A) TEER was measured across Caco-2 cell monolayers 60 min after apical treatment with
solutions of PCC as described in Methods. PCC solutions were prepared in either transport
buffer containing 1% (v/v) fasted-state simulated intestinal fluid (FaSSIF) (solid circles) or in
100% FaSSIF (open circles). Mean values from at least 3 monolayers are plotted. Error bars
indicate standard deviation. Arrow indicates EC50 TEER for PCC in 100% FaSSIF. (B) PCC
120
solutions (250 µM) were prepared in different dilutions of FaSSIF (v/v in transport buffer). Cell
monolayers were rinsed 1x following TEER measurement at 60 min endpoint and extracted with
ethanol. The amount of PCC in the cell extract was determined by LC-MS as described in
Methods, and normalized to the amount of PCC initially added (% Dose). Mean TEER values
(vertical bars) and PCC % dose remaining associated with cells (triangles) from at least 3
monolayers are plotted. Error bars indicate standard deviation. Asterisks indicate a significant
difference (p<0.05) between parameters after PCC treatment in diluted FaSSIF versus PCC
treatment in transport buffer alone.
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Figure 2.4 Mannitol Papp and PPE cell association evaluated in Caco-2 cell monolayers
after PPE treatment with standard buffer or FaSSIF in the apical compartment.
Mannitol Papp was calculated from the amount of 14C-mannitol appearing in the basolateral
compartment during the 0 – 60 min period (0 - 90 min for HPC) after co-treatment with a single
concentration of PPE (250 µM HPC, 250 µM PCC, 13 mM NaCap, 2 mM EDTA and 600 µM 3-
NC). PPEs were prepared in either transport buffer containing 1% (v/v) FaSSIF (open bars) or
in 100% FaSSIF (closed bars). For EDTA experiments, a second dose solution was prepared in
transport buffer and added to the basolateral compartment. Inset: Cell monolayers were rinsed
1x following the end of the treatment period and extracted with ethanol. The amount of each
PPE in the cell extract was determined by LC-MS as described in Methods, and normalized to
the amount of PPE initially added. Values are mean % dose (SD) for three monolayers.
Asterisks indicate significant difference (p<0.05) in parameters between dose solutions prepared
in 100% FaSSIF versus standard buffer.
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Figure 2.5. Impact of Stirring on EC50 TEER for HPC evaluated in Caco-2 cell
monolayers with or without agitation.
TEER was measured across Caco-2 cell monolayers 15 min after treatment with solutions of
HPC prepared in 1% (v/v) FaSSIF in transport buffer without agitation (standard condition) or
with agitation at three different rates on a rotary shaker. Arrows indicate approximate EC50 TEER
under standard condition and 160 rpm. Mean values from at least 3 monolayers are plotted.
Error bars indicate standard deviation.
CHAPTER 3
NOVEL IN VITRO APPROACHES TO ASSESS LOCAL AND SYSTEMIC
TOXICITY OF PARACELLULAR PERMEABILITY ENHANCERS
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Abstract
The purpose of this work was to evaluate whether paracellular permeability enhancers
(PPEs) are likely to cause (i) systemic toxicity by allowing the bacterial toxin
lipopolysaccharide (LPS) to cross the intestinal epithelium, or (ii) localized toxicity to the
epithelial cells at or near effective concentrations. This was examined by measuring
increases in the flux of LPS across Caco-2 cell monolayers upon treatment with different
concentrations of PPEs, and by a multi-faceted assessment of cytotoxicity, which included
histological quantitation of cell monolayer microerosions, measurement of lactate
dehydrogenase (LDH) leakage, and the ability of monolayers to recover their barrier function
following PPE treatment. The paracellular permeability enhancing ability of PPEs was
assessed by measuring a decrease in transepithelial electrical resistance (TEER) and an
increase in the apparent permeability coefficient (Papp) of 14C-mannitol and 14C-
carboxyinulin, known markers for paracellular transport, following exposure of Caco-2 cell
monolayers to various concentrations of PPEs for 15 minutes. Treatment of Caco-2 cell
monolayers with increasing concentrations of amphiphilic PPEs palmitoyl carnitine chloride
(PCC), hexadecylphosphocholine (HPC), and GW4936 caused a gradual increase in the
amount of LDH present in the apical medium, with a TC50 LDH value (PPE concentration
causing 50% of the maximum LDH leakage) that was 3 to 5-fold higher than the EC50 TEER
value (PPE concentration causing a 50% drop in TEER). Non-amphiphilic PPEs (EDTA and
3-nitrocoumarin (3-NC)) did not cause detectable LDH leakage at or above efficacious
concentrations. Nearly complete recovery of monolayer TEER was achieved within 3 hrs
following removal of PCC, HPC and GW4936 at concentrations approximately equal to the
EC50 TEER. Histological assessment following HPC treatment revealed morphological
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changes suggestive of cellular damage at HPC concentration of 
 300 µM, but large areas of
monolayer defects or aberrations due to cell sloughing were not evident even after treatment
with high concentrations (< 600 µM) of HPC. Papp of mannitol and carboxyinulin were
significantly enhanced at relatively non-toxic concentrations of HPC (200 – 300 µM).
However, Papp for the amphiphilic molecule LPS was not substantially enhanced until
cytotoxic concentrations of HPC were administered. This work establishes that amphiphilic
PPEs can enhance the permeability of hydrophilic compounds at concentrations that do not
damage the epithelial (Caco-2) cells, and that these concentrations do not result in substantial
transepithelial exposure to bacterial toxin LPS. However, the separation between effective
and cytotoxic concentrations is relatively small.
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Introduction
The oral route is the preferred route of administering drugs. However, potential drug
candidates may exhibit poor intestinal bioavailability because they do not easily traverse the
intestinal epithelium. For example, hydrophilic molecules exhibit poor permeability across
the intestinal epithelium because they do not easily partition across lipophilic cell
membranes, which comprise the majority of drug absorption surface area. Therefore, if these
molecules are not substrates for carrier proteins, they are likely to cross the epithelium via
the aqueous paracellular space, a pathway that represents a small percentage of the total
surface area available for absorption1.
Furthermore, the flux of ions and solutes through the paracellular pathway is tightly
controlled by the intercellular junctional complex via the interactions of specialized
membrane domains that interface with like regions in adjoining cells. Three distinct
specialized regions form the intercellular junctional complex: the tight junction (TJ),
adherens junction (AJ) and desmosomes. The TJ is the most apical component and is
generally considered to be the limiting barrier to paracellular permeability2.
One approach to improve the intestinal absorption of poorly absorbed molecules is to
transiently open the intercellular spaces between the intestinal epithelial cells by modifying
the normal interactions of the tight junction (TJ) proteins through the use of a co-
administered paracellular permeability enhancer (PPE).
Amphiphilic PPEs represent a large number of molecules under active study3.
Amphiphilic PPEs likely exert their effect in part by perturbing the apical cell membrane
order, which could result in indirect modulation of integral or cell associated enzymes such
as protein kinase C4or disturb the composition of lipid rafts. The latter are thought to
organize important signaling and integral membrane proteins, including the TJ protein
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complex5 in close association to each other. Thus, depending on the extent of membrane
perturbation, amphiphilic PPEs could cause a transient opening f the TJ, possibly mediated
through modulation of cell signaling pathways, or a complete disruption of TJs caused by
membrane damage.
The intestinal epithelium provides a protective role in keeping harmful components
from the external environment from entering the body. Indeed, pathological conditions
characterized by leaky TJs or intestinal barrier disruption are thought to allow toxins to
penetrate the epithelium leading to local inflammation or septic shock6,7. Thus, a concern
exists that PPE modulation of the intestinal epithelium, particularly by membrane active
amphiphilic PPEs, may result in the absorption of unwanted toxins, though clear evidence to
support this concern is lacking. This perceived danger represents a major impediment to the
use of PPEs in humans. Therefore, we designed the following studies using Caco-2 cell
monolayers to investigate whether transient opening of TJs caused by amphiphilic PPEs
increases the flux of the bacterial toxin lipopolysaccharide (LPS), a bacterial fragment that
has been implicated in systemic toxicity following intestinal epithelial injury7.
Because amphiphilic PPEs are known to have a relatively narrow window between
concentrations that selectively act to open TJs and those that cause membrane damage and
cell death, studies were designed to characterize the efficacy to cytotoxicity continuum in
cell monolayers caused by a group of structurally diverse PPEs. Cytotoxicity was assessed
using markers of cell membrane damage (LDH leakage), and the ability of the monolayers to
recover their barrier function (recovery of TEER). In addition, a novel histological technique
was employed that allowed the visualization and quantification of the extent of cell
sloughing, a parameter that may be particularly important in understanding the increased flux
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of relatively large bacterial fragments such as LPS across cell monolayers. The effect of
PPEs on the flux of LPS across Caco-2 cell monolayers was examined in the context of their
localized cytotoxicity to the epithelial cells.
Methods
Materials
The synthesis of 3-nitrocoumarin (3-NC) was as described previously.8 (2R,3Z)-2-
(decanoylamino)-8-phenyl-3-octen-1-yl methyl phosphate lithium salt (GW4936) was
provided by GlaxoSmithKline. D-(1-14C)-mannitol (56 mCi/mmol) and (14C)-carboxyinulin
(1.4 mCi/g) were purchased from Perkin Elmer Life Sciences (Boston, MA). EDTA was
obtained from USB Corp (Cleveland, OH). Other chemicals and reagents, including
palmitoyl-D,L-carnitine chloride (PCC), hexadecylphosphocholine (HPC), sodium caprate
(NaCap), fluorescein isothiocyanate labeled LPS (FITC-LPS) isolated from Escherichia coli
serotype O111:B4, triton-X-100 (TRX), phosphatidylcholine, taurocholate, Hanks’ balanced
salt solution, HEPES buffer, and glucose were purchased from Sigma Chemical Co. (St
Louis, MO). Cell culture reagents were purchased from Invitrogen (Carlsbad, CA).
Transwellswere purchased from Corning Costar (Cambridge, MA). Fasted-state simulated
intestinal fluid (FaSSIF) was prepared as previously reported9. The mixture contained 3 mM
sodium taurocholate and 0.75 mM phosphatidylcholine in a buffered, isosmotic sodium salt
solution (pH 7.1). Male human serum was obtained from Bioreclamation, Inc. (Hicksville,
NY). The thawed serum was filtered through a 0.22 µM filter and adjusted to pH 7.1
immediately prior to use.
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Cell Culture
The Caco-2 cell line was obtained from American Type Culture Collection. Caco-2
cells were grown in 75 cm2 tissue culture flasks in the presence of cell culture medium
(minimum essential medium (MEM) with Earle’s salts, 10% (v/v) fetal bovine serum, and
1:100 dilutions of 100X stock solutions of non-essential amino acids and antibiotic-
antimycotic agents (penicillin G, streptomycin, amphotericin B)). Cells were passaged
approximately every four days. Cells between passage numbers of 26 and 40 were used for
transport studies. At approximately 90% confluency, the cells were detached using 0.05%
trypsin containing EDTA. The cells were seeded at a density of 120,000 cells/cm2 on
polycarbonate membranes of Transwell™ cell culture inserts (pore size 0.4 µm, diameter 1
cm2). Cell culture medium was replaced every second day. Cells were considered fully
differentiated and ready for PPE experiments after 21-days. Transepithelial electrical
resistance (TEER) values of mature cell monolayers were between 300 and 600 ohm*cm2, as
measured using Endohm Voltohmmeter (World Precision Instruments, Sarasota FL) after
correction for filter resistance.
Treatment of monolayers with PPEs
Cell monolayers were equilibrated for approximately 60 min in transport buffer
(Hanks’ balanced salt solution supplemented with 25 mM D-glucose and 25 mM HEPES, pH
7.1) at 37ºC prior to the addition of PPEs. At the end of the equilibration period, TEER was
measured using Endohm Voltohmmeter (World Precision Instruments, Sarasota FL) while
the cell monolayers were maintained at 37ºC with slide warmer. This measurement was
defined as initial TEER. PPE efficacy measurements were initiated upon replacement of the
apical transport buffer with dose solutions (0.4 mL) containing either 14C-mannitol, 14C-
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carboxyinulin or FITC-LPS and the PPE dissolved in modified transport buffer. For
amphiphilic compounds, 1% FaSSIF (v/v) in transport buffer was used to stabilize dose
preparations. Dose solutions of NaCap were prepared in Ca2+-free transport buffer to avoid
precipitation. Dose solutions of 3-NC were prepared in transport buffer adjusted to pH 5.6 to
improve stability. These modifications were included in control wells and did not adversely
affect the integrity of the monolayers. The basolateral compartment contained 1.5 mL of
pre-warmed transport buffer. Monolayers were placed on a rotary shaker and agitated at 160
rpm (Lab-line Model 3520 Orbit Shaker), a speed that was determined in previous studies to
reduce the unstirred water layer thickness without damaging the monolayer integrity
(Chapter 2). The treatment duration was 15 min at 37ºC.
LDH leakage assay
At the end of the PPE treatment period, an aliquot of the apical compartment was
diluted 1:10 with transport buffer and assayed for LDH leakage according to directions
provided in the CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega
Corporation, Madison, WI). Briefly, the diluted sample was transferred to 96-well plate,
then mixed with an equal volume of reagent and incubated for 10 min at room temperature.
The coupled enzymatic reaction was stopped with 50uL of stop solution. The fluorescent end
product resorufin was read in a Cytofluor fluorescent plate reader (Applied Biosystems,
Foster City, CA) using an excitation wavelength of 530 nm and an emission wavelength of
590 nm. Fluorescence readings from samples obtained from PPE-treated monolayers were
compared to the maximum amount of LDH present in monolayers, and reported as % total
LDH. The total LDH was obtained by treating the monolayer with 0.18 % (v/v; 2.9 mM)
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Triton-X-100 (TRX), as specified in the assay directions, which resulted in 100% lysis of
apical cell membranes.
Reversibility of PPE effect
The ability of cell monolayers to recover their barrier properties following the 15 min
PPE treatment period was assessed after removal of the PPE dose solution and a single wash
with either transport buffer or cell culture media followed by incubation with a fresh aliquot
of the same solution at 37°C for up to 4 h. Additional studies were conducted with PCC
using transport buffer, cell culture medium, or 100% FaSSIF (apical) and human serum
(basolateral) as the recovery media. In this study, the amount of PCC remaining with the
cells was assessed at each time point using LC/MS as described in Chapter 2.
Histological assessment of monolayers
At the end of the PPE treatment period, monolayers were fixed with neutral buffered
formalin for approximately 24 h. Monolayers were then dehydrated with increasing
percentages of ethanol, and stained with hematoxylin and eosin (H&E). Stained cells were
mounted on slides and encoded so that their treatment condition was hidden. Blinded
samples were qualitatively examined for damage by a pathologist. To quantify missing and
non-stained cells within the monolayer, ten fields were selected from each monolayer using a
random number generator. These fields were photographed at 10X magnification using an
Olympus BX51 microscope. The images were then exported into Image-Pro-Plus 5.1
(Media Cybernetics, Inc.), and segmented. The lighter areas (i.e., aberrant areas or areas of
damage) were counted and the area counts were exported to an Excel spreadsheet. For each
field, the areas of damage were summed and divided by the total area in the field to obtain
132
the aberrant area as a percentage of the total field area. The data for each monolayer are
reported as the mean of ten fields.
Assessment of paracellular permeability enhancement due to PPEs
The paracellular permeability enhancing ability of PPEs was measured after
treatment of cell monolayers on the apical side of the Transwell™ compartment with
increasing concentrations of PPEs. Two measures were used to assess changes to the
paracellular pathway: 1) a decrease in TEER measured at the end of the 15 min treatment
period; and 2) an increase in the amount of the paracellular marker compounds 14C-mannitol
and 14C-carboxyinulin appearing in the basolateral side during the 15 min PPE treatment
period.
TEER, a surrogate marker for the TJ permeability of cell monolayers, was assessed
immediately prior to PPE treatment and at specified intervals during the treatment or
recovery period using an Endohm Voltohmmeter (World Precision Instruments) maintained
at 37ºC with a slide warmer. The change in TEER due to PPE-treatment is normalized to the
change in TEER measured across control monolayers (% control).
Radiolabeled markers 14C-mannitol and 14C-carboxyinulin (donor concentrations 10
and 100 µM, respectively) that had accumulated in the basolateral compartment over the
entire treatment period were quantified by mixing 0.5 mL aliquots with 5 mL of UniverSol
ES scintillation fluid (ICN, Costa Mesa, CA). Radioactivity in each sample was measured in
a Tri-Carb 2500TR scintillation spectrometer (Perkin-Elmer Life and Analytical Sciences,
Boston, MA).
The amount of FITC-LPS that had crossed cell monolayers during the PPE treatment
period was quantified using a Cytofluor plate reader (Applied Biosystems, Foster City, CA)
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at excitation/emission wavelengths of 485/530 nm. Fluorescence units for each sample were
converted to concentration of FITC-LPS by comparison to known concentrations of FITC-
LPS standards. The limit of quantification was 5 ng/mL.
Calculations.
TEER was measured across control and PPE-treated monolayers at the end of the
treatment period. The % control TEER values for individual wells were plotted versus PPE
concentration, and fit to a four parameter Hill model with power-of-the-mean variance. The
median EC50 TEER, which is defined as the PPE concentration which decreases TEER to 50%
of the control TEER value, was estimated from the fitted curves.
The amount of hydrophilic markers or LPS appearing in the basolateral compartment
at 37ºC from t=0 to t=T after each treatment condition was used to calculate the apparent
permeability coefficient (Papp) according to equation (1),
Papp = dQ/dt * 1/(A)*1/(C0) units = nm/sec (1x10-7 cm/sec) (1)
where dQ/dt is the amount Q of marker or LPS measured in basolateral compartment after
time T, A is membrane surface area and C0 is the initial concentration of compound.
Data Analysis
Data are expressed as mean ± standard deviation (SD) from at least three
measurements. Statistically significant increases in Papp were assessed using a two-sided
Student’s t test. The samples were assumed to have unequal variance. Significant
differences were assigned at p<0.05. For histological quantitation experiments, a weighted
one-way analysis of variance (ANOVA) model of aberration was fit to the treatment groups
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for assessment of statistical significance. Weighting was proportional to the inverse of the
squared standard deviation of aberration.
Results
LDH leakage after PPE treatment
Treatment with increasing concentrations of amphiphilic PPEs GW4936, HPC and
PCC caused a gradual increase in the amount of LDH released in the apical medium (Figure
3.1). A 15 min treatment time with agitation of the monolayers at 160 rpm on a rotary
shaker was used. These conditions were previously found to approximate the transient
exposure of a PPE to a particular point of the intestinal epithelium, and to reduce the
unstirred water layer thickness to more in vivo like value (Chapter 2). As GW4936, HPC
and PCC concentrations approached 500 µM, the LDH leakage was 49 - 70% of the total
LDH present in the monolayer. The toxic concentration that caused leakage of 50% of total
LDH (TC50 LDH) was estimated from the plot of % Total LDH versus PPE concentration, and
is listed in Table 3.1 for each PPE tested. The TC50 LDH values for GW4936, HPC and PCC
were 3 to 5-fold higher compared to the EC50 TEER values, a measure of paracellular
permeability potency determined under these conditions (Tables 2.2, 2.4 and 2.5).
The amphiphilic PPE NaCap, which had an EC50 TEER of 14 mM under these
conditions, caused a slight but statistically significant elevation in LDH at a concentration of
13 mM (6% of total LDH), which further increased to 20% of total LDH at 16 mM;
however, at higher concentrations of NaCap the amount of LDH gradually decreased, and at
concentrations > 30 mM, the measured LDH was significantly lower than that of control
monolayers (data not shown), suggesting that NaCap interfered with the LDH assay
measurement. Therefore, TC50 LDH could not be obtained for this compound.
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The non-amphiphilic compounds EDTA and 3-NC did not cause any increase in
LDH leakage into the apical compartment, even after exposure for longer time periods (60
min) and concentrations up to 20 mM or 2 mM concentrations (data not shown).
Reversibility of PPE effects
After treatment with amphiphilic PPEs at concentrations approximately equal to the
EC50 TEER for 15 min, all monolayers showed a decrease in barrier function with a measured
TEER that was 20-40% of control monolayers (Figure 3.2). After removal of PPEs, a single
rinse, and then incubation in transport buffer at 37°C, only partial recovery in TEER was
observed over the 4 h recovery period (Figure 3.2 (A)). In contrast, when cell culture
medium was used as the rinse and recovery solution, monolayers treated with the same
amphiphilic PPEs recovered to > 90% of control TEER within 4 h after removal of the PPEs
(Figure 3.2 (B)).
After 15 min treatment with non-amphiphilic PPE EDTA, monolayers recovered
rapidly in the presence of either transport buffer or cell culture medium (Figure 3.2)
suggesting more reversible TJ effects compared to a similar treatment period using
amphiphilic PPEs. Longer treatment periods with EDTA (30, 60 or 90 min) and subsequent
monitoring of TEER following removal of dose solutions showed similar reversibility after
30 min EDTA treatment (data not shown); however, after 60 or 90 min EDTA treatment,
monolayers did not recover TEER over the 4 h recovery period in either transport buffer or
cell media (data not shown). Monolayers treated with 500 µM 3-NC for 60 min, did not
recover in either transport buffer or cell culture medium; instead, the TEER continued to
decrease throughout the recovery period (Figure 3.2). Even after incubation for 24 hrs in cell
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culture media, no TEER recovery was evident after treatment with this concentration of 3NC
(data not shown).
Additional studies were conducted in order to better understand the basis for the
different recovery observed in the presence of transport buffer versus cell culture medium
after treatment with amphiphilic compounds. Monolayers were treated with PCC as before,
and then rinsed and allowed to recover with either transport buffer, cell culture medium or
100% FaSSIF (apical compartment) / human serum (basolateral compartment). The amount
of residual PCC in cell monolayers was measured by extracting the cells with ethanol
followed by analysis of the extract using LC/MS (as described in Chapter 2). As shown in
Table 3.2, the amount of PCC remaining in the monolayer was substantially reduced after
rinsing and subsequent incubation with FaSSIF/serum or with cell culture medium at all time
points measured compared to the amount of PCC present initially. At all time points, the
amount of residual PCC was similar for monolayers treated with FaSSIF/serum or cell
culture medium, and was significantly lower compared to monolayers that were rinsed and
incubated with transport buffer alone. For example, the amount of PCC remaining in the
monolayers after transport buffer treatment was 4-fold higher than that after treatment with
FaSSIF/serum or cell culture medium at 2 h following removal, lending support to the
hypothesis that the reason for poor recovery of TEER in the presence of transport buffer was
due to inefficient removal of amphiphilic PPEs.
The recovery of TEER in the corresponding monolayers in the presence of each
recovery buffer after initial treatment with PCC is shown in Figure 3.3. Interestingly, even
though comparable amounts of PCC remained in monolayers in both FaSSIF/serum and cell
culture medium treated cells, the recovery of TEER was more rapid in cell culture medium-
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treated monolayers, suggesting that other factors present in cell culture medium were
contributing to the more rapid recovery of TEER. At later time points (
 240 min), however,
incubation with both FaSSIF/serum and cell culture medium resulted in full recovery of
TEER, whereas transport buffer-treated cells did not fully recover (Figure 3.3).
In order to estimate the cytotoxic threshold dose of HPC beyond which monolayers
would not recover their barrier function, the reversibility of TEER was assessed after
treatment with increasing concentrations of HPC followed by removal and subsequent
incubation in the presence of cell culture medium. As shown in Figure 3.4, monolayers
recovered 90% of the control TEER value within 3 hrs at HPC concentrations  300 µM.
Thus, based on TEER reversibility, the cytotoxic threshold concentration of HPC is
approximately 300 µM.
Histological assessment of monolayer damage after HPC treatment
In order to further assess the cytotoxicity resulting from transient treatment of Caco-2
cell monolayers with increasing doses of HPC, cell monolayers were fixed immediately after
treatment, stained with H&E, and then examined for signs of abnormality. Representative
photomicrographs are shown in Figure 3.5. In control monolayers, cells appeared mostly
confluent with small randomly scattered areas of darker stained cells mixed with other small
areas of lightly stained cells (Figure 3.5A), perhaps indicating non-uniformity in the cell
monolayer. Monolayers treated with HPC at concentrations of 100 and 200 µM, appeared
similarly healthy to those of untreated control cell monolayers. However, at HPC
concentration of  300 µM HPC (shown for 300 µM in Figure 3.5B, and for 600 µM in
Figure 3.5C), noticeable morphological changes were evident, including multiple aberrant
areas of transparent and swollen cells with no distinct membranes. As a positive control for
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membrane damage, 0.18% (v/v, 2.9 mM) TRX was incubated with cell monolayers, a
treatment previously determined to cause complete lysis of cell membranes. Distinct areas
of cell sloughing are evident after treatment with TRX, though a remnant of (dead) cellular
material remained attached to the Transwell filter surface (Figure 3.5D).
These aberrant areas (areas of transparent, swollen cells with no distinct cell
membrane) were quantified using Image Pro Plus 5.1. A representative photomicrograph
and the corresponding segmentation of the aberrant areas are shown in Figure 3.6. Gradual
increases in the average aberrant areas were found for HPC concentrations  400 µM (n=3
monolayers, Table 3.3), although due to the variable nature of the damage, assessed using 10
photographic fields per monolayer, ANOVA analysis did not reveal significant differences at
any HPC concentration versus that found for control monolayers. Thus, in some
photomicrographs for control monolayers, the aberrant area comprised as much as 7% of the
total area, whereas in some photomicrographs for monolayers treated with 600 µM, the
aberrant area was only 2%. However, TRX treatment, which clearly eroded significant areas
of the cell monolayer, resulted in a significantly higher percentage of monolayer aberrations
compared to control monolayers.
Hydrophilic marker and LPS flux across monolayers after HPC treatment
Using a concentration range spanning relatively paracellular permeability effects to
cytotoxic concentrations of HPC, the increase in the transepithelial flux of hydrophilic
markers 14C-mannitol and 14C-carboxyinulin was evaluated in Caco-2 cell monolayers. As
shown in Figure 3.7, Papp values of 14C-mannitol and 14C-carboxyinulin were significantly
enhanced during the 15 min treatment period with relatively non-toxic concentrations of
HPC (200-300 µM). For example, after co-treatment with 200 µM HPC, the Papp for 14C-
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mannitol was increased approximately 4-fold, from the baseline value in untreated
monolayers of 2 nm/sec to 8 nm/sec. Likewise for 14C-carboxyinulin, the increase in Papp
was 4-fold, from 0.7 to 2.7 nm/sec. At higher HPC concentrations, further increases in Papp
for these hydrophilic markers was achieved; however, based on the cytotoxicity evaluations
(LDH leakage, reversibility in TEER and histological examination of cells) these increases
are likely due in part to membrane and cell monolayer damage at HPC concentrations greater
than 300 µM.
Over the same HPC concentration range, the effect on the flux of the amphiphilic
bacterial toxin LPS was evaluated (Figure 3.7). With a donor concentration of 50 µg FITC-
LPS/mL, the amount of FITC-LPS appearing in the receiver compartment was below the
limit of quantitation (5 ng/mL or Papp = 1.7 nm/sec) until HPC concentrations reached  400
µM. Therefore, FITC-LPS does not traverse the cell monolayers significantly over the
effective concentration range of HPC. It traverses monolayers only after treatment with HPC
at concentrations that cause substantial damage to cell monolayers. However, further
investigations will be required in order to quantify FITC-LPS flux behavior across Caco-2
cell monolayer after treatment with relatively non-toxic concentrations of HPC.
Discussion
In vitro cytotoxicity caused by PPEs has been measured previously by others. These
studies have utilized a variety of functional assays that measure the metabolic status of the
cells, for example, the ATP-generating ability of cells assessed using a tetrazolium dye
reduction assay (e.g., 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide,
MTT)10, or cellular membrane damage, using assays such as propidium iodide exclusion or
LDH leakage11. Using these assays, a relatively narrow window has been found between
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PPE concentrations that open TJs to allow increased absorption of hydrophilic molecules,
and those that impact ATP generation or cause membrane damage12, particularly for
amphiphilic PPEs. Amphiphilic PPEs, a structural class comprising many of the PPEs that
have been studied to date, are likely to accumulate in cell membranes due to their structural
similarity to membrane phospholipids, which may lead to slight membrane perturbation at
low concentrations but to membrane lysis at a higher PPE concentrations. For example, the
amphiphilic PPE, PCC, has been reported to transiently increase the paracellular absorption
of hydrophilic markers across Caco-2 cells at a concentration of approximately 200 µM
without causing lysis of cell membranes13,14. However, at PCC concentrations of
approximately 400 µM, the cellular ATP-generating machinery, measured by the MTT
assay, is inhibited and propidium iodide penetration is increased signifying cytotoxicity11,12.
In the current study, PPE-induced cellular membrane damage, a likely initial event
for amphiphilic PPE-induced cytotoxicity, was assessed by measuring the amount of
cytosolic enzyme LDH that was released into the apical compartment of Caco-2 cells grown
on Transwells. This assay was chosen because of its relative simplicity and potential use in
future in vivo PPE cytotoxicity measurements to enable in vitro-in vivo comparisons. As
shown by others11, increasing doses of PCC resulted in increasing amounts of LDH leakage
from Caco-2 cell monolayers (Figure 3.1). Comparison of the derived toxicity parameter,
TC50 LDH (the concentration that caused release of 50% of the total LDH) to the efficacy
parameter EC50 TEER, revealed that the TC50 LDH for PCC is approximately 5-fold higher
(Table 3.1). However, even at PCC concentrations of 100-200 µM, significant LDH leakage
(5 – 14% of total LDH) is detected relative to that found in control monolayers.
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The amphiphilic compounds, GW4936 and HPC, also caused a significant and
gradual increase in the amount LDH leakage, with significant LDH leakage occurring at
concentrations of 100 – 200 µM (Figure 3.1 and Table 3.1). The amphiphilic PPE, NaCap,
which requires approximately 10-fold higher concentrations to open the paracellular
pathway, also showed an increase in LDH leakage at the effective concentration of 13 mM,
though an accurate assessment of the amount of LDH leakage caused by NaCap was not
possible because NaCap interfered with the measurement of LDH at higher concentrations.
Consistent with their structural properties, the non-amphiphilic compounds 3-NC and EDTA
did not cause an increase in LDH in the apical compartment of Caco-2 cells after 15 min
treatment with concentrations that were 4 to 10 fold higher than EC50 TEER concentrations.
Despite substantial LDH leakage at EC50 TEER concentrations, reversibility of the
TEER effect could be achieved after removal of amphiphilic PPEs and incubation with cell
culture medium (Figure 3.2B). Recovery of monolayer barrier function in the presence of
cell culture medium, but not transport buffer, has been observed by others after treatment
with amphiphilic compound sodium dodecyl sulfate15. A key component of TEER
reversibility was shown in these studies to be the complete removal of the amphiphilic PPE
from the cell monolayers. As shown for PCC, TEER recovered fully in the presence of cell
culture medium or FaSSIF/serum (Figure 3.3), conditions that also substantially reduced the
amount of PCC remaining associated with the cell monolayers (Table 3.2). The biorelevant
buffers FaSSIF or serum were previously shown (Chapter 2) to either prevent interaction of
amphiphilic PPEs with the cell membrane (FaSSIF) or enhance the flux of amphiphilic PPEs
across the membrane (serum). As these studies have further illustrated, the altered
disposition of amphiphilic PPEs due to biorelevant buffers affects the recovery of cell
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monolayer barrier function after treatment with amphiphilic PPEs. Thus, if complete
removal of PCC and other amphiphilic PPEs is achieved, such as when using FaSSIF/serum
or cell culture medium, the effect of these PPEs on cells is entirely reversible at
concentrations approximately equal to the EC50 TEER (Figure 3.2B). Thus, the anticipated
recovery of the intestinal barrier function after in vivo treatment with amphiphilic PPEs is
may be quite rapid due to the presence of blood components and/or intestinal fluids.
The decrease in TEER due to EDTA treatment was fully reversible after the 15 min
treatment period with either transport buffer or cell culture as the recovery buffer (Figure
3.2), although after longer EDTA treatment times (
 60 min) monolayers did not recover
their barrier function even in the presence of cell culture medium. Thus, extended treatment
with EDTA, an agent which is thought to be relatively non-toxic and is used routinely to
understand the cellular processes associated with disassembly and reformation of the TJs
(Ca2+-switch assay), can result in irreversible effects, suggesting cytotoxicity. Interestingly,
the decrease in TEER across Caco-2 cell monolayers caused by the non-amphiphilic PPE 3-
NC was not reversible with either cell culture medium or transport medium as the recovery
buffer (Figure 3.2). These data suggest that 3-NC acts via irreversible modifications to
proteins, which has been previously proposed based on its structure (Table 1.3), because 3-
NC contains an , -unsaturated carbonyl moiety that may act as a Michael acceptor for
protein nucleophiles.16 This finding is likely to preclude the use of 3-NC as a PPE in
humans.
A third important component included in the evaluation of PPE-induced cytotoxicity
in these studies was the assessment of whether transient PPE treatment creates microerosions
in cell monolayers due to cell sloughing. Indeed, intestinal epithelial cell sloughing has been
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observed after intestinal ischemia-reperfusion injury, and is thought to contribute to the
absorption of intestinal toxins resulting in septic shock17. Thus, to address the concern that
PPE-induced changes to the epithelial barrier could cause similar epithelial denudation, areas
of monolayer aberrations were quantified in H&E stained monolayers following treatment of
Caco-2 cell monolayers with increasing concentrations of HPC.
Although a trend toward increasing areas of monolayer aberrations was observed
with increasing concentrations of HPC (Table 3.3), the increases were not statistically
significant compared to control monolayers. Furthermore the average (7%) aberration
caused by the highest concentration of HPC tested (600 µM) was found to be approximately
3-fold lower than the area of epithelial denudation caused by ischemia-reperfusion injury in
porcine ileum17. Further, it should be noted that the percent aberration determined using this
technique represents the maximum area of cell sloughing caused by HPC, because under
higher magnification, some of the areas quantified as aberrant were found to have cells
present, albeit lightly-stained. Thus, even at concentrations of HPC that appeared to cause
membrane damage (leakage of > 50% of total LDH), large areas of cell sloughing are not
observed.
In contrast, after treatment with 0.18% (v/v, 2.9 mM) TRX, a positive control for cell
lysis in the LDH assay, large areas of cell sloughing were evident, with the average area of
cell denudation representing 55% of the total field area (Table 3.3). Thus, 10% TRX results
in much greater areas of cell sloughing (8-fold greater) compared to those caused by the
highest concentration of HPC tested; yet the damage assessed by LDH leakage after
treatment with these conditions differed by less than 2-fold. Therefore, the histological
quantitation technique employed in these studies for the first time to assess PPE-induced
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toxicity, provides a unique measure of epithelial damage, one which may provide a better
indication of whether systemic toxicity due to absorption of bacterial fragments through
large areas of damaged epithelium is likely to occur.
The bacterial toxin LPS is a well-established causative agent of sepsis following
intestinal injury7,18. LPS is a fragment derived from the cell wall of gram negative bacteria
and is structurally composed of a core lipid A molecule, which contains several lipophilic
alkyl chains attached to a phosphodisaccharide unit (Figure 3.8). Attached to the lipid A is a
large polysaccharide of varying length thereby giving LPS a variable and large molecular
weight (3 to 20 kDa) that may aggregate into large micelles due to its amphiphilic quality
with molecular weights of the micellar particles of 1,000 to 20,000 kDa19. The primary
mechanism of LPS absorption across the intestinal epithelium is not clear. It has been shown
to be transcytosed across T84 cell monolayers by a receptor mediated process20, while others
have found that FITC-LPS can be additionally absorbed via the paracellular pathway in
Caco-2 cells that are incubated under hypoxic conditions21. Thus the changes in LPS
absorption across the intestinal epithelium after various sources of insult or injury have been
measured across cell monolayers or intestinal tissue21-23, however, this is the first known
attempt to measure the increase in LPS flux across cell monolayers after modulation of the
barrier function by a PPE.
Using the Caco-2 cell monolayer system, the flux of FITC-LPS derived from E. Coli
with a molecular weight of approximately 10 - 20 kDa was measured in the presence of
increasing concentrations of HPC under conditions for which cytotoxicity parameters were
characterized. The flux of two hydrophilic markers, 14C-mannitol and 14C-carboxyinulin, of
differing molecular size were also measured. FITC-LPS was not detected in the basolateral
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compartment of control monolayers, or after treatment with HPC at concentrations < 400 µM
for 15 min, whereas a concentration-dependent increase in flux for 14C-mannitol and
14C-carboxyinulinin at the same HPC concentrations was observed (Figure 3.7). This result
is consistent with the lack of transepithelial flux of LPS across hemorrhagic shock injured rat
intestinal tissue observed previously by others22, although the short duration of the test and
lack of detection sensitivity in this study might have contributed to this result. Attempts
were made to increase the sensitivity of detection by using alternate detection methods.
LC/MS/MS was investigated as an alternate detection method, however, no improvements in
detection sensitivity over that of fluorescence were obtained. Detection sensitivity was
improved by 3 orders of magnitude (5 pg/mL) using the Limulus amebocyte lysate bioassay,
however, consistent results for standards were not obtained (data not shown). Further
attempts to increase the sensitivity by increasing the donor concentrations of FITC-LPS (100
– 1000 µg/mL) resulted in a decrease in TEER across the monolayers (in the absence of
HPC; data not shown), therefore these conditions were not used. Thus, while these data are
reasonable based on the large molecular weight, amphiphilic nature of LPS and purported
transcytotic mechanism of LPS absorption across non-altered epithelium, further studies will
be needed to confirm the lack of LPS enhancement at relatively non-toxic concentrations of
amphiphilic PPEs such as HPC. At high concentrations of HPC, i.e., those which caused
significant LDH leakage and a trend toward increased aberrant monolayer areas, an increase
in FITC-LPS flux was observed. Thus, when the cell monolayer barrier is damaged by a
PPE, an increase in LPS absorption can be observed. It remains to be tested whether the
selective opening of TJs by a PPE will also result in increased absorption of LPS across cell
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monolayers, or whether in vivo modulation of the intestinal epithelium caused by a PPE will
result in increased LPS absorption.
In summary, amphiphilic PPEs were found to cause cell membrane damage resulting
in release of LDH at concentrations only slightly higher than those causing a reversible
decrease in TEER or increase in hydrophilic marker flux. Recovery of the barrier function in
cells was aided by the use of cell culture medium, a buffer that aids in the complete removal
of amphiphilic PPEs from the cell membrane, and a buffer that is also more biorelevant. As
shown for HPC, even though noticeable morphological changes were evident at
concentrations  300 µM, large areas of monolayer defects or aberrations due to cell
sloughing were not evident even after treatment with high concentrations of HPC,
concentrations that result in large amounts of LDH release. Finally, transient treatment of
Caco-2 cell monolayers with amphiphilic PPE, HPC, at concentrations spanning the range
from primarily paracellular, reversible effects, to those causing membrane damage, results in
detectable LPS flux only at cytotoxic concentrations. The multi-faceted in vitro assessment
of cytotoxicity summarized in this work establishes that enhancement of hydrophilic
compound permeability with amphiphilic PPEs can be achieved with relatively non-toxic
concentrations, and that these concentrations do not result in substantial transepithelial
exposure to bacterial toxin LPS. For the first time in these studies, an evaluation of the
potential for systemic toxicity due to PPE treatment was explored by examining the effect
PPE on the absorption of LPS. Thus, these studies have broadened the scope of in vitro PPE
toxicity assessment.
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Table 3.1 Comparison of EC50 TEER to TC50 LDH after 15 min treatment of Caco-2 cell
monolayers
PPE EC50 TEER (µM)a TC50 LDH(µM)b TC50 LDH/EC50
TEER
GW4936 160 500 3.1
HPC 110 500 4.5
PCC 83 425 5.1
NaCap 14000 c --
EDTA 1200 d --
3-NC 510 d --
aValues taken from Table 2.2 (3-NC), Table 2.4 (HPC, PCC, NaCap, EDTA) and 2.5
(GW4936).
bValues estimated from a plot of % of Total LDH versus PPE concentration and defined
as the PPE concentration that causes release of 50% of the total LDH present in
monolayers. The total LDH was assessed by treatment of cells with 0.2% Triton-X-100.
cValue not obtainable due to interference with LDH measurement.
dNegligible LDH release at highest concentration tested, 20 mM EDTA or 2 mM 3-NC,
after treatment for 60 min.
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Table 3.2 Amount of PCC associated with Caco-2 cell monolayers after dose removal
and incubation in different buffers
Recovery buffer Time (min) Cell-associated PCC (% dose)a
Initial treatment 15 13.1 +/- 1.2
Transport buffer 120 7.8 +/- 0.8
240 7.3 +/- 0.6
420 4.9 +/- 0.2
FaSSIF-serum 120 2.1 +/- 0.1
240 1.6 +/- 0.5
420 1.3 +/- 0.2
Cell culture medium 120 2.7 +/- 0.1
240 2.2 +/- 0.2
420 1.7 +/- 0.4
aValues are mean ± standard deviation for 3 monolayers.
153
Table 3.3 Histological quantitation of monolayer aberrations after treatment with HPC
or TRX
Monolayer
ID
HPC Concentration
(µM)
Avg %
Aberrationa
SDb Avg % Aberrationc
1 0 1.1% 0.6% 2.6%
2 0 3.9% 2.3%
3 0 2.8% 1.3%
4 50 1.3% 0.5% 2.4%
5 50 3.2% 0.9%
6 50 2.6% 1.0%
7 100 3.9% 0.9% 2.6%
8 100 1.8% 0.6%
9 100 2.0% 0.6%
10 200 1.6% 0.8% 2.7%
11 200 2.7% 1.0%
12 200 3.8% 0.8%
13 300 3.9% 1.2% 3.4%
14 300 3.8% 1.9%
15 300 2.3% 1.4%
16 400 2.9% 1.0% 4.5%
17 400 8.1% 2.0%
18 400 2.5% 0.9%
19 600 11% 6.2% 7.2%
20 600 5.0% 2.3%
21 600 5.5% 2.4%
22 TRX (2.9 mM) 65% 23% 54.7%
23 TRX (2.9 mM) 45% 11%
24 TRX (2.9 mM) 54% 26%
aAverage % aberration of total field area for 10 randomly selected fields
bStandard deviation of % aberration of total field area for 10 randomly selected fields
cAverage % aberration for treatment group (n=3 monolayers)
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Figure 3.1 LDH leakage into the apical compartment of Caco-2 cells after treatment
with amphiphilic enhancers.
The amount of LDH released into the apical compartment of Caco-2 cell monolayers
grown on Transwells was measured after 15 min treatment with amphiphilic PPEs, as
described in Methods. Values are reported as the mean % of Total LDH for 3
monolayers ± standard deviation. The total LDH was quantified by treatment of cells
with 0.2% Triton-X-100. Asterisk (*) indicates lowest PPE concentration that caused
significantly higher LDH leakage compared to control monolayers (p<0.05).
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Figure 3.2 Recovery of TEER across Caco-2 cells after treatment with PPEs.
The ability of the monolayers to recover their barrier function after transient treatment
with PPEs at concentrations approximately equal to the EC50 TEER (200 µM for HPC,
PCC and GW4936; 13 mM for NaCap; 2 mM for EDTA; and 500 µM for 3-NC) was
assessed by measuring TEER immediately following treatment (initial value, black bars),
and after removal of PPEs, and subsequent incubation with either transport buffer or cell
culture medium. TEER was measured at 1, 2 or 4 h after PPE removal (gray bars) and
reported as % Control TEER for cells incubated in transport buffer (A) or in cell culture
medium (B). Values mean ± standard deviation for at least 3 monolayers.
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Figure 3.3 Recovery of TEER across Caco-2 cells after treatment with PCC and
incubation in different buffers.
Cells were treated with PCC at 200 µM for a period of 15 min. At the end of the
treatment period, TEER was measured (arrow), then the PPE solutions were removed, the
monolayers were rinsed 1x, followed by incubation in either transport buffer (), cell
culture medium (), or 100% FaSSIF (apical) / human serum (basolateral)(). TEER
was measured at the indicated time points and reported as % Control TEER. Control
monolayers ()were rinsed and incubated with the same buffers but did not receive
treatment with PCC. TEER for control monolayers did not change more than 10%
compared to the initial value up to 240 min, but decreased by 15% in FaSSIF/serum
controls at 420 min. Values mean ± standard deviation for at least 3 monolayers.
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Figure 3.4 Recovery of TEER across Caco-2 cells after treatment with HPC.
Cells were treated with HPC at the indicated concentrations or with TRX (0.18%, 2.9
mM) for a period of 15 min. At the end of the treatment period, TEER was measured
(arrow), then the PPE solutions were removed, the monolayers were rinsed 1x, followed
by incubation in cell culture medium. TEER was measured at the indicated time points
and reported as % Control TEER. Control monolayers ()were rinsed and incubated with
the same buffers but did not receive treatment with HPC. TEER for control monolayers
did not change more than 10% compared to the initial value. Values are mean ± standard
deviation for at least 3 monolayers.
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Figure 3.5 Representative photomicrographs of Caco-2 cell monolayers after 15 min
treatment with HPC or TRX.
Cells were treated with transport buffer (control, panel A), 300 µM HPC (panel B), 600
µM HPC (panel C), or TRX (0.18%, 2.9 mM) (panel D). Percentages indicate aberrant
area as % of total field area.
160
Figure 3.6 Representative photomicrograph and corresponding segmentation of
aberrant area of Caco-2 cell monolayers using Image Pro Plus 5.1 software.
Top panel depicts a randomly selected field from a monolayer treated with 600 µM HPC,
photographed at 10X magnification using an Olympus BX51 microscope. Bottom panel
depicts the image following segmentation. The red portion indicates the aberrant areas in
the field. In this photomicrograph the aberrant area represents 14 % of total field area.
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Figure 3.7 Increase in paracellular marker or LPS permeability across Caco-2 cell
monolayers following co-administration with HPC or TRX.
The apparent permeability coefficient (Papp) for 14C-mannitol (closed bars), 14C-
carboxyinulin (open bars) and FITC-LPS (red bars) were determined over the 15 min
treatment period in the absence or presence of increasing concentrations of HPC as
described in Methods. Values are mean ± standard deviation for 3 to 9 wells. Hash mark
(#) indicates LPS was not detected in basolateral compartment. Asterisk (*) indicates
lowest HPC concentration that caused significantly higher Papp compared to control
monolayers (p<0.05).
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CHAPTER 4
IN VITRO-IN VIVO RELATIONSHIP OF EFFICACY AND TOXICITY
PARAMETERS FOR THE PARACELLULAR PERMEABILITY ENHANCER HPC
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Abstract
The purpose of this work was to evaluate whether transient in situ treatment of rat intestine with
an effective dose of an amphiphilic paracellular permeability enhancer would result in non-
specific damage to the intestinal epithelium or an increase in exposure to lipopolysaccharide
(LPS), a bacterial fragment that has been implicated in systemic toxicity following intestinal
epithelial injury. Male rats were anesthetized and a 10 cm segment of ileum was cannulated and
rinsed. The efficacy of hexadecylphosphocholine (HPC) was assessed by measuring an increase
in the amount of 3H-mannitol and 14C-carboxyinulin appearing in the urine following ileal co-
administration with increasing concentrations of HPC for 30 minutes. Non-specific damage to
the intestine caused by HPC was assessed by measuring lactate dehydrogenase (LDH) in the ileal
lumen and by histological examination of tissues. The local and systemic response to LPS was
assessed by measuring concentrations of TNF in ileal lumen and in blood after ileal co-
administration with 250 µg LPS/kg in the presence of HPC. The presence of macrophages and
TNF in ileal tissue were detected by immunohistochemical staining techniques. The minimum
effective concentration of HPC in this model, 2 mM (0.8 mg/kg), caused an average increase in
mannitol absorption of 5-fold (from 3% to 16% of the administered dose) and in carboxyinulin
absorption of 15-fold (from 0.4% to 6%). This HPC dose also resulted in elevated levels of LDH
in the ileal lumen, and in morphological changes suggestive of epithelial damage relative to
vehicle-treated animals. These data differ from previous results obtained in Caco-2 cell
monolayers that indicated relatively minor cytotoxic effects of HPC at effective concentrations.
After LPS co-administration with 2 mM HPC, elevated TNF levels were not detected in
plasma. Thus, the transient intestinal exposure to amphiphilic paracellular permeability enhancer
HPC at concentrations that resulted in a significant increase in the absorption of hydrophilic
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molecules also caused measurable, local epithelial damage, but did not result in significant
systemic exposure to LPS.
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Introduction
The oral route is the preferred route of administering drugs. However, some drugs may
exhibit poor oral bioavailability because they do not easily traverse the intestinal epithelium.
One approach to improve the intestinal absorption of poorly absorbed molecules is to transiently
open the intercellular spaces between the intestinal epithelial cells by modifying the normal
interactions of the tight junction (TJ) proteins through the use of a co-administered paracellular
permeability enhancer (PPE).
While studied extensively in vivo in animals, and in vitro using cell monolayers such as
Caco-2, the PPE approach has not been approved for use in humans. One reason for the
reluctance to use the PPE approach is the concern that PPEs may enhance the permeability of
luminal toxins leading to adverse events or pathological conditions. Indeed, pathological
conditions characterized by leaky TJs or intestinal injury are thought to allow toxins to penetrate
the epithelium leading to local inflammation or septic shock1,2. Thus, the possibility exists that
toxin absorption may be enhanced via PPE-mediated selective opening of TJs through the
paracellular pathway, or through non-specific injury in which larger defects in the epithelium
may be created, although this has not been demonstrated directly. Indeed, non-selective effects
of amphiphilic PPEs have been observed in vitro at concentrations that are only slightly higher
than those that appear to selectively open TJs3. Furthermore, much higher concentrations of
these same PPEs are required in vivo to enhance absorption of poorly absorbed compounds4,
thereby heightening concerns about intestinal injury and subsequent increases in toxin
permeability after amphiphilic PPE treatment.
Evidence was provided in Chapter 3 regarding the enhanced in vitro absorption of the
bacterial toxin LPS following treatment of Caco-2 cell monolayers with cytotoxic concentrations
of HPC. However, it is unknown whether HPC-induced absorption enhancement of LPS, a
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bacterial fragment that has been implicated in systemic toxicity following intestinal epithelial
injury2, would also occur in vivo across the intestinal epithelium, a barrier with the full
complement of cell types and barrier components.
Therefore, we designed the following studies to characterize the in vivo effects caused by
HPC after transient intestinal exposure in an intact animal. A bolus dose of HPC was
administered directly to an isolated segment of the intestine of an anesthetized rat and then the
dose was removed after 30 min. The absorption of hydrophilic markers 14C-carboxyinulin and
3H-mannitol, which are routinely used to assess changes to the intestinal barrier in humans and
animals5-7, was measured, and the intestinal epithelial damage caused by this concentration of
HPC was also assessed. We then investigated whether the minimum effective concentration of
HPC would increase the penetration of exogenously administered LPS by immunohistological
examination of the intestinal tissue and by monitoring the release of TNF into biological fluids.
Methods
Materials
Hexadecylphosphocholine (HPC) was obtained from Avanti Polar Lipids, Inc.
(Alabaster, AL). D-(1-3H)-mannitol (17 Ci/mmol; 93 µCi/mg) and (14C)-carboxyinulin
(1.4 mCi/g) were purchased from Perkin Elmer Life Sciences. (Boston, MA). LPS, isolated
from Escherichia coli serotype O111:B4EDTA, triton-X-100 (TRX), and protease inhibitors,
leupeptin, aprotinin, bestatin were obtained from Sigma Chemical Co. (St Louis, MO).
Phosphate buffered saline (PBS) and cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). Transwells were purchased from Corning Costar (Cambridge, MA).
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Purification of 3H-mannitol
3H-mannitol purity was approximately 80% as assessed by reversed-reverse phase HPLC,
which utilized a silica-based AtlantisHILIC column, 3 µm particle size, 2.1 x 50 mm (Waters
Corp., Milford, MA) and mobile phase comprised of 95:5, acetonitrile:water. Purification was
accomplished using the same chromatographic system after dissolving 200 µCi of 3H-mannitol
in mobile phase and eluting components under isocratic conditions utilizing a flow rate of
0.3 mL/min. Less polar impurities, eluting before mannitol, were collected in separate fractions
with peak detection aided by a Radiomatic Flo-one radiochemical detector operated in a 1:20
split mode (Perkin-Elmer Life and Analytical Sciences, Boston, MA). Eluate was mixed with
scintillant Ultima-Flo M (Perkin-Elmer Life and Analytical Sciences, Boston, MA) at a ratio of
1:4.
Purity improvement in 3H-mannitol was assessed using Caco-2 cell monolayers as
described in Chapter 3. Purified 3H-mannitol was considered to have adequate purity if identical
Papp values for 3H-mannitol and 14C-mannitol were obtained, the latter having 96% purity based
on HPLC-radiochemical detection. Briefly, cell monolayers were equilibrated for approximately
60 min in transport buffer (Hanks’ balanced salt solution supplemented with 25 mM D-glucose
and 25 mM HEPES, pH 7.1) at 37ºC prior to the addition of PPEs. Mannitol flux measurements
were initiated upon replacement of the apical transport buffer with dose solutions (0.4 mL)
containing either 14C-mannitol or 3H-mannitol in transport buffer.
Rat in situ intestinal model
All studies were conducted using protocols approved by the institutional animal care and
use committee at GlaxoSmithKline. Male Sprague-Dawley rats, weighing approximately 300 g
were obtained from Charles River Laboratories, Inc. (Raleigh, NC) with jugular vein and bladder
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cannulae already implanted. Animals were allowed at least 1 week for recovery from surgery
and acclimation, prior to experimentation.
Immediately prior to dosing, fasted rats were anesthetized with isoflurane (IsoFlo®,
Abbott Animal Health, N. Chicago, IL) vapor in oxygen atmosphere (Model 100F vaporizer,
Ohio Medical Products, Airco, Inc., Madison, WI) at a concentration of 5%. Following onset of
deep anesthesia, the percentage of isoflurane was reduced to a maintenance level of 1.5% to 2%.
Previously implanted jugular vein and bladder cannulae were opened, and predose samples of
urine and blood were collected. The bladder cannula was extended to facilitate collection of
urine by gravity flow into vials.
All surgical procedures were performed using aseptic technique. A midline abdominal
incision was made to expose the peritoneal compartment. The lower small intestine was
identified by its proximity to the cecum, and a segment of ileum relatively devoid of intestinal
contents was selected for isolation. An incision was made in the isolated ileum approximately
5 cm from the cecum, and a glass cannula was inserted and secured with silk suture. The 10 cm
of ileum proximal to the inserted cannula was estimated by comparison to a similar length of silk
suture, and a second incision was made followed by insertion of a second glass cannula. The
luminal openings exposed by both incisions, but not implanted with a cannula, were sealed using
Vetbond tissue adhesive (3M Animal Care products, St. Paul, MN) to prevent leakage of
intestinal contents into the peritoneal cavity. The isolated ileal segment was then rinsed with 3 x
3 mL of pre-warmed PBS.
Dose solutions containing hydrophilic markers or LPS, either with or without HPC, were
filtered through a Millex® HV 0.45 µm sterile filter (Millipore Corporation, Billerica, MA) and
administered via a syringe fitted to a 22 gauge needle by injection through a rubber septum
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directly into the isolated, pre-flushed ileal segment. The segment was gently put back into the
peritoneal cavity and the incision was partially occluded and overlaid with gauze sponges
moistened with normal saline. After 30 min, the segment was rinsed with 3 x 3 mL of PBS in
order to remove the dose solution, and placed gently back into the peritoneal cavity. Animals
were maintained under anesthesia for the remainder of the experimental period (total
experimental period = 4 h after dose administration).
At the end of the experiment, the ileal segment was flushed again with 3 x 3 mL PBS,
and the animal was sacrificed by an injection of potassium chloride solution into the heart. The
ileal segment was then excised from the animal and the length of the non-stretched segment was
measured.
Measurement of intestinal absorption of hydrophilic markers
Solutions containing 14C-carboxyinulin and 3H-mannitol (2 µmol/kg body weight or
10 mg/kg body weight and 0.36 mg/kg body weight, respectively) were co-administered with
HPC (0.4, 1.0, 2.0 and 10 mM in PBS) into the isolated ileal segment in a volume of 1 mL/kg
body weight. The exact amount of dose administered was assessed by weighing the syringe
before and after dose administration. Absorption of markers was allowed to proceed for 30 min,
at which time dose solutions were removed by rinsing the segment with 3 x 3 mL of PBS. Urine
was collected in 30 min intervals over the 4 h experimental period by allowing urine to flow
through the bladder cannula via gravity into pre-weighed vials situated on a shelf below the
animals. The total weight of each urine sample was recorded, and then duplicate 20 µL aliquots
were removed and mixed with UniverSol ES scintillation fluid (ICN, Costa Mesa, CA).
Radioactivity in each aliquot was measured in a Tri-Carb 2500TR scintillation spectrometer
(Perkin-Elmer Life and Analytical Sciences, Boston, MA) using modified dual-isotope settings
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for 3H (0 – 12 keV) and 14C (20 – 156 keV). The accuracy of the dual-isotope method was
confirmed by spiking known amounts of each isotope into the same vial in varying 3H:14C
amounts (20:1 to 0.1:1). In order to assess the total recovery of administered radioactivity,
aliquots of each ileal rinse were assessed for radioactivity in a similar manner. The ileal rinse
samples required centrifugation at 2700 x g for 15 min prior to analysis in order to remove
particulate material. Animals were also dosed with 14C-carboxyinulin and 3H-mannitol in PBS
alone (control condition) or with 10% (v/v) TRX, a condition known to cause intestinal damage
as assessed by histological examination.
Measurement of intestinal membrane damage using LDH leakage
Ileal rinse samples from animals treated with increasing concentrations of HPC, PBS or
10% TRX were frozen immediately after collection and stored for < 1 week at -80°C.
Immediately prior to analysis, samples were carefully thawed and 1 mL aliquots were
centrifuged at 2700 x g for 15 min at 4°C prior to analysis. Aliquots of the samples were then
assayed according to directions provided in the CytoTox-ONE Homogeneous Membrane
Integrity Assay (Promega Corporation, Madison, WI). Briefly, the sample was transferred to
96-well plate, then mixed with an equal volume of reagent and incubated for 10 min at room
temperature. The coupled enzymatic reaction, in which the NADH produced in the LDH-
mediated conversion of lactate to pyruvate is utilized in the diaphorase-mediated reduction of
resazurin to resorufin, was stopped with 50 µL of stop solution. The fluorescent end product,
resorufin, was read in a Cytofluor fluorescent plate reader (Applied Biosystems, Foster City,
CA) using an excitation wavelength of 530 nm and an emission wavelength of 590 nm. LDH
leakages samples that were obtained by treating Caco-2 monolayer with 0.18% (v/v; 2.9 mM)
TRX, were used as quality control samples to verify assay performance.
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Further investigations were necessary in order to identify components in ileal rinse
samples responsible for the observed interference and degradation of measured LDH present in
ileal rinse samples. For these studies, an in vitro cell lysate containing a high concentration of
LDH was generated by treating Caco-2 cells with 0.18% TRX. The extent of attenuation of
measured LDH activity in this sample by ileal contents was assessed by diluting the cell lysate
sample 1:10 with ileal flush samples obtained by successive 3 mL PBS rinses of isolated ileum
from non-dosed animals. The measured LDH in these samples was compared to that obtained
after dilution of the cell lysate 1:10 with PBS. Further investigations were performed with
pretreated blank ileal contents samples. Blank ileal rinse was pretreated by 1) boiling for 2 min;
2) ultrafiltration through 5,000, 10,000, 30,000 or 50,000 Da nominal molecular weight limit
(NMWL) Ultrafree® filter units or 3,000 NMWL Microcon® filter units (Millipore Corporation,
Billerica, MA); 3) dialysis across a 500 Da NMWL Spectra/Por® cellulose ester membrane
(Spectrum Laboratories, Inc., Rancho Dominguez, CA) for 24 h; or 4) addition of protease
inhibitor cocktail, including leupeptin, aprotinin, bestatin (final concentration = 10 mM, 1 mM,
10 mM, respectively). Each of these approaches was intended to degrade or remove the
components of the ileal contents interfering with the LDH assay.
Histological assessment of intestinal damage and immunohistological assessment of intestinal
response to LPS
Immediately after treatment with dose solutions containing HPC, 10% TRX or PBS
vehicle alone for 30 min, either with or without LPS (250 µg/mL), the animals were sacrificed
and the ileal segments were infused immediately with 10% neutral buffered formalin by injection
into the proximal end of the ileal segment. Next the segments were removed from the animal
and pinned to a corkboard in order to retain orientation, and fully immersed in 10% neutral
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buffered formalin for approximately 48 hours. Tissues were processed routinely for
histopathology consisting of removing the water by dehydration in graded solutions of alcohol
then infiltrating with paraffin. Prior to embedding in paraffin, ileal segments were cross-
sectioned at approximately 5mm intervals then each cross-section was placed with the proximal
end of the section facing down in the cassette. The first section from the proximal most portion
of the ileal segment was marked on each block followed by each consecutive section being
embedded in the same block in an orderly manner (see Figure 4.1)
For each rat, serial sections, approximately 4 µm thick, from each paraffin block were
placed on a separate slide. A hematoxylin and eosin stain (H&E) and three
immunohistochemical (IHC) stains were performed as described below. Appropriate negative
(omission of primary antibody), positive, and isotype controls were also evaluated to assess the
quality and specificity of staining.
The slides for IHC were first deparaffinized using EZ Prep (Ventana Medical Systems,
Tucson, AZ), a proprietary mild detergent that facilitates the removal of paraffin from the slide.
A final rinse was then performed using a tris-based buffer solution (Reaction Buffer, Ventana
Medical Systems).
The slide for the IHC detection of resident macrophages was incubated with a mouse
anti-rat CD163 clone ED2 (Serotec Ltd, Oxford, UK) antibody at 0.25 mg/ml for 3 h, followed
by treatment with biotinylated anti mouse secondary antibody (Vector Laboratories, Inc.,
Burlingame, CA), and then treatment with 3,3'-diaminobenzidine tetrahydrochloride (DAB) Map
detection (Ventana Medical Systems). Pretreatments using Cell Conditioning One (CC1,
Ventana) for retrieval of antigens lost by formalin fixation crosslinking and avidin biotin
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blocking were performed to block any endogenous biotin prior to use of the biotinylated
secondary. Counterstaining with hematoxylin was done prior to coverslipping.
In a similar fashion, a third slide was immunostained for detection of activated
macrophages with a mouse anti rat CD68 clone ED1 (Serotec Ltd, Oxford, UK) antibody at a
dilution of 1/1000 for 1 hr with heat, followed by treatment with a biotinylated rat absorbed
horse anti mouse (Vector Laboratories, Inc.) at a dilution of 1/150 for 32 minutes then treated
with DAB Map Kit (Ventana Medical Systems). The slides were counterstained with
hematoxylin and bluing (Ventana Medical Systems), rinsed, and then dehydrated with alcohol
and xylene, and coverslipped. Diluent used for dilution of primary and secondary antibodies was
Ventana Discovery Ab Diluent (Ventana Medical Systems). Positive control slide was also run
at the time using rat spleen tissue and a negative control on ileal tissue absent of the primary
antibody. ED1 and ED2 ICH staining were performed on a Ventana Discovery XT® automated
immunostainer.
A fourth slide was immunostained for detection of TNF by incubation with a rabbit anti-
rat TNF polyclonal antibody (Biosource International Inc., Camarillo, CA) at 0.30 mg/ml for
1 hour, followed by an anti-rabbit biotinylated secondary antibody (Vector Laboratories, Inc.), 
and then treatment with streptavidin alkaline phosphatase. The streptavidin was labeled with
permanent red chromagen (DakoCytomation, Carpinteria, CA) and a hematoxylin counterstain.
Pretreatment with citrate was done followed by avidin biotin blocking. Staining was performed
on the Dako Autostainer Plus® (DakoCytomation).
Blinded H&E-stained slides were qualitatively examined for damage by a pathologist. In
order to quantify the extent of damage to the intestine, intestinal villi length were measured in
the following manner: intestinal sections were randomly selected using a random number
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generator, and ten fields from each section were photographed at 10X magnification using an
Olympus BX51 microscope. The images were then exported into Image-Pro-Plus 5.1 (Media
Cybernetics, Inc., Silver Springs, MD), and the villus height for at least 3 villi in each field were
measured from the serosal surface to the tip of each villus. The height of each villus for each
field was exported to an Excel® spreadsheet, where further calculations were performed.
In order to quantify the number of cells staining positive for ED1 (indicating activated
macrophages) or ED2 (indicating resident macrophages), intestinal sections were randomly
selected using a random number generator, and ten fields from each section were photographed
at 40X magnification using an Olympus BX51 microscope. In each field, the number of
positively stained cells in the lamina propria of the mucosal layer were counted, and then
summed for each animal. The average number of positively stained cells for each animal was
obtained by dividing the total number of positive cells by the number of sections counted. This
number was reported as the total number of positively stained cells per number of sections
counted per animal for ED1, and ED2, respectively.
In order to quantify the number of cells immunostaining positive for TNF, a pathologist
examined each section on the slide and a subjective score was assigned based on the percentage
of cells in the lamina propria of the mucosal layer that stained positive for TNF for the entire
slide. A score of 1 indicated minimal positive immunoreactivity or 0-25% of the cells in the
lamina propria staining positive for TNF, a score of 2 indicated mild positive immunoreactivity
(25-50% of cells positive), a score of 3 indicated moderate immunoreactivity (50-75% of cells
positive), and a score of 4 indicated marked immunoreactivity (75-100% of cells positive),
respectively.
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Measurement of TNF in biological fluids
Blood samples (0.5 mL) were collected via the jugular vein cannula into syringes
containing citrate-dextrose anticoagulent solution (Sigma) to yield a final concentration in blood
of 10 % (v/v)) at predose, 0.5, 1, 1.5, 2, 3, and 4 h after dose administration. The blood was
transferred to polypropylene tubes and centrifuged immediately at 2000 x g for 15 min at 4°C to
prepare plasma. Plasma was transferred to clean tubes and frozen immediately in dry ice.
Samples were stored at -80°C until analysis. Samples were thawed immediately prior to analysis
and duplicate aliquots were transferred to a 96-well plate. Quantification of TNF was
accomplished using an Enzyme Linked Immuno-Sorbent Assay (ELISA, Biosource
International, Inc., Camarillo, CA) according to directions provided in the kit. Briefly, samples
were allowed to incubate in 96-well plates coated with immobilized rat TNF antibody in the
presence of reagent containing a biotinylated second antibody for 90 min. Samples were
removed and plates were washed thoroughly. The resulting immobilized complex containing
TNFwas detected by adding streptavidin-horseradish peroxidase (HRP), and then incubation
with tetramethylbenzidine (TMB), a substrate for HRP. The amount of converted substrate was
quantified after incubation for 30 min by monitoring the UV absorbance in each sample at 450
nm using a SpectraMaxPlus UV spectrophotometer (Molecular Devices, Sunnyvale, CA). The
amount of TNF is each sample was calculated using standard curve fitting parameters provided
by the spectrophotometer (Softmax® Pro software utlilizing the endpoint ELISA HRP TMB
curve) over the concentration range of 15 – 5000 pg/mL.
To assess the TNF present in each ileal rinse (rinse 1, obtained immediately after 30
min treatment period, and rinse 2, which was collected at the termination of the experiment),
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samples were assayed using the same ELISA kit. The ileal rinse samples required centrifugation
at 2700 x g for 15 min prior to analysis in order to remove particulate material.
Data Analysis
Data are expressed as mean ± standard deviation (SD) from at least 3 animals.
Statistically significant increases in radiolabeled marker absorption, LDH leakage, and TNF
present in the ileal rinse samples were assessed using a two-sided Student’s t test. The samples
were assumed to have unequal variance. For villi length data, a one-way analysis of variance
(ANOVA) linear mixed model of villi length was fit to the treatment groups for assessment of
statistical significance. For immunohistological macrophage data, a one-way ANOVA weighted
model of log-transformed immuno-positive cells was fit to the treatment groups for assessment
of statistical significance. Significant differences were assigned at p<0.05.
Results
Intestinal absorption of hydrophilic compounds in the presence of HPC
To confirm the completeness of urinary recovery and assess the time course for urinary
excretion of 3H and 14C, an iv dose of 3H-mannitol and 14C-carboxyinulin was administered to
anesthetized rats and the amount of radioactivity excreted into urine was measured. As shown in
Figure 4.2, both isotopes were readily recovered following iv administration, with an average
cumulative excretion of 94% of the dosed 3H and 98% of the dosed 14C recovered during the 4 h
collection period. Since 98 – 99% of the recovered radioactivity was excreted within 3.5 h
following iv administration, subsequent studies utilized a time period of 3.5 h following removal
of intestinally administered 3H-mannitol and 14C-carboxyinulin (total experimental period = 4 h).
The typical urine flow rates for animals used in these experiments ranged between 0.2 – 0.4
mL/h over the 4 h collection period.
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The transient exposure of HPC to a particular intestinal segment was simulated in this
model by injecting the dose directly into an isolated section of ileum and then removing the dose
after a 30 min treatment period. The completeness of dose removal was assessed by comparing
the amount of administered radioactivity recovered in the first rinse of the dosed ileal segment to
the total amount recovered in both ileal rinses. For vehicle dosed animals (no HPC), recovery in
the first ileal rinse averaged 99.8% and 97.6% of the 3H and 14C, respectively, of that recovered
in both rinses, suggesting complete removal of dosed material in the first rinse. Similar
recoveries were observed in the presence of HPC or 10% TRX (data not shown).
For vehicle dosed animals, the average amount of radioactivity appearing in urine after a
30 min exposure was 3.0 % and 0.4 % of the administered 3H and 14C, respectively. After co-
administration with increasing concentrations of HPC (0.4, 1, 2, 10 mM), the average cumulative
amount of 3H and 14C appearing in the urine over the 4 h experimental period gradually
increased (Figure 4.3), with a statistically significant increase in average 3H and 14C urinary
excretion (16 % and 6% of the administered dose, respectively) observed after co-administration
of 2 mM HPC (0.8 mg/kg). Additional increases in urinary excretion of radioactivity were
observed at 10 mM HPC, the highest HPC concentration tested. The highest amount of
radioactivity was found in urine after co-administration of 10% TRX (160 mM), a dose known to
cause intestinal damage as assessed by histological examination, with 52 % of the administered
3H and 34% of the administered 14C being excreted into urine.
The ratio of 3H to 14C excreted into the urine following iv or ileal administration of
3H-mannitol and 14C-carboxyinulin is shown in Table 4.1. After iv administration, the ratio of
excreted 3H to 14C is approximately unity. This is expected because all of the radioactivity is
administered directly into the blood and therefore all is excreted into the urine in an equivalent
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amount. However, after intestinal administration, a lower percentage of dosed 14C is excreted
into the urine versus the amount of 3H, which results in a 3H/14C urinary excretion ratio > 1. In
control rats (no HPC), the 3H/14C urinary excretion ratio was the highest, suggesting that normal
intestine preferentially absorbs the smaller 3H-mannitol compared to the larger
14C-carboxyinulin. In the presence of increasing concentrations of HPC, the ratio of 3H/14C
excreted in the urine gradually decreases, suggesting that the intestinal barrier becomes less
restrictive to 14C-carboxyinulin. The lowest 3H/14C urinary excretion ratio (i.e., the highest
relative absorption of 14C-carboxyinulin to 3H-mannitol) is observed after co-administration with
10% TRX.
The total recovery of 3H and 14C following ileal administration was measured by adding
the amount of radioactivity excreted in the urine to the amount of radioactivity recovered in both
ileal rinses. The total recovery of both isotopes after intraileal dosing was highest in vehicle-
dosed animals (90% 3H, 98 % 14C), but decreased by approximately10 -15% after co-
administration with either HPC or 10% TRX (data not shown).
Assessment of intestinal membrane damage after treatment with HPC using LDH leakage
assay
Following treatment of the intestinal segment with HPC or TRX, the amount of cytosolic
enzyme, LDH, appearing in lumen of the intestinal segment was measured. As shown in Figure
4.4, detectable amounts of LDH were measured in all treatment groups in both the first ileal rinse
performed immediately after treatment, and the final ileal rinse at the end of the 4 h experimental
period. Following treatment with the minimum effective dose of HPC (2 mM), the amount of
measured LDH in both ileal rinse samples increased relative to that measured after treatment
with PBS vehicle alone, though due to variability the increase was not statistically significant.
180
However, after treatment with 10% TRX, a significant increase in measured LDH was observed
relative to control animals (Figure 4.4). The amount of LDH generated from in vivo treatment
with 10% TRX was approximately 7 - 10 % of the total LDH, as estimated from a 10 cm section
of ileum for which the mucosa was scraped and then lysed in vitro using TRX.
The caveat to comparing relative magnitudes of LDH measured in ileal rinse samples is
that components present in the ileal rinse samples were found to degrade or interfere with the
measurement of LDH in the samples. The cause of the degradation of LDH present in ileal flush
samples was investigated in separate experiments in which cell lysate generated from Caco-2
cells, which contained a high concentration of LDH, was diluted with blank ileal contents (i.e.,
ileal contents obtained from successive PBS rinses of isolated segments from non-dosed
animals). As shown in Figure 4.5, successive rinses of the ileum were found to quench the
measured LDH activity present in the Caco-2 cell lysate. While the measured LDH was only
marginally quenched by the third successive ileal contents sample, the measured LDH activity in
this sample was found to decrease with time after incubation at room temperature (Figure 4.5),
suggesting that components present in the third ileal contents sample were degrading LDH or
LDH assay components. Additional approaches intended to identify the interfering components
included pretreatment of blank ileal contents by boiling, ultrafiltration (3,000 to 50,000 Da
NMWL), dialysis (500 Da NMWL) and mixing with protease inhibitor cocktails, prior to use as
Caco-2 cell lysate diluent. All pretreatments were found to increase the measured LDH in the
Caco-2 cell lysate by 2-3 fold compared to non-pretreated samples (data not shown). However,
the pretreated ileal contents samples still appeared to contain unknown component(s) with
molecular weight < 500 Da that attenuated the measured LDH activity in Caco-2 cell lysate
samples by 70-80% compared to PBS alone (data not shown).
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Histological assessment of intestinal damage after HPC treatment
In order to further assess the intestinal damage resulting from transient treatment of
isolated ileal segments with 2 mM HPC or 10% TRX, segments were fixed immediately after
treatment, stained with H&E, and then examined for signs of abnormality. Representative
photomicrographs are shown in Figure 4.6.
In PBS-treated ileal segments (control tissue), the epithelium had tall, uniformly
arranged, and evenly spaced villi, with an intact epithelial cell lining. Occasionally, small
clusters of goblet cells were observed along the epithelial lining. Subtle to minimal congestion
was noted in the submucosa of some segments.
Rats treated with 2 mM HPC, the minimum effective dose based on absorption of
radiolabeled marker compounds, had ileal segments with villi that varied from moderate villus
blunting to complete villus loss or retraction depending on the segment examined. In addition,
depending on the segment examined, individual segments contained a minimal to marked
increase in goblet cell prominence, minimal to marked dilation in lacteals, and subtle to mild
cellular debris in the lumen.
Ileal segments from rats treated with 10% TRX were characterized by villi that were
generally evenly spaced, uniformly tall, and intact, except for the uppermost tips of the majority
of the villi, which were denuded. Above these bunted villus tips was a distinct zone of cellular
debris containing predominantly sloughed epithelial cells and fibrin. Below the mucosal layer,
within the submucosa, there was a distinct zone characterized by small minimally to mildly
congested vessels. These findings are summarized in Table 4.2.
To assess the changes in the intestinal epithelium, villus length was selected for
quantitative analysis. For each treatment group, randomly selected intestinal sections were
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photographed at 10X magnification and ten images from each section were imported into the
grid-based software, Image Pro Plus version 5.1®; each selected villus was measured. For
control animals, the mean villus length was found to be 520 µm. Mean villus length decreased
slightly for 10% TRX-treated animals (460 µm), but was substantially reduced for HPC-treated
animals (370 µm, p<0.05). Due to variability among the villi measurements, only the decrease
in villi length due to HPC treatment resulted in a statistically significant result. However, the
trend observed for villi length determinations supports the qualitative observation that 10% TRX
treatment resulted in primary denudation of villus tips, whereas HPC treatment resulted in amore
substantial loss of villi uniformity overall (Table 4.2).
Immunohistological assessment of intestinal response after LPS administration
Using the same dosing procedure, LPS was co-administered with PBS, 2 mM HPC or
10% TRX directly into an isolated segment of ileum, followed by removal after a 30 min
treatment period. The intestinal response to exogenous LPS administration was first assessed by
examination of H&E stained intestinal sections that had been fixed immediately after treatment.
Rats treated with LPS + PBS had ileal segments characterized by villi that were unevenly
spaced. Individual villi varied in both width and height, from tall and thin to short and wide.
The mean villus length was found to be shorter after treatment with LPS + PBS compared to
PBS alone (400 µm versus 520 µm). However, due to the variability of villus length, this
difference was not statistically significant. Wider villi were supported at the base by mild to
moderately dilated lacteals. A moderate to marked increase in goblet cell prominence, and an
expansion of the lamina propria were also noted. Thus, this dose of LPS (250 µg/kg) elicited a
marked intestinal response when dosed in PBS vehicle alone.
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Co-administration of LPS with 2 mM HPC resulted in an increase in the severity of the
intestinal lesions compared to those observed after administration of 2 mM HPC alone.
Depending on the segments examined, the variation in the amount of villus loss or retraction
increased within the individual segment, and from segment to segment. There was marked
dilation of lacteals (score = 4), and minimal to marked prominence of goblet cells (score = 1 to
4). The amount of cellular debris in the lumen increased slightly as well. In contrast, co-
administration of LPS with 10% TRX resulted in only slight changes in the appearance of the
treated ileal segment compared to 10% TRX alone. However, the degree of villus loss or
retraction was increased slightly from a score of 1 to 2 in the presence of LPS with 10% TRX.
The villus loss or retraction after 10% TRX with LPS, however, was still less than that observed
for HPC (Table 4.2), either with or without LPS co-administration.
The intestinal response to exogenous administration of LPS with different dose vehicles
was further explored using immunohistochemical staining techniques. Treated ileal tissue was
stained for proteins indicative of resident (CD163 clone ED2) or activated (CD68 clone ED1)
macrophages, as well as for TNF-expressing cells. For the ED1 and ED2 stained slides for
each treatment group, randomly selected intestinal sections were photographed at 40X
magnification and ten images from each section were examined for positively stained cells. A
qualitative assessment was made for the TNF stained slides for each animal from each
treatment group.
Following LPS co-administration in PBS, the number of activated macrophages (ED1)
was significantly increased compared to the number found after treatment with PBS alone (Table
4.3). Thus, LPS (250 µg/kg) dosed in the absence of HPC resulted in macrophage activation,
suggesting that some penetration of LPS across ileal tissue occurred during the 30 min exposure.
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The number of activated macrophages was also significantly increased after co-administration of
LPS with 2 mM HPC compared to the number found after treatment with 2 mM HPC alone
(Table 4.3). However, no significant increases in the number of activated macrophages after co-
administration of LPS with 10% TRX were observed compared to the number observed after
administration of 10% TRX alone.
No significant increases in the number of resident macrophages (ED2) were noted after
LPS co-administration in PBS, 2 mM HPC or 10% TRX compared to ileal segments dosed with
these vehicles alone (data not shown).
The number of cells staining positive for TNF were found to be low and not
significantly different among treatment groups as assessed by random inspection of stained
samples (data not shown). This result was due in part to the sub-optimal contrast observed
between positive cells and background staining.
TNF release into biological fluids after LPS administration
The biological response following LPS administration was further assessed by measuring
concentrations of TNF in the systemic circulation and in the ileal luminal contents. In order to
confirm the release of TNF into the blood in response to LPS under these experimental
conditions, iv doses of 50, 250, and 1250 µg LPS/kg body weight were administered to
anesthetized rats and the concentrations of TNF in plasma were measured using ELISA.
Detectable TNF was observed at all iv dose levels of LPS (data not shown), however, the
250 µg/kg dose level yielded a robust systemic TNF release under these experimental
conditions, with a concentration maximum of > 5000 pg/ml, occurring 1.5 – 2 h after LPS
administration (Figure 4.7).
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Despite the high TNF plasma levels after iv administration of LPS, and the substantial
intestinal damage caused by 2 mM HPC or 10% TRX, no increase in TNF concentrations were
detected in plasma following ileal co-administration of 250 µg/kg LPS with 2 mM HPC or 10%
TRX (Figure 4.8). Thus, no evidence for a systemic biological response to LPS was found after
co-administration with the minimum effective dose of HPC or 10% TRX.
In order to assess the local response to LPS, the concentration of TNF in the first ileal
rinse, collected immediately after ileal administration of LPS, and in the second ileal rinse,
collected 3.5 h after dose removal, was also measured using ELISA. As shown in Table 4.4,
increasing TNF concentrations were measured in both the ileal rinse samples following co-
administration with LPS compared to those measured after dosing with the vehicles alone.
However, due to variability in TNF concentrations, the only significant increase in TNF
concentration caused by LPS was observed in the second ileal rinse after co-administration with
2 mM HPC (Table 4.4).
Discussion
HPC is an amphiphilic PPE that has been previously studied in vitro for its mechanism of
action, potency, and cytotoxicity using cell monolayers8. This study represents the first
investigation of the in vivo action of HPC to increase the absorption of hydrophilic compounds
or to cause non-specific damage to the intestinal epithelium.
For this study, an in situ rat intestinal model was employed in which a segment of the
lower intestine was isolated and transiently exposed to HPC. The ileum was chosen because this
segment of small intestine has the highest level of bacteria (108 versus 102 in the upper small
intestine),9 and therefore, may pose the highest risk to bacterial fragment absorption after PPE
treatment.
186
Transient intestinal exposure is likely to occur after oral administration of a PPE due to
GI motility, and therefore is an important component to include in an in situ evaluation of PPE
action. In order to perform the surgical procedures and the subsequent sample collections
required for measurement of marker absorption and PPE-related toxicity, animals were
maintained under isoflurane anesthesia for a 4 h experimental time period. Consistent with the
reported decrease in urine flow caused by isoflurane10, animals in these studies exhibited a
reduced urinary flow rate ( 0.2 – 0.4 mL/h) compared to reported values for conscious animals (2
mL/h)11. Despite this reduction in urinary output, complete urinary excretion of 3H and 14C was
achieved within 3.5 h after iv administration of 14C-carboxyinulin and 3H-mannitol to isoflurane-
anesthetized rats. Therefore, the 4 h experimental time period was sufficient to insure complete
collection of absorbed markers after ileal dose administration. Inferences about the rate of
marker excretion, and therefore rate of marker absorption, however, cannot be made based on
data obtained with this model.
Mannitol and inulin have been reported by others to be poorly absorbed across the
intestinal epithelium in pre-clinical animals and man12-14, and therefore, represent good markers
to estimate the magnitude of absorption improvement that can be achieved with a PPE. Oral
administration of hydrophilic compounds and subsequent measurement of their excretion into
urine has been used by others as a non-invasive technique to assess changes to the intestinal
epithelial barrier15-17. This method was adopted in these studies to measure the enhanced
absorption of 3H-mannitol and 14C-carboxyinulin after ileal co-administration with increasing
concentrations of amphiphilic PPE HPC.
The baseline absorption for these molecules in this rat model averaged 3% and 0.4% of
the administered dose of 3H-mannitol and 14C-carboxyinulin, respectively. The higher
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absorption of mannitol relative to carboxyinulin has been observed by others after oral
administration to rats16,18, and is not surprising based on the smaller size of mannitol (molecular
radius, Mr = 4.1 Å) compared to carboxyinulin (Mr = 7.5 Å). In the presence of increasing
concentrations of HPC, the absorption of carboxyinulin gradually increased relative to mannitol,
as evidenced by the gradual decrease in the 3H:14C urinary excretion ratio from 8:1 to 2:1 over
HPC concentration range of 0 – 10 mM (Table 4.1). This HPC dose-versus-excretion ratio
response suggests that the intestinal barrier becomes more permissive to the larger molecule 14C-
carboxyinulin, and represents an initial stage in understanding the nature of the barrier disruption
caused by HPC. Interestingly, the baseline absorption of mannitol was only 2.4-fold higher than
that of carboxyinulin across Caco-2 cell monolayers (Chapter 3, Figure 3.7). This result is
possibly due to the relative tightness of the paracellular space in Caco-2 cells, which is similar to
colon19, with a reported paracellular pore radius of approximately 5 Å20. As shown by Watson,
et.al. for a series of polyethylene glycol polymers, as the Mr of the probe molecule approaches
the radius of the paracellular pore (Mr ~ 4.5 Å for markers in Caco-2 system), the difference in
permeability between markers that differ substantially in size is very small21. Thus for mannitol,
which is approaching the size of the paracellular pore in the Caco-2 cell model, the difference in
its absorption relative to the much larger molecule carboxyinulin is small compared to the
difference in absorption of these two markers in vivo across the intestinal epithelium, which
reportedly has a larger effective paracellular pore radius (9 Å)18.
The minimum effective concentration of HPC that enhanced the absorption of mannitol
and carboxyinulin in this model was found to be 2 mM. The minimum effective concentration
found in vitro in Caco-2 cell monolayers was approximately 10-fold lower (Chapter 2, 3).
Others have also found that effective in vitro concentrations of amphiphilic PPEs are lower
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relative to those required in vivo to improve the intestinal absorption of poorly absorbed
compounds in animals and humans4,22. Among the factors that may contribute to the apparent
better potency in vitro are the in vivo components such as intestinal fluids, mucus layer, and
transient exposure due to PPE depletion or GI motility—factors that may interfere with, or
deplete PPEs, and which are not typically incorporated in cell culture models used to determine
PPE potency23,24 (Chapter 2). For HPC, rapid depletion from the ileal lumen is unlikely,
because HPC was found to be slowly absorbed in rats after oral administration (Tmax = 24
h)25,26, and was also found to have a relatively low permeability coefficient across Caco-2 cell
monolayers (Papp = 2 x 10-7 cm/sec, Chapter 2, Table 2.3). However, as highlighted in the
histological findings, HPC treatment resulted in a reduction in the number of villi and an
increased prominence of mucus-secreting goblet cells (Table 4.2). Both of these conditions are
likely to have resulted in lower absorption of mannitol and carboxyinulin due to a decrease in
absorptive surface area, and an increase in mucus layer thickness, respectively. Furthermore, the
excess amount of mucus could have interfered with the interaction of HPC with the cell
monolayers, a condition which has been postulated by others to decrease the in vivo effectiveness
of amphiphilic PPEs24.
The histological findings in these studies were a key component of the evaluation of
intestinal damage caused by HPC. Clearly, the minimum effective concentration of HPC caused
major changes to the intestinal epithelium (Figure 4.6 and Table 4.2). These effects were highly
variable, but overall quite different compared to the effects caused by the non-ionic detergent
TRX. While HPC caused substantial villus loss or retraction and an increase in goblet cell
prominence, the epithelial layer on the villi remained relatively intact. In contrast, TRX caused
minimal denudation of the epithelial cell layer (only at the villus tips) without the dramatic
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increase in goblet cells or changes to the villi (Table 4.2). Thus, depending on the PPE used,
very different types of intestinal damage can be observed. This could have important
implications for whether or not the absorption of bacteria or bacterial-related products such as
LPS would also be enhanced after PPE treatment.
Another indication of intestinal damage caused by the minimum effective concentration
HPC was the increase in LDH in the ileal rinse samples (Figure 4.4). The LDH leakage assay,
which measures the amount of cytosolic enzyme LDH that has leaked out of membrane-damaged
cells, has been used previously by others to assess the intestinal membrane damage in vivo27,28,
and also in Chapter 3 to assess HPC-induced membrane damage to Caco-2 cell monolayers.
Unfortunately, due to components present in the ileal rinse samples that were found to degrade
or interfere with the measurement of LDH in the ileal rinse samples (Figure 4.5), this assay was
not useful to make quantitative comparisons about the extent of membrane damage caused by
each treatment, nor to compare the extent of membrane damage observed in vivo in rats versus in
vitro in cell monolayers. Thus, both 2 mM HPC and 10% TRX caused an increase in the amount
of LDH that was measured in the ileal rinse samples, indicating that both treatments caused cell
membrane damage, but further quantitative comparisons cannot be made.
Therefore, based primarily on histological analysis, it appears the transient intestinal
exposure to amphiphilic enhancer HPC at concentrations that resulted in a significant increase in
the absorption of hydrophilic molecules also caused measurable epithelial damage. A
concurrence of intestinal damage with improved in vivo absorption after PPE treatment is not
surprising, given the amphiphilic nature of HPC and its likely accumulation in cell membranes.
Indeed, intestinal damage after in vivo administration of other amphiphilic PPEs has been
reported in the literature27,29. Therefore, the finding that HPC causes significant intestinal
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damage at the minimum concentration required to increase the absorption of hydrophilic markers
is consistent with literature reports on other structurally-related (i.e., amphiphilic) PPEs.
Interestingly, after HPC treatment in vitro in Caco-2 cells, no gross morphological
changes in cell monolayers were noted at effective concentrations, and cells were able to rapidly
recover their barrier function after HPC removal (Chapter 3, Figure 3.4). This in vitro data
suggested that enhancement of hydrophilic marker flux could be achieved with relatively non-
toxic concentrations of HPC. Thus, the gross changes observed in rat intestine after HPC
treatment would not have been anticipated based on the in vitro toxicity evaluation of HPC.
Adverse intestinal events such as diarrhea have also been observed after oral administration of
HPC (miltefosine) to humans for the treatment of leishmaniasis30, suggesting that the gross
intestinal effects observed in rats are not specific to this animal species, or an artifact of the in
situ model used in these studies. While one of the reasons for marked intestinal damage
following in vivo HPC administration could be the higher HPC concentrations administered to
rat ileal segments in vivo, other factors are likely to be involved, including the presence of other
cell types (e.g., goblet cells) in the intestinal epithelium. It is also important to note that higher
concentrations of amphiphilic compounds do not always result in greater in vivo intestinal
damage. For example, 0.2% TRX caused complete and irreversible cell lysis in Caco-2 cell
monolayers (Chapter 3, Figure 3.4), but 50-fold higher concentrations of TRX (10%)
administered to rat ileum in these studies, resulted in relatively minor intestinal denudation.
Thus, Caco-2 cell monolayers appear to be limited in their ability to predict PPE-induced
intestinal toxicity in vivo.
A major goal of these studies was to determine if transient intestinal exposure to HPC at
concentrations that improved the absorption of hydrophilic marker compounds would also result
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in enhanced absorption of LPS. LPS, a fragment derived from the cell wall of gram negative
bacteria, is a well-established causative agent of sepsis following intestinal injury2,31. Although
others have examined the increase in LPS intestinal absorption in various animal models of
intestinal injury or disease32-34, this study represents the first investigation of whether LPS
absorption is enhanced across the intestinal epithelium after transient treatment with a PPE.
The biological response to exogenous LPS administration was measured in this study in
several ways. First, plasma levels of TNFwere used to assess the systemic biological response
to LPS after intestinal co-administration with HPC or TRX. TNF is a cytokine secreted by
macrophages and epithelial cells in response to LPS35. Systemic concentrations of TNF have
been successfully used by others to assess the factors involved in the progression of sepsis after
intestinal injury36,37. In this study, high concentrations of TNFwere detected in plasma after iv
administration of 250 µg/kg LPS (> 5000 pg/mL), thus confirming that systemic exposure to
LPS could elicit TNF release in this animal model (Figure 4.7). However, ileal administration
of the same dose of LPS did not result in an increase in TNF concentrations in plasma (Figure
4.8), even when co-administered with 2 mM HPC or 10% TRX, treatments that caused marked
intestinal damage. Thus, LPS was not absorbed into the systemic circulation in a quantity
sufficient to elicit the release of TNF. It is estimated that the absorbed amount of LPS after
transient ileal administration was < 20% of the administered dose, based on the lowest tested iv
dose of LPS (50 µg/kg) that resulted in detectable serum concentration of TNF (data not
shown). Thus, even though 34% of the administered dose of the comparably sized, albeit
hydrophilic, compound carboxyinulin was absorbed after co-administration with 10% TRX, <
20% of the administered LPS was absorbed, based on the absence of TNF concentrations in
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plasma. Lower absorption of LPS compared to carboxyinulin was also observed across Caco-2
cell monolayers after co-administration of TRX (Chapter 3, Figure 3.7).
In addition to the amphiphilic nature of LPS, it is possible that additional factors
contributed to the low systemic exposure to LPS. For example, it is well-known that the lamina
propria of the intestine contains multiple immune cells types, including macrophages, T cells,
B cells and dendritic cells, which serve to prevent against bacterial invasion into the systemic
circulation38. In these studies, the number of activated macrophages in the lamina propria was
significantly increased following LPS administration in either PBS or 2 mM HPC (Table 4.3),
suggesting that intestinal defenses were activated by this concentration of LPS. The absence of
transepithelial flux of LPS across hemorrhagic shock injured rat intestinal tissue has been noted
previously by others33, supporting the notion that LPS does not reach the systemic circulation
even across damaged intestinal epithelium. However, other groups have detected LPS in the
mesenteric blood after intestinal injury32,34. Thus, more studies will be needed to assess the
extent of LPS systemic exposure following intestinal co-administration with a PPE.
Interestingly, even in the absence of HPC, intestinal defenses were activated by LPS.
This has also been observed in normal monkey ileum after LPS administration, where LPS was
shown to penetrate into the lamina propria, resulting in neutrophil activation39. While the
integrity of the rat intestinal paracellular space has been shown to be unaffected by LPS
administration with concentrations as high as 250 µg/mL40 (the concentration used in the current
study) this LPS concentration is more than 100-fold higher that the reported normal LPS
concentration in rat ileum (1.8 µg/mL)32. Thus, the biological response seen after LPS+PBS,
may be due in part to the high LPS concentration administered in this study. Because significant
intestinal changes resulted from LPS+PBS, it is difficult to conclude with any certainty that HPC
193
exacerbated the local intestinal response to LPS. However, HPC + LPS did result in a significant
elevation of activated macrophages in the lamina propria (Table 4.3) and a significant increase in
the local concentrations of TNF in the ileal rinse compared to that seen after administration of
HPC alone (Table 4.4). Interestingly, this type of localized secretion of TNF to the luminal
rather than blood side after luminal administration of LPS to ischemia-injured intestine has been
reported by others34, supporting the notion that the damaged intestine responds to LPS with a
local, rather than a systemic biological response. It should also be noted that TNFwas detected
in ileal rinses after TRX or HPC treatment in the absence of LPS. While this is not surprising
based on literature evidence that TNF is an important cytokine involved in the tissue repair
processes following injury41, it does obscure any conclusions about the local intestinal response
to LPS in the presence of a PPE. Thus, further studies will be needed to clarify the local
intestinal response to LPS following intestinal co-administration with a PPE.
In summary, these studies have established the minimum effective in vivo concentration
of HPC required to improve the absorption of hydrophilic compounds mannitol and
carboxyinulin. This concentration of HPC (2 mM, 0.8 mg/kg), was approximately 10-fold
higher than the concentration required to improve the absorption of mannitol and carboxyinulin
across Caco-2 cells. Transient treatment with this dose of HPC also caused marked intestinal
damage, including villus loss or retraction and an increase in goblet cell prominence, however,
no significant areas of intestinal denudation were noted. These studies found no evidence for
increased systemic absorption of LPS when co-administered with 2 mM HPC, based on the
absence of TNF concentration elevations in plasma. Thus, even though marked intestinal
damage was caused by HPC, no significant systemic exposure to LPS was observed, perhaps due
to physico-chemical properties of LPS and due to the local intestinal defense mechanisms
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present in the intestinal lamina propria. Further studies will be required to clarify whether the
intestinal absorption of bacterial toxins such as LPS are enhanced after transient exposure to a
PPE that acts more selectively to open the paracellular pathway.
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Table 4.1 Urinary excretion ratio of 3H to 14C after administration of 3H-mannitol and 14C-
carboxyinulin to anesthetized rats
Vehicle Dose Route 3H to 14C Excretion Ratioa
PBS IV 0.96 ± 0.01
PBS IL 8.1 ± 1.6
HPC, 0.4 mM IL 5.5 ± 0.5b
HPC, 1.0 mM IL 2.7 ± 0.7
HPC, 2.0 mM IL 3.1 ± 0.7
HPC, 10 mM IL 2.0 ± 0.3
TRX, 10% IL 1.5 ± 0.1
aDetermined by dividing the 0 - 4 h cumulative urinary excretion of 3H (% dose) by the %
dose of 14C excreted over the same time period. Values are the average ± standard deviation
for at least 3 animals, except where noted.
bValues are the average ± standard deviation for 2 animals.
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Table 4.2 Histological assessment of H&E stained rat ileal segments collected immediately
after 30 min exposure to PBS, 2 mM HPC or 10% TRX
Treatment group
Measured Parameter Control (PBS) 2 mM HPC 10% TRX
Are the villi uniform
around the section?
Yes No Mostly even
How much retraction/loss
of the villi?
0 to 1 3 to 4 1
Is the epithelial lining
intact?
Yes Varies No (Villus tips
are denuded)
Are goblet cells highly
prominent?
No 1 to 4 No
How dilated are the
lacteals?
1 1 to 4 1
Is there congestion
present in the submucosa?
No No Yes
How much debris is
present in the lumen?
0 1 to 2 4
Histological scoring: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked or severe
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Table 4.3 Mean number of activated macrophages detected in ileal tissue following
treatment with HPC or TRX in the presence or absence of LPS
Vehicle No LPS + LPS
PBS 1.2 7.0*
2 mM HPC 8.0 20.6*
10% TRX 5.6 7.5
Asterisk (*) indicates significantly higher number of macrophages after LPS administration
compared the number found after treatment with the same vehicle in the absence of LPS
(p<0.05).
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Table 4.4 Average TNF concentrations (pg/mL) in ileal rinse samples after ileal
administration of LPS (250 µg/kg) to anesthetized ratsa
Vehicle Ileal Rinse 1 Ileal Rinse 2
No LPS + LPS No LPS + LPS
PBS BDb 27 ± 53 13 ± 12 98 ± 84
2 mM HPC 56 ± 20 207 ± 262 32 ± 40 288 ± 129*
10% TRX 28 ± 67 61 ± 65 156 ± 92 130 ± 58
aValues are mean ± standard deviation for 3 to 8 animals. Asterisk (*) indicates significantly
higher TNF concentrations compared to the TNF concentrations found after treatment
with the same vehicle in the absence of LPS (p<0.05).
bBelow Detection.
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Figure 4.1 Embedding scheme for ileal sections
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Figure 4.2 Cumulative urinary excretion of 3H and 14C after iv administration of 3H-
mannitol and 14C-carboxyinulin to rats.
Fasted male rats were anesthetized with isoflurane and dosed iv with 3H-mannitol and
14C-carboxyinulin at a dose level of 2 µmol/kg via an indwelling jugular vein cannula. Urine
samples were collected via a bladder cannula in 30 min intervals over a 4 h time period and
analyzed for radioactivity. The amount of 3H (closed circles) and 14C (open circles)
measured in urine are reported as mean % dose ± standard deviation for 3 animals.
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Figure 4.3 Cumulative 4 h urinary excretion of 3H and 14C after intraileal co-
administration of 3H-mannitol and 14C-carboxyinulin with increasing concentrations of
HPC or 10% TRX.
Fasted male rats were anesthetized with isoflurane and a 10 cm segment of rat ileum was
cannulated and rinsed. Solutions of 3H-mannitol and 14C-carboxy inulin (2 µmol/kg),
prepared with PBS alone, with HPC, or with 10% TRX, were injected into the segment. After
a 30 min period, the dose solution was removed from the ileum. Urine samples were
collected via a bladder cannula. The cumulative amount of 3H (closed bars) and 14C (open
bars) measured in urine over the 4 h period are reported as mean % dose ± standard deviation
for 3-8 animals per treatment group. Asterisk (*) indicates significantly higher excretion of
radioactivity compared to control animals (p<0.05).
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Figure 4.4. Amount of measured LDH in ileal contents following treatment with HPC or
TRX.
Isolated segments of rat ileum were dosed with PBS (control), 2 mM HPC or 10% (v/v) TRX
(160 mM) for a period of 30 min, followed by removal of the dose solution by rinsing with
PBS. LDH was measured in this initial ileal rinse (filled bars), and in a second rinse
performed 4 h after dosing (final ileal rinse, hatched bars) using an LDH assay kit as
described in Methods. Values are mean ± standard deviation for 3 - 5 animals. Asterisk (*)
indicates significantly higher LDH compared to control animals (p<0.05).
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Figure 4.5 Inhibition of LDH activity after dilution with ileal contents.
Fasted male rats were anesthetized with isoflurane and a 10 cm segment of rat ileum was
cannulated and rinsed with successive 3 mL injections of PBS. Each sample containing ileal
contents was then used to dilute Caco-2 cell lysate, which contained a high concentration of
LDH. Measured LDH values for Caco-2 lysate diluted with ileal contents were compared to
those obtained after dilution with PBS (control), and reported as a percentage of this maximal
value (% Control). Values are mean ± standard deviation for 2 animals. The measurement
of LDH in the ileal contents 3 sample was repeated at the indicated times after storage at
room temperature (n=1 per time point).
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Figure 4.6 Representative photomicrographs of rat ileal sections following 30 min
treatment with PBS, 2 mM HPC or 10% TRX.
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Panel (A) ileal sections from rats treated with PBS; panel (B) ileal sections from rats treated
with 10% TRX; arrows indicate villus tips that have been denuded or areas of blood vessel
congestion (long arrow in B2); asterisk indicates luminal debris; panel (C) ileal sections
from rats treated with 2 mM HPC; arrows indicate areas where villi have been lost or
retracted; double asterisk indicates villi that have highly prominent goblet cells.
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Figure 4.7 TNF concentration in rat plasma following iv administration of LPS.
LPS (250 µg/kg) was dissolved in PBS and administered iv to an anesthetized rat. Blood was
collected at the indicated times and samples were centrifuged to obtain plasma. The
concentration of TNF in each sample was measured using ELISA. Values are mean TNF
concentration for duplicate measurements from a single animal. Data points marked with (^)
indicate that measured concentration was below or above the standard curve range of 15 –
5000 pg/mL.
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Figure 4.8 TNF concentrations in rat plasma following ileal administration of LPS.
Fasted male rats were anesthetized with isoflurane and a 10 cm segment of rat ileum was
cannulated and rinsed. Isolated segments of ileum were dosed with LPS (250 µg/kg)
dissolved in PBS, 2 mM HPC or 10 % (v/v) TRX (160 mM) for a period of 30 min, followed
by removal of the dose solution. Blood was collected at the indicated times and samples
were centrifuged to obtain plasma. The concentration of TNF in each sample was
measured using ELISA. Values are reported as a percentage of the predose TNF
concentration, and represent the mean ± SD for 3 animals per treatment group.
CHAPTER 5
CONCLUSIONS
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The overarching goal of this dissertation research was to critically evaluate the current in vitro
models used to assess the potency and toxicity of PPEs, develop new experimental approaches to
improve our ability to predict the in vivo efficacy and toxicity of PPEs, and answer the critical
question on what is the risk for systemic exposure to microbial toxins when PPEs are used to
improve intestinal absorption of hydrophilic compounds. This is of considerable interest
because many therapeutic agents are poorly absorbed from the intestine after oral administration,
the favored route of drug administration. The physico-chemical properties of therapeutic
molecules that lead to poor oral absorption are many times difficult to improve without making
structural changes that result in loss of potency for the therapeutic target. In such cases, use of
selective and reversible modulators of tight junctions that can transiently enhance the
paracellular permeability of hydrophilic compounds is potentially a viable approach for
improving oral bioavailability of therapeutic agents. While studied extensively in vitro in cell
culture models and in vivo in animals, this approach has not been approved for use in humans.
Cell culture models, such as Caco-2 cell monolayers, are routinely used to assess
enhancer potency in order to rank chemical analogs, or compare potency of known PPEs to
novel putative enhancers. The implicit assumption in these comparisons is that Caco-2 cells are
a good model to estimate in vivo PPE potency. Evidence in the literature, however, suggests that
the in vivo effective concentrations of PPEs (i.e., the concentration that increases intestinal
absorption of hydrophilic molecules) in animal models are often much higher relative to the
effective concentrations determined in cell monolayers, and the extent of under-prediction is
different for different compounds. The causes for the mis-prediction of in vivo potency based on
in vitro studies for some non-amphiphilic compounds have been determined. For example, in
order to obtain in vivo efficacy using the cationic polymer chitosan higher concentrations are
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required due to the presence of anionic mucus, a component that is missing from cell monolayer
systems typically used to estimate PPE potency1. The in vivo efficacy of the peptide fragment
Zot requires higher concentrations because this peptide PPE is degraded by luminal peptidases,
enzymes that are not included in cell monolayer evaluations of PPE potency2. However, the
causes for the mis-predicted in vivo efficacy of amphiphilic compounds based on in vitro PPE
potency determinations have not been elucidated clearly.
Studies in this dissertation have demonstrated for the first time that components present
in the intestinal fluid, when introduced into the cell monolayer system, can substantially reduce
the in vitro potency of amphiphilic PPEs (Chapter 2); in contrast, the in vitro potency of non-
amphiphilic compounds was unaffected by intestinal fluid. It is hypothesized that amphiphilic
PPEs are sequestered in the bile salt-lecithin mixed micelles of intestinal fluid, which reduces
their access to the cell membranes; thus much higher bulk concentrations of amphiphilic PPEs
are needed in the presence of the components of intestinal fluid to achieve the same effect . This
hypothesis was substantiated by studies in Chapter 2, which showed that FaSSIF reduced the
cell-associated amphiphilic PPEs, while also causing a reduction in the potency of these
compounds. Clearly, further studies will be needed to determine the extent to which the
intestinal fluid contributes to the mis-prediction of in vivo potency of different amphiphilic
compounds. Retrospective analysis of literature data provides evidence for the in vivo
sequestration of amphiphilic PPEs; for example, PCC was not effective when administered into
the duodenum of rats, the intestinal region with the highest concentration of bile, yet was
effective when administered in the jejunum, ileum and colon3.
Interestingly, not all the amphiphilic PPEs used in the in vitro studies were affected to the
same extent by intestinal fluid. For example, NaCap, a 10-carbon fatty acid, was unaffected by
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the simulated intestinal fluid, whereas HPC and GW4936 were moderately affected when
compared to PCC (Chapter 2). The lack of effect of the simulated intestinal fluid on NaCap may
be due to the fact that >10 mM concentrations of the PPE were needed to decrease TEER and
increase the flux of mannitol; at such high concentrations, NaCap cannot be effectively
sequestered by the components of FaSSIF. These data suggest that rational structure-based
approaches can be developed to avoid intestinal fluid sequestration. Utilization of the FaSSIF
conditions introduced in these studies should greatly aid the investigation of how structural
modifications of the lipophilic chain(s) or the polar headgroups of amphiphilic molecules may
lead to less sequestration and consequent attenuation in potency by intestinal fluid.
While the in vitro potency of NaCap was not reduced in these studies by intestinal fluid,
the concentrations of NaCap, required to improve the intestinal absorption of hydrophilic
compounds in vivo, is substantially higher than would be predicted based on in vitro potency
determinations in cell monolayers4,5. Thus, it appears that other factors are involved in the mis-
prediction of in vivo potency for NaCap by in vitro cellular models. Evidence for another factor
contributing to the mis-prediction in the in vivo potency of NaCap can be found in the high
permeability of NaCap across the Caco-2 cell monolayers, reported in these studies for the first
time (600 – 700 nm/sec under biorelevant conditions, Chapter 2). Indeed, rapid absorption of
NaCap has been reported recently in dogs6. Thus, for NaCap, a likely contributing factor to the
requirement for higher in vivo concentrations is its rapid depletion from the intestinal lumen due
to absorption. In contrast to the high permeability of NaCap, the in vitro permeability coefficient
for HPC was quite low (20 nm/sec under biorelevant conditions, Chapter 2). While not yet
tested as an in vivo PPE, HPC has been investigated as a therapeutic agent for the treatment of
cancer, and found to be slowly absorbed in rats (Tmax = 24 h) 7,8. Thus, the biorelevant (i.e., in
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the presence of serum or stirring) in vitro permeability coefficients of PPEs determined in these
studies provide important information regarding the rate of PPE absorption/depletion that is
likely to occur in vivo, and therefore, can be a key piece of information to predict whether
controlled-release formulations could be successfully employed to improve in vivo efficacy of
PPEs. In this example of HPC and NaCap, one would predict that the in vivo effectiveness of
NaCap could be enhanced by a controlled-release formulation, whereas that of HPC would be
less affected. Indeed, a substantial improvement in the NaCap-induced absorption of a poorly
absorbed traditional Chinese natural product was recently demonstrated through the use of
controlled-release formulations9.
Another likely contributing factor to mis-prediction of in vivo PPE potency is the
transient PPE exposure to intestinal cells in a given intestinal segment due to GI motility, which
is often not incorporated into cell monolayer-based determinations of PPE potency. GI motility
was simulated in these studies by shortening the in vitro treatment time to 15 min, and including
agitation of cell monolayers in order to lessen the thickness of the unstirred water layer. PPE
treatment time for in vitro studies described in the literature ranges from 1 -2 h, a period that is
likely to be much longer than the duration of the intestinal contact time for a PPE due to GI
motility (Chapter 2). Clearly, these extended incubation times could grossly overestimate the
potency of a PPE; as shown in this study, in which 3-NC was effective when incubated with
Caco-2 cells for 
 30 min, but did not show any efficacy after 15 min incubation (Chapter 2).
Interestingly, the reduction in unstirred water layer, a known barrier to lipophilic drug
permeability10, improved the measured in vitro potency for some PPEs, and increased the
transepithelial flux of all the amphiphilic (and lipophilic, in the case of 3-NC) PPEs (Chapter 2).
Thus, transepithelial movement of amphiphilic or lipophilic PPEs across cell monolayers is
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controlled to some extent by the unstirred water layer. By implication, the access of these PPEs
to the apical surface of the cells, and subsequently to the site of action inside the cell, is also
controlled by the unstirred water layer and could be underestimated in vitro if evaluated in the
absence of sufficient stirring.
Thus, these studies have identified three important deficiencies in cell monolayer
protocols that are typically used to evaluate PPE potency that may lead to mis-prediction of in
vivo PPE potency: (1) the lack of intestinal fluid on the apical side of monolayers, (2) the lack of
agitation, and (3) PPE treatment times that are too long. The lack of intestinal fluid and long
treatment times result in overestimation of the amphiphilic PPE potency, whereas the lack of
agitation leads to underestimation of the PPE potency. The fourth parameter that was
investigated in these studies, the addition of serum to the basolateral side of the monolayers, did
not lead to substantial changes in PPE potency measurements. Therefore, we recommend that an
in vitro cellular model used to assess potency of amphiphilic absorption enhancers should
incorporate (i) the use of FaSSIF in the apical compartment, (ii) stirring or agitation of the
medium so as to reduce the height of the unstirred water layer, and (iii) incubation of the cell
monolayers with the test PPE for a period of approximately 15 minutes.
Caco-2 cells are also routinely used to measure the toxic effects of PPEs. Literature
reports of PPE toxicity evaluation focus on cell viability, employing assays such as the MTT
assay11 or the LDH leakage assay12. For amphiphilic compounds, a very narrow window
between concentrations that open TJs and those that decrease cell viability is routinely reported,
and was also found in these studies (Chapter 3). For example, PCC, HPC and GW4936 all
caused a significant leakage of LDH into the apical medium of cell monolayers at the EC50 TEER
concentrations (Chapter 3). Interestingly, despite substantial LDH leakage at EC50 TEER
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concentrations, reversibility of the TEER effect could be achieved after removal of amphiphilic
PPEs and incubation with the appropriate recovery buffer (Chapter 3), indicating that the
epithelial barrier can be rapidly restituted if PPEs are thoroughly removed in the presence of the
appropriate (in vivo-like) buffer components. Rapid restitution of intestinal epithelium after
superficial damage has been demonstrated by others13, and could be occurring after PPE-induced
epithelial damage by a similar process, wherein non-damaged cells spread to cover the gaps left
by neighboring cell damage.
While in vitro cell membrane damage and reversibility are important measurements, the
studies in this dissertation broadened the scope of in vitro PPE toxicity assessment to investigate
whether PPE treatment caused large defects in the monolayer, a type of damage that is found in
ischemia-reperfusion injury due to cell sloughing14. Areas of intestinal denudation are routinely
assessed following ischemia-reperfusion injury, but have not been previously assessed following
PPE-induced epithelial damage. The quantitation of areas of epithelial cell denudation after PPE
treatment may therefore allow a direct comparison of PPE-derived intestinal damage to that of
ischemia, a pathological condition that has been shown to permit increased absorption luminal
toxins resulting in endotoxemia15. The evaluation of large defects in monolayers was
accomplished in these studies by applying quantitative histological software to
photomicrographs of H&E stained monolayers that had been exposed to HPC. Quantification of
areas of cell monolayer aberrations revealed gradual increases in the average aberrant areas
caused by HPC at concentrations  400 µM (Chapter 3). While the nature of the damage was
variable, large areas of monolayer defects or aberrations due to cell sloughing were not evident
even after treatment with the highest concentration tested (600 µM) of HPC, a concentration that
resulted in large amounts of LDH release (Chapter 3). However, after treatment with TRX,
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which is known to cause complete cell lysis in vitro, large areas of cell sloughing were evident
(Chapter 3), suggesting that the lack of observed aberrations upon HPC treatment of the cell
monolayers was not due to any problem with the technique. Direct comparison of the area of
monolayer aberration caused by the highest concentration of HPC used in this study to previous
assessments of epithelial denudation caused by intestinal ischemia14, revealed that HPC
treatment resulted in lesser areas of denudation compared to that denuded after ischemia. Thus,
the histological quantitation technique introduced in these studies provides a unique measure of
PPE-induced toxicity, one which may provide a better indication of whether systemic toxicity
due to absorption of large, amphiphilic bacterial fragments such as LPS is likely to occur through
damaged epithelium. Therefore, we recommend the incorporation of a quantitative assessment
of monolayer aberrations as part of a multifaceted assessment of PPE-induced toxicity.
A major concern regarding PPE technology is that the PPEs may also enhance the
permeability of luminal toxins leading to adverse events or pathological conditions. This
absorption could be facilitated by either the selective opening of epithelial TJs or the non-
specific damage to the epithelial barrier. For example, a leaky intercellular barrier has been
postulated to lead to increased absorption of antigens resulting in intestinal bowel disease16. In
addition, intestinal trauma is thought to lead to increased absorption of bacterial fragments that
can result in septic shock17,18. In these studies, an evaluation of the potential for systemic
toxicity due to PPE treatment was explored for the first time by examining the effect of the
model amphiphilic PPE, HPC, on the absorption of LPS, an established player in pathological
conditions15.
Evidence was provided in these studies that the flux of LPS could be enhanced in vitro
across Caco-2 cell monolayers, but only when co-administered with a relatively toxic
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concentration of HPC (Chapter 3). In contrast, the enhancement of the flux of hydrophilic
molecules mannitol and carboxyinulin could be achieved with relatively non-toxic
concentrations of HPC, and the magnitude of flux improvement of mannitol and carboxyinulin at
all HPC concentrations was substantially greater than that seen for LPS. This finding was
substantiated in an in vivo study, which showed that after co-administration of LPS with HPC to
rat intestine at the minimum effective concentration, which also caused some intestinal damage,
no evidence for systemic exposure to LPS was found, based on the lack of TNF detected in
plasma (Chapter 4). This important in vivo finding provides evidence that large quantities of
bacterial fragments would not be absorbed into the systemic circulation after transient treatment
with a PPE. Contributing to low LPS absorption is likely its large size and amphiphilic
character, as well as the full complement of cell types present in the intestinal epithelium that can
mount an inflammatory response to prevent systemic absorption of LPS. As observed after a 30
min intestinal exposure to LPS, goblet cells became more prominent, the number of activated
macrophages increased and the lacteals (lymph vessels) became dilated (Chapter 4). Thus, the
intestine quickly responds to limit systemic LPS exposure, even in the absence of PPE-induced
effects. These studies raise serious questions about the current dogma that absorption enhancers
are likely to cause systemic toxicity by increasing the permeability of intestinal epithelium to
bacterial toxins. Further studies should be undertaken to more fully characterize the risk of
systemic LPS exposure due to PPE-induced changes to the intestine, including the direct
measurement of fluorescently-labeled LPS in the mesenteric blood, and the use of more TJ-
selective PPEs, such as Zot and synthetic peptides homologous to the extracellular loops TJ
proteins (e.g., occludin peptide, OP90-103), in order to discern whether selective opening of the
paracellular space may be safely achieved without increased absorption of LPS. Further
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characterization of the local intestinal inflammatory response to LPS after PPE treatment would
also be important, particularly after chronic administration of a PPE, in order to assess whether
the local intestinal effects observed in these studies would lead to intestinal inflammatory
conditions similar to those observed with intestinal inflammatory disease. In addition, other
bacterial products, such as flagellin, or smaller chemotactic peptides, such as formylated
methionine-leucine-phenylalanine, should be co-dosed with (less damaging) PPEs in order to
more fully characterize the risks of increased toxin exposure due to PPE treatment.
HPC is an amphiphilic PPE that was recently reported to open TJs in vitro via inhibition
of PLC-dependent processes19. The investigation of HPC in these studies using an in situ rat
intestinal model represents the first effort to characterize in vivo PPE efficacy and toxicity
parameters of HPC. Approximately 10-fold higher HPC concentrations were required to achieve
a statistically significant increase in the absorption of mannitol and carboxyinulin in this in situ
model compared to the concentration required for the enhanced flux of these molecules in vitro
across Caco-2 cell monolayers (Chapter 4 and Chapter 2). Transient treatment with this dose of
HPC also caused marked intestinal damage, including villus loss or retraction, and an increase in
goblet cell prominence. These histological findings would not have been anticipated based on
the in vitro toxicity assessment of HPC in Caco-2 cell monolayers, and together may have
contributed to the lack of absorption improvement of mannitol and carboxyinulin at lower HPC
concentrations through the reduction in intestinal surface area and the increase in the thickness of
the mucus layer. Adverse intestinal events such as diarrhea have also been observed after oral
administration of HPC (miltefosine) to humans for the treatment of leishmanisis20, suggesting
that the gross intestinal effects observed in rats are not specific to this animal species, or an
artifact of the in situ model used in these studies. Thus, these studies highlight the fact that in
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vitro cellular models are useful tools for assessing absorption enhancers, but these models should
be used in conjunction with appropriate in vivo studies for a thorough mechanistic evaluation of
the efficacy and toxicity of putative PPEs.
In summary, these studies have significantly advanced the understanding of the important
deficiencies in the use of the in vitro cell monolayer system to assess PPE potency. By including
biorelevant refinements that address the identified in vitro deficiencies, a more predictive in vitro
monolayer system has been proposed to assess the in vivo potency of amphiphilic PPEs; this new
system is likely to become the foundation for any future implementation of in vitro systems for
initial PPE evaluations and structure-PPE potency relationships. This research also represents an
important investigation into whether PPE-induced intestinal leakiness in vitro and in vivo also
results in the enhanced absorption of unwanted luminal toxins, a prevalent safety concern
preventing the use PPEs in humans. The model amphiphilic PPE HPC was found to increase the
in vitro flux of LPS across Caco-2 cells, but only at relatively toxic concentrations. Furthermore,
after in vivo co-administration of LPS with the effective (and also intestinally damaging) dose of
HPC to rats, no evidence for systemic absorption of LPS was found. The novel methodology
employed to characterize the local and systemic toxicity caused by PPEs is the first ever attempt
to address the concerns about the systemic exposure to microbial toxins by PPEs, and the
evidence obtained thus far suggests that the concerns regarding systemic toxicity of PPEs need to
be challenged with more rigorous studies in experimental animals.
Thus, the studies conducted in this dissertation have made significant contributions to the
field of oral absorption enhancers by (i) identifying the deficiencies in the currently used in vitro
cellular models to assess the potency of PPEs, (ii) refining the cellular models for evaluation of
PPE potency to make them more relevant to the in vivo environment in which the PPEs function,
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(iii) developing methods/models to assess toxicity of PPEs to the intestinal epithelial cells that
are relevant to the larger concerns about the systemic toxicity of these agents caused by allowing
the microbial toxins to enter the systemic circulation, and (iv) evaluating an in situ rat intestinal
model for assessing the efficacy and toxicity of PPEs.
224
References
1. Schipper NG, Varum KM, Stenberg P, Ocklind G, Lennernas H, Artursson P 1999.
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on
absorption enhancement. Eur J Pharm Sci 8(4):335-343.
2. Salama NN, Fasano A, Lu R, Eddington ND 2003. Effect of the biologically active
fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral
absorption of mannitol. Int J Pharm 251(1-2):113-121.
3. Sutton SC, LeCluyse EL, Cammack L, Fix JA 1992. Enhanced bioavailability of
cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions.
Pharm Res 9(2):191-194.
4. Chao AC, Nguyen JV, Broughall M, Griffin A, Fix JA, Daddona PE 1999. In vitro
and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on
mucosal morphology. Int J Pharm 191(1):15-24.
5. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB 2005. Oral delivery of low-
molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic
levels. J Drug Target 13(10):573-583.
6. Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS 2002. Effect of
sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in
pigs. Eur J Pharm Sci 17(3):131-138.
7. Kaufmann-Kolle P, Drevs J, Berger MR, Kotting J, Marschner N, Unger C, Eibl H
1994. Pharmacokinetic behavior and antineoplastic activity of liposomal
hexadecylphosphocholine. Cancer Chemother Pharmacol 34(5):393-398.
8. Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl H 1991.
Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat
3(1):71-78.
9. Lin X, Xu DS, Feng Y, Li SM, Lu ZL, Shen L 2006. Release-controlling absorption
enhancement of enterally administered Ophiopogon japonicus polysaccharide by sodium
caprate in rats. J Pharm Sci 95(11):2534-2542.
10. Lennernas H, Palm K, Fagerholm U, Artursson P 1996. Comparison between active
and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human
jejunum in vivo. International Journal of Pharmaceutics 127(1):103-107.
11. Dorkoosh FA, Setyaningsih D, Borchard G, Rafiee-Tehrani M, Verhoef JC,
Junginger HE 2002. Effects of superporous hydrogels on paracellular drug permeability and
cytotoxicity studies in Caco-2 cell monolayers. Int J Pharm 241(1):35-45.
225
12. Duizer E, van der Wulp C, Versantvoort CH, Groten JP 1998. Absorption
enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl
carnitine in Caco-2 and IEC-18 cells. J Pharmacol Exp Ther 287(1):395-402.
13. Moore R, Carlson S, Madara JL 1989. Rapid barrier restitution in an in vitro model of
intestinal epithelial injury. Lab Invest 60(2):237-244.
14. Blikslager AT, Roberts MC, Argenzio RA 1999. Prostaglandin-induced recovery of
barrier function in porcine ileum is triggered by chloride secretion. Am J Physiol 276(1 Pt
1):G28-36.
15. Tomlinson JE, Blikslager AT 2004. Interactions between lipopolysaccharide and the
intestinal epithelium. J Am Vet Med Assoc 224(9):1446-1452.
16. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI 1986.
Increased intestinal permeability in patients with Crohn's disease and their relatives. A
possible etiologic factor. Ann Intern Med 105(6):883-885.
17. Gathiram P, Wells MT, Raidoo D, Brock-Utne JG, Gaffin SL 1989. Changes in
lipopolysaccharide concentrations in hepatic portal and systemic arterial plasma during
intestinal ischemia in monkeys. Circ Shock 27(2):103-109.
18. Drewe J, Beglinger C, Fricker G 2001. Effect of ischemia on intestinal permeability
of lipopolysaccharides. Eur J Clin Invest 31(2):138-144.
19. Ward PD, Ouyang H, Thakker DR 2003. Role of phospholipase C-beta in the
modulation of epithelial tight junction permeability. J Pharmacol Exp Ther 304(2):689-698.
20. Soto J, Soto P 2006. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti
Infect Ther 4(2):177-185.
